60LET YEARS
Rak
v Sloveniji
2007
Cancer
in Slovenia
EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY
REGISTER RAKA REPUBLIKE SLOVENIJE
CANCER REGISTRY OF REPUBLIC OF SLOVENIA
POROČILO RR št. 49
REPORT No. 49
Ljubljana 2010
ISSN 1318-5845
RAK V SLOVENIJI 2010 - ovitek:Letno porocilo 4.5.2010 11:51 Page 1
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Rak 
v Sloveniji
2007
Cancer 
in Slovenia
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Naslov / Title:  Rak v Sloveniji 2007 / Cancer in Slovenia 2007
Uredniški odbor / Editorial Board
Maja Primic Žakelj, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Mateja Krajc, 
Vera Pompe–Kirn, Primož Strojan, Vesna Zadnik,
Branko Zakotnik, Tina Žagar
Računalniška obdelava / EDP analysis
Jurij Modic, Vesna Zadnik, Tina Žagar, Katja Jarm, Cveto Šval
Oblikovanje in priprava za tisk / Design & Typesetting
Studio N, studio za oblikovanje in grafično pripravo
Tisk / Printing
Present d. o. o.
Izdajatelj / Published by
Onkološki inštitut Ljubljana / Insitute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Naklada / Published in
600 izvodov / 600 copies
Nasvet za citiranje / Recommended reference
Rak v Sloveniji 2007. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka
Republike Slovenije, 2010.
Cancer in Slovenia 2007. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry,
Cancer Registry of Republic of Slovenia, 2010.
Osebje Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic
of Slovenia
Maja Primic Žakelj, vodja / head
Barbara Babuder, Andrej Kirn, Andrej Krašovec, Lavrence Kresnik, Neža Milčič, 
Darja Strle, Fani Škrlec, Nataša Šturm in Tina Žagar
Naslov / Correspondence to
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:
http://www.onko-i.si/rrs/
http://www.onko-i.si/crs/
2
Vsebina Contents
Predgovor  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Uvod . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Viri podatkov in metode registracije  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Viri in nabor podatkov . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Priprava podatkov za računalniško obdelavo  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Kakovost podatkov RRRS in popolnost registracije  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Statistične metode  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Incidenca in umrljivost  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Grobe in starostno specifične stopnje  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Starostno standardizirane stopnje  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Kumulativne incidenčne stopnje in kumulativno tveganje  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Prevalenca  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Prebivalstvo Slovenije . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Rak v Sloveniji 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Zahvala  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Reference  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Foreword  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Introduction  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Data sources and methods of registration  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Data sources and list of data collected  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Preparation of data for computer processing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Data quality and completeness of registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Statistical methods  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Incidence and mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Crude and age-specific rates  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Age-standardised rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Cumulative incidence rate and cumulative risk  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Prevalence  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Population of Slovenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Cancer in Slovenia 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Acknowledgement  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
References  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
3
Slike / Figures 
Slika 1: Breme raka, Slovenija 2007.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Figure 1: Cancer burden, Slovenia 2007.
Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2007.  . . . . . . . . . . . . . 30
Figure 2: Percentage distribution of all cancer sites by age groups and by sex, Slovenia 2007. 
Slika 3: Najpogostejše lokacije raka po spolu in pri obeh spolih skupaj, Slovenija 2007. . . . . . . . . . . 31
Figure 3: The leading cancer sites by sex and in both sexes together, Slovenia 2007.
Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu,
Slovenija 1950–2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Figure 4: Crude and cumulative annual incidence and mortality rates of all cancer sites by sex,
Slovenia 1950–2007. 
Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2007. . . . . . . . . . . 33
Figure 5: Crude annual incidence rate of selected primary cancer sites by sex, Slovenia 
1950–2007. 
Slika 6: Zemljevidi nemelanomskega kožnega raka pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 34
Figure 6: Maps of non-melanoma skin cancer in males by administrative units;
standardised incidence ratio in 4 time periods, Slovenia 1961–2007.
Slika 7: Zemljevidi nemelanomskega kožnega raka pri ženskah po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 35
Figure 7: Maps of non-melanoma skin cancer in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007.
Slika 8: Zemljevidi raka debelega črevesa in danke pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 36
Figure 8: Maps of colorectal cancer in males by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 9: Zemljevidi raka debelega črevesa in danke pri ženskah po upravnih enotah ; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 37
Figure 9: Maps of colorectal cancer in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 10: Zemljevidi pljučnega raka pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 38
Figure 10: Maps of lung cancer in males by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 11: Zemljevidi pljučnega raka pri ženskah po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 39
Figure 11: Maps of lung cancer in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 12: Zemljevidi raka prostate pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 40
Figure 12: Maps of prostate cancer in males by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 13: Zemljevidi raka dojke pri ženskah po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 41
Figure 13: Maps of breast cancer in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
4
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Slika 14: Zemljevidi želodčnega raka pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 42
Figure 14: Maps of stomach cancer in males by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 15: Zemljevidi želodčnega raka pri ženskah po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 43
Figure 15: Maps of stomach cancer in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 16: Zemljevidi kožnega melanoma pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 44
Figure 16: Maps of skin melanoma in males by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 17: Zemljevidi kožnega melanoma pri ženskah po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 45
Figure 17: Maps of skin melanoma in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 18: Zemljevidi raka glave in vratu pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 46
Figure 18: Maps of head and neck cancer in males by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 19: Zemljevidi raka sečnega mehurja pri moških po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 47
Figure 19: Maps of bladder cancer in males by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 20: Zemljevidi raka materničnega telesa pri ženskah po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 48
Figure 20: Maps of uterine corpus cancer in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Slika 21: Zemljevidi raka materničnega vratu pri ženskah po upravnih enotah; 
standardizirani količniki incidence v 4 časovnih obdobjih, Slovenija1961–2007.  . . . . . . . . . 49
Figure 21: Maps of uterine cervix cancer in females by administrative units; 
standardised incidence ratio in 4 time periods, Slovenia 1961–2007. 
Podatki v tabelah / Data in tables 
Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 1998–2007 in 2010. . . . . . . . . . . . . . . . . . . . 50
Table 1: Observed and estimated cancer incidence, Slovenia 1998–2007 and 2010. 
Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski 
standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2007. . . . . . . . . . . 51
Table 2: Incidence, crude incidence rate and according to World, European and 
Slovenian standard population standardized incidence cancer rates, Slovenia 2007. 
Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, 
Slovenija 2007.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2007.  
Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Table 4: Cancer incidence by site, by sex and by age, Slovenia 2007. 
5
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter 
kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2007.  . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Table 5: Crude and age-specific cancer incidence rate per 100,000 and 
cumulative rate (CR) by site and by sex, Slovenia 2007. 
Tabela 6a: Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, 
Slovenija 2007.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Table 6a: Incidence of most frequent cancer sites by statistical regions and by sex, 
Slovenia 2007.  
Tabela 6b: Starostno standardizirana incidenčna stopnja najpogostejših lokacij raka 
po statističnih regijah in spolu, Slovenija 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Table 6b: Age-standardised incidence rate of most frequent cancer sites by 
statistical regions and by sex, Slovenia 2007.  
Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po 
histološki vrsti in lokaciji, Slovenija 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by 
histological type and by site, Slovenia 2007.  
Tabela 8: Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2007.  . . . . . . . 77
Table 8: Incidence of non-Hodgkin´s malignant lymphomas by site, by sex and by age, 
Slovenia 2007. 
Tabela 9: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) 
po stadiju, lokaciji in spolu, Slovenija 2007.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
Table 9: Cancer incidence (without cases registered from death certificates only) by stage, 
by site and by sex, Slovenia 2007. 
Tabela 10a: Število in deleži bolnikov, zbolelih leta 2007, ki so bili v okviru prvega zdravljenja 
operirani, zdravljeni s sistemsko terapijo ali obsevani.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Table 10a: Number of patients diagnosed in 2007, that were treated by surgery, sistemic 
therapy or radiotherapy during their first treatment.  
Tabela 10b: Število bolnikov, zbolelih v letu 2007, ki so bili v okviru prvega zdravljenja operirani, 
po lokaciji raka in bolnišnici posega. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Table 10b: Number of patients, diagnosed in 2007, that were treated by surgery during their 
first treatment by primary sites and tretament institution.
Tabela 10c: Število bolnikov, zbolelih v letu 2007, ki so v okviru prvega zdravljenja prejeli 
sistemsko terapijo, po lokacijah raka in bolnišnici posega.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Table 10c: Number of patients diagnosed in 2007, that were treated by sistemic therapy 
during their first treatment by primary sites and tretament institution.
Tabela 11: Prevalenca po spolu in izbrani primarni lokaciji, Slovenija, 31. 12. 2007. . . . . . . . . . . . . . . . . . . 84
Table 11: Prevalence of cancer patients by sex and by selected primary site, Slovenia, 
December 31, 2007.  
Tabela 12: Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2007.  . . . . . . . . . . . . . . . . . . . . . . . . 85
Table 12: Mortality by site, by sex and by age, Slovenia 2007.  
Izbor publikacij / Selected publications  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
6
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Ob 60-letnici Registra raka Republike Slovenije
Pred slabim desetletjem sem na velikem mednarodnem kongresu poslušal predavanje enega
najuglednejših evropskih biostatistikov, ki je svoje trditve dokazoval s podatki našega, slovenskega
Registra raka in je obenem – skoraj kot v opravičilo publiki – našteval dobre lastnosti našega Registra.
Njegove besede sem doživel kot veliko priznanje tej naši službi in Onkološkemu inštitutu, osebno
pa so me navdale s ponosom.
Na Onkološkem inštitutu Ljubljana, osrednji onkološki ustanovi v Sloveniji, se zavedamo
kakovosti in pomena Registra raka Republike Slovenije. Njegovemu razvoju zato posvečamo
posebno pozornost. Med drugim ga čaka informacijska posodobitev ter skrb za še večjo
točnost zbranih podatkov.
Ob lepem jubileju Registra raka izrekam vsem njegovim nekdanjim in sedanjim sodelavkam
in sodelavcem v imenu vseh zaposlenih na Onkološkemu inštitutu iskrene čestitke.
Janez Žgajnar
Strokovni direktor Onkološkega inštituta Ljubljana
On the 60th Anniversary of Cancer Registry of Republic of
Slovenia
Less than a decade ago, I had the opportunity to listen to a lecture by an eminent European
biostatistician who provided the evidence for the ideas and assumptions presented in his
lecture from the data of the Cancer Registry of Slovenia. At the same time, while presenting
the evidence, he was also revealing the qualities and advantages of our Registry. I could feel
his great appreciation for our Cancer Registry and our Institute in his words, which made me
glow with pride. At the Institute of Oncology Ljubljana, the principal national institution for
cancer treatment, we are very much aware of the benefits and significant role of Cancer
Registry in Slovenian oncology. We are therefore particularly concerned for the further growth
of the Registry, including upgrading its information system and thereby also assuring higher
level of accuracy in data gathering.
May I, on this important anniversary, take this opportunity to congratulate, on behalf of the
employees of the Institute of Oncology Ljubljana and on my own behalf, our colleagues who
used to work at the Registry and those who are working there at present for their successes
and achievements at work.
Janez Žgajnar
Medical director of Institute of Oncology Ljubljana
7
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Predgovor Foreword
Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi.
Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna
profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do
upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu.
Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija
in register raka. V njej delujejo še bolnišnični register OI, ki omogoča podrobnejši pregled nad
bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče) in RRRS oskrbuje z velikim
delom podatkov, državni register za vodenje in spremljanje organiziranega presejalnega programa
za raka materničnega vratu (ZORA) in – od leta 2007 – informacijski sistem za vabljenje žensk in za
epidemiološko spremljanje organiziranega presejalnega programa za raka dojk (DORA).
Podatki o raku, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, skupaj s podatki o umrljivosti,
ki jih zbira in obdeluje Inštitut za varovanje zdravja RS, so osnova za ocenjevanje bremena rakavih
bolezni v državi. Pomembni so za načrtovanje in ocenjevanje onkološkega varstva na področju
primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje
zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska
oprema, posteljne zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji
in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.
Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in
drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja
podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in
objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3.
V vsakem poročilu pa zadnja leta objavimo še, kakšna je pričakovana incidenca raka v letu, ko
je poročilo izdano (v tokratnem poročilu torej za leto 2010); izračunana je s posebno statistično
metodo.
RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov
za leto 1950 je bila objavljena v Zdravstvenem vestniku leta 1951. Podatki za leta 1957–1971 so
bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije Epidemiological
and Vital Statistics in v World Health Statistics Report. Od leta 1965 so bili podatki spet redno
objavljani v posebnih letnih poročilih z naslovom Rak v Sloveniji (1965–1977) in Incidenca raka
v Sloveniji (1978–2006), in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so
objavljene tudi 4 monografije: Zemljevidi incidence raka v Sloveniji 1978–1987, Preživetje bolnikov
z rakom v Sloveniji 1963–1990, Preživetje bolnikov z rakom v Sloveniji 1983–1997 in Preživetje
bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji. Seznam drugih pomembnejših del,
objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.
Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so
v vseh devetih zvezkih knjige Rak na petih kontinentih (Cancer Incidence in Five Continents), ki jo
izdaja Mednarodna agencija za raziskovanje raka, in v podatkovnih zbirkah EUROCIM,
GLOBOCAN, ACCIS, preživetje slovenskih bolnikov pa je obdelano v mednarodnih raziskavah
EUROCARE II, EUROCARE III, EUROCARE IV in EUNICE.
Šestdeseta obletnica delovanja RRRS nam je izziv za novost, s katero želimo podatke o raku še
bolj približati vsem uporabnikom. Razvijamo namreč interaktivni državni spletni portal, ki smo ga
poimenovali SLORA po začetnih črkah besed »Slovenija in rak«. Dostopen bo na elektronskem
naslovu www.slora.si. Omogočal bo preprost in hiter dostop do podatkov o raku v Sloveniji, ki
jih zbira RRRS (incidenca, prevalenca in preživetje) ali Inštitut za varovanje zdravja (umrljivost)
na ravni države in primerjavo z drugimi državami v Evropski uniji in v svetu. S strokovnimi
razlagami bo olajšal razumevanje podatkov in seznanjal vse uporabnike z nevarnostnimi
dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnosti zdravljenja raka, s tem pa bo
prispeval tudi k vrednotenju učinkovitosti Državnega programa obvladovanja raka. S
komunikacijskim mostom med uporabniki in strokovnjaki bo prispeval k objektivnemu in
verodostojnemu informiranju o raku.
Uvod 
8
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
SAVINJSKA
PODRAVSKA
GORENJSKA
POMURSKA
OSREDNJESLOVENSKA
JUGOVZHODNA SLOVENIJA
SPODNJEPOSAVSKA
ZASAVSKA
Viri in nabor podatkov
Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS
(Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92 in št. 65/00).
Osnovni vir podatkov so prijavnice rakave bolezni. Registru jih pošiljajo iz vseh bolnišnic in
diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma,
če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje.
S prijavnicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka
oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Dodatni
vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Inštitut za varovanje zdravja RS
in pa obdukcijski zapisniki z diagnozo maligne bolezni. Veliko časa porabimo za poizvedbe o
bolnikih, za katere nimamo popolnih podatkov ali pa dobimo o njih prvo informacijo šele ob smrti.
Za izračun preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba
živa, mrtva ali izgubljena iz registra prebivalstva). Te podatke dobimo štirikrat letno iz Centralnega
registra prebivalstva, in sicer za vse osebe iz RRRS, ki so po naših podatkih še žive. V letošnjem letu
bomo skupaj s prenovo računalniške baze s posebej varovano spletno tehnologijo neposredno
povezani s Centralnim registrom prebivalstva (CRP), zato bomo ta podatek lahko pridobivali
sproti. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum
izgube, ki nam ga pošlje Centralni register prebivalstva, odvisno od tega, kateri datum je kasnejši.
Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS
odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v desetletju 1996–2005, je
znašal le 0,1 %.
Pri analizi prostorske razporeditve raka upoštevamo Uredbo o standardni klasifikaciji teritorialnih
enot – SKTE (2000), ki predpisuje delitev slovenskega ozemlja na 11 ravneh. Točno opredeljevanje
stalnih naslovov bolnikov z rakom nam omogoča redna povezava z Registrom prostorskih enot
Geodetske uprave RS. V zemljevidih izbranih rakov, prikazanih na Sliki 6, smo uporabili raven
delitve SKTE-4, upravne enote. V Tabeli 6 smo do Letnega poročila 2002 prikazovali podatke po
9 zdravstvenih regijah, v skladu z omenjeno uredbo pa smo potem prešli na raven SKTE-3, na 12
statističnih regij.
Slovenske statistične regije 
Viri podatkov in metode registracije
9
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
PTUJ
TOLMIN
SEŽANA
KOČEVJE
LJUBLJANA
KRANJ
IDRIJA
MOZIRJE
LITIJA
NOVO MESTO
ŽALEC
RADOVLJICA
KRŠKO
CERKNICAPOSTOJNA
KOPER
ČRNOMELJ
NOVA GORICA
KAMNIK
ŠKOFJA LOKA
LAŠKO
CELJE
GROSUPLJE TREBNJE
SEVNICA
RIBNICA
BREŽICE
ILIRSKA BISTRICA
AJDOVŠČINA
DOMŽALE
LOGATEC
MARIBOR
MURSKA SOBOTA
JESENICE
ORMOŽ
LENDAVA
TRŽIČ
LENART
VELENJE
ŠMARJE PRI JELŠAH
RADLJE OB DRAVI
VRHNIKA
SLOVENSKA BISTRICA
LJUTOMER
SLOVENJ GRADEC
RAVNE NA KOROŠKEM
METLIKA
ŠENTJUR PRI CELJU
GORNJA RADGONA
SLOVENSKE KONJICE
DRAVOGRAD
PIRAN
ZAGORJE OB SAVIHRASTNIK
TRBOVLJE
IZOLA
ZAGORJE OB SAVI
Slovenske upravne enote
Priprava podatkov za računalniško obdelavo
Podatke, prispele v RRRS na prijavnicah, posebej usposobljene medicinske sestre najprej kodirajo
v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.
Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne
klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene, do takrat pa smo
uporabljali osmo. Prav pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo
morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni
za onkologijo, od poročila za leto 2001 njeno tretjo izdajo. V tej izdaji je spet nekaj novosti, med
drugimi navedba, katere histološke vrste sodijo med maligne. Po tretji reviziji so med maligne
uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski
šifri C96.7). V skladu z novimi pravili tudi mejno malignih tumorjev jajčnikov ne uvrščamo več v
kategorijo C56, pač pa v D39.1.
Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra
219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0
(carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji
MKB so vse intraepiteljiske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987
registriramo tudi prijavljene intraepitelijske karcinome dojke, od leta 1995 pa intraepitelijske
karcinome mehurja in kožne melanome Clark I. 
Ker so podatki o stadiju bolezni po klasifikaciji TNM na prijavnicah pogosto pomanjkljivi, za
opredelitev stadija bolezni večinoma uporabljamo poenostavljeno razvrščanje v eno od treh
skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer
opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do
obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev pri solidnih
10
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
tumorjih praviloma sledi klasifikaciji TNM. V omejeni stadij je tako uvrščen primer bolezni, pri
katerem je tumor označen s T1 ali T2 (razen pri dojki, malignem melanomu in ščitnici, pri katerih
so vključeni tudi tumorji T3, in materničnem vratu, telesu in sarkomih, pri katerih so vključeni
le tumorji T1) in pri katerem niso prizadete področne bezgavke in ni zasevkov v oddaljenih
organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot
T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov
v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa
uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali
organih (M1). Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.
Kakovost podatkov RRRS in popolnost registracije
Kakovost podatkov registrov raka osvetljujejo naslednji kazalci: odstotni delež mikroskopsko
(histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz
zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.
Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register
in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s
posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih
diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji
takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi
kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke
o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.
Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških
poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako
išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo
izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih
populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih
malignomov, ki se zdravijo samo ambulantno.
11
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Incidenca in umrljivost 
Incidenca in umrljivost pomenita absolutno število vseh na novo ugotovljenih primerov kake
bolezni v točno določeni populaciji oz. število vseh umrlih za to boleznijo v enem koledarskem
letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je
bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne
štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v
debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na
območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.
Za oceno incidence v letošnjem letu (prikazano v Tabeli 1) je uporabljena metoda po Dybi in
Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva
samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv
rojstne kohorte.
Grobe in starostno specifične stopnje
Groba incidenčna stopnja je število novih primerov bolezni, preračunana na 100.000 oseb
opazovane populacije. Natančneje je definirana kot število novih primerov bolezni v
določenem časovnem obdobju, praviloma enem letu (= incidenca), deljeno s številom oseb,
ki so na začetku tega obdobja izpostavljene tveganju, da zbolijo; izražamo jo na 100.000 oseb-
let. Starostno specifična stopnja pove to relativno število (incidenčno stopnjo) v posamezni
petletni starostni skupini.
Starostno standardizirane stopnje
Če analiziramo incidenco v daljšem časovnem obdobju (če se starostna struktura prebivalstva
v času spreminja) ali če primerjamo incidenco med populacijami z različno starostno strukturo,
je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja
je teoretična incidenčna stopnja, pri kateri predpostavimo, da je starostna struktura opazovane
populacije taka kot v standardni populaciji. V Tabeli 2 prikazujemo poleg grobe incidenčne
stopnje rakavih bolezni v Sloveniji še starostno standardizirene stopnje na svetovno, evropsko
in slovensko standardno populacijo z metodo neposredne standardizacije; čim manjši je delež
starejšega prebivalstva v standardni populaciji, tem večja je razlika med grobo in starostno
standardizirano stopnjo. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi
statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije
ob popisu leta 2002. Uporabljena standardna populacija je vedno enaka za oba spola, kar v
posameznih primerih privede do navidez paradoksalne situacije, da so standardizirane stopnje
pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri
drugem spolu pa manjše. V letošnjem letnem poročilu se je tak primer pojavil pri izračunu
starostno standardiziranih stopenj s slovenskim standardom (Tabela 2).
Pri prikazih zemljevidov raka (Slika 6) v štirih časovnih obdobjih smo uporabili metodo posredne
standardizacije. Z njo smo izračunali standardizirani količnik incidence (SKI), ki je razmerje med
opazovanim in pričakovanim številom raka v primeru, da bi bile starostno specifične
incidenčne stopnje v posameznih upravnih enotah in v vsakem od 4 obdobij take, kot so bile
povprečne starostno specifične stopnje v Sloveniji v vsem opazovanem obdobju (1961–2007).
SKI je približek relativni ogroženosti z rakom v posamezni upravni enoti v opazovanem
časovnem obdobju. Za grafični prikaz smo izračunane vrednosti SKI razdelili v 9 enako velikih
razredov. Upravne enote z majhno ogroženostjo so obarvane v odtenkih modre, tiste s
Statistične metode 
12
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
povprečno, rumeno, tiste z večjo, pa v odtenkih rdeče. Različna obarvanost zemljevidov v 4
obdobjih kaže po eni strani časovni trend ogroženosti v posamezni upravni enoti, po drugi pa
razlike v ogroženosti z rakom med upravnimi enotami glede na slovensko povprečje v
celotnem obdobju 1961–2007. 
Kumulativne incidenčne stopnje in kumulativno tveganje
Kumulativna incidenčna stopnja (KS) je petkratna vsota starostno specifičnih incidenčnih stopenj
po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Prikazana
je v zadnjem stolpiču Tabele 5. Je poseben primer neposredne starostne standardizacije, kjer
je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od
izbora standarda. Kumulativno incidenčno stopnjo smo uporabili za prikaz časovnega trenda
incidence in umrljivosti v spodnjem delu Slike 4. Primerjava z obliko krivulje grobe incidenčne
stopnje (zgornji del slike 4) kaže, da večanja incidence raka ne moremo pripisati le staranju
prebivalstva v Sloveniji, ampak da k njeni rasti prispevajo še drugi nevarnostni dejavniki.
Kumulativno tveganje (KT) je verjetnost posameznika, da zboli za rakom v izbranem starostnem
obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje
izražamo v odstotkih. Če je kumulativna incidenčna stopnja manjša kot 10/100, jo lahko
uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa
kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: KT = 100 (1 – e–KS/100).
Kumulativno incidenčno stopnjo raka dojk pri ženskah 7,3/100 tako lahko uporabimo za oceno
kumulativnega tveganja raka dojk, ki je v tem primeru 7,3-odstotno. To pomeni oceno, da bo
7,3 % deklic, rojenih leta 2007, (ali približno ena od 14) do 74. leta starosti verjetno zbolelo za
rakom dojk.
Prevalenca
Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj
so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom
izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so do datuma izračuna
živi določeno število let po diagnozi (npr. manj kot 1 leto, 1–4, 5–9 , 10 let in več). Pri raku so
ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni,
npr. enoletna vključuje bolnike v času prvega zdravljenja, od prvega do petega leta bolnike v
obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje
bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
13
Podatki o številu prebivalcev in o starostni strukturi so ključnega pomena pri izračunavanju in
interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna
struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis
prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta
1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima
letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji
spremlja Centralni register prebivalstva, je mogoče dobiti točen podatek o številu in starostni
strukturi prebivalcev na katerikoli dan. V letnih poročilih uporabljamo podatek o prebivalcih na
datum 30. junij posameznega leta, kot ga dobimo iz Statističnega urada RS. Podatki za leto
2007 o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo in po spolu
za posamezne statistične regije so navedeni v spodnjih dveh tabelah.
Prebivalci Slovenije po
starosti in spolu na dan 
30. 6. 2007
Prebivalci Slovenije po
statističnih regijah in spolu
na dan 30. 6. 2007
Prebivalstvo Slovenije 
14
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Starostna skupina Skupaj Moški Ženske
0–4 92.074 47.251 44.823
5–9 90.658 46.806 43.852
10–14 98.320 50.493 47.827
15–19 116.906 60.324 56.582
20–24 135.658 70.525 65.133
25–29 153.990 80.515 73.475
30–34 151.880 79.094 72.786
35–39 145.716 75.053 70.663
40–44 157.574 80.259 77.315
45–49 154.407 78.825 75.582
50–54 158.637 81.760 76.877
55–59 138.072 69.941 68.131
60–64 101.952 49.044 52.908
65–69 97.647 44.974 52.673
70–74 85.848 36.020 49.828
75–79 70.016 25.789 44.227
80+ 70.051 18.452 51.599
Vse 2.019.406 995.125 1.024.281
Statistična regija Skupaj Moški Ženske
Gorenjska 200.585 98.531 102.054
Goriška 119.945 59.605 60.340
JV Slovenija 140.532 70.186 70.346
Koroška 73.594 36.747 36.847
Notranjsko-Kraška 51.830 25.928 25.902
Obalno-Kraška 107.062 53.298 53.764
Osrednjeslovenska 506.829 247.417 259.412
Podravska 320.863 157.765 163.098
Pomurska 121.964 59.164 62.800
Savinjska 260.121 129.234 130.887
Spodnjeposavska 70.839 35.204 35.635
Zasavska 45.242 22.046 23.196
Slovenija 2.019.406 995.125 1.024.281
Leta 2007 je za rakom na novo zbolelo 11.607 ljudi, 6.083 moških in 5.524 žensk, umrlo pa
5.537 ljudi, 3.146 moških in 2.391 žensk. Konec decembra 2007 je živelo 76.459 ljudi, ki so kdaj
koli od ustanovitve RRRS zboleli za rakom (Slika 1). Ocenjujemo, da bo leta 2010 za rakom
zbolelo 12.685 prebivalcev Slovenije, 6.683 moških in 6.011 žensk. Ocene incidence za
posamezne lokacije raka, skupaj s povprečnimi petletnimi vrednostni za zadnje 10-letno
obdobje, so prikazane v Tabeli 1.
Rak je v raznih življenjskih obdobjih različno pogosta bolezen; skoraj izjema je pri mlajših od
19 let. Manj kot 3 % vseh primerov raka je med 20. in 34. letom starosti, več kot tri četrtine
bolnic in bolnikov pa zboli po 50. letu. Medtem ko med 35. in 49. letom zboli za rakom nekaj
več žensk kot moških (11,7 % žensk in 7,3 % moških), se med 50. in 74. letom to razmerje obrne;
delež zbolelih je spet večji med ženskami po 75. letu starosti, tudi zato, ker je njihova
pričakovana življenjska doba daljša (Slika 2). 
Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo
primerjavo z drugimi državami z različno starostno strukturo v Tabeli 2 poleg grobih stopenj
izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo
uporabili tri standardne populacije, svetovno, evropsko in slovensko.
Prvih pet po številu novih primerov najpogostejših rakov (kože, debelega črevesa in danke,
pljuč, dojke in prostate) dosega 56,5-odstotni delež vseh novih primerov rakave bolezni (Slika 3).
Pri moških je bil leta 2007 najpogostejši rak prostate (Slika 3). Na prvem mestu je zamenjal
pljučnega raka, ki je bil najpogostejši rak pri moških vse od leta 1967 do leta 2004. Pri ženskah
ostaja rak dojk na prvem mestu z 21-odstotnim deležem, sledijo mu kožni rak, rak debelega
črevesa in danke ter pljučni rak (Slika 3).
Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 505 % pri moških in za
320 % pri ženskah; v zadnjih 10 letih pa za 35 % pri moških in za 27 % pri ženskah. Groba
umrljivostna stopnja se je v zadnjih 10 letih zvečala za 18 % pri moških in za 16 % pri ženskah
(Slika 4). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva, saj se je
kumulativna incidenčna stopnja zvečala od leta 1950 pri moških za 230 %, v zadnjih 10 letih
za 10 %, pri ženskah pa od leta 1950 za 139 % in v zadnjih 10 letih za 12 %. Starostno
standardizirana, kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (Slika 4).
Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše
in da vse več bolnikov ozdravi ali živi z rakom, medtem ko jih je poprej več umrlo.
Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka
večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri 85/100.000; prav
tako je ustaljena incidenčna stopnja raka glave in vratu. Pri ženskah se veča pogostost raka
dojk, pljučnega raka in raka materničnega telesa, medtem ko se incidenčna stopnja raka
materničnega vratu od leta 2003 počasi manjša. Pri obeh spolih se veča pogostost raka
debelega črevesa in danke, malignega melanoma in drugih kožnih rakov, podobno kot drugod
v svetu pa je želodčnega raka pri obeh spolih počasi vse manj (Slika 5).
Zemljevidi ogroženosti z rakom v štirih časovnih obdobjih pri obeh spolih odsevajo po eni
strani časovni trend posameznih rakavih bolezni, po drugi strani pa bodisi ustaljeni ali
spreminjajoči se zemljepisni vzorec razširjenosti bolezni (Slika 6). Tako je npr. ogroženost z
rakom dojk večja v predelih zahodne Slovenije, z želodčnim pa na vzhodu. Pri moških je okolica
Kočevja že dolga leta področje z večjo ogroženostjo s pljučnim rakom, v severovzhodnem,
vinorodnem predelu Slovenije pa je več raka glave in vratu. 
Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz Tabele 3 je razvidno, da je bila
leta 2007 pri 94 % od 11.607 na novo registriranih primerov raka diagnoza potrjena mikroskopsko
(histološko ali citološko), pri 5,6 % z drugimi preiskavami, le 0,4 % primerov pa je bilo vpisanih
Rak v Sloveniji 2007
15
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
le na osnovi zdravniškega poročila o vzroku smrti. Ta, zadnja odstotna vrednost, ki je že več let
podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili
zdravljeni v bolnišnici. Kakšna je bila morfološka slika malignomov pri 10.913 primerih, pri
katerih je bila diagnoza potrjena mikroskopsko, kaže Tabela 7. V njej so posebej primeri, ki so
potrjeni histološko (92 %), in tisti, ki so bili potrjeni samo citološko (8 %).
V Tabeli 6a je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Te
številke so pomembne za načrtovanje zdravstvenih zmogljivosti, starostno standardizirane
vrednosti v Tabeli 6b pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso
posledica razlik v starostni strukturi prebivalcev.
Tabela 8 kaže starostno porazdelitev ekstranodalnih in nodalnih lokacij ne-Hodgkinovih
malignih limfomov. Ker je število ekstranodalnih lokacij majhno, so prikazane le absolutne
številke.
Tabela 9 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena
je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno operacijo
in tudi obdukcijo, če le bolnik ni bil poprej zdravljen.
Za leto 2007 prvič prikazujemo osnovne podatke o zdravljenju bolnikov. Iz Tabele 10a je razvidno,
kako so bili bolniki zdravljeni, v Tabelah 10b in 10c pa, v katerih zdravstvenih ustanovah so bili
bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem
se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.
Tabela 11 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2007. V letošnjem
poročilu poleg celotne prikazujemo tudi delno, to je prevalenco bolnikov, zbolelih do enega
leta pred referenčnim datumom ter v obdobjih 1–4, 5–9 in 10 let in več.
V Tabeli 12 so uradni podatki o umrljivosti za rakom v letu 2007. Tabelo so pripravili na Inštitutu
za varovanje zdravja RS.
16
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih
zdravstvenih ustanov so RRRS pošiljali prijavnice s podatki o novih bolnikih z rakom in njihovi
nadaljnji usodi ter nam pomagali dopolniti prijave z manjkajočimi informacijami.
Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega
registra Onkološkega inštituta v Ljubljani Ana Dotzauer in Maruška Ferjančič.
Naše delo bi bilo bistveno težje brez dolgoletnega sodelovanja s Centralnim registrom
prebivalstva RS, Inštitutom za varovanje zdravja RS in Statističnim uradom RS.
Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše
zahvaljujemo.
Uredniški odbor
Zahvala
17
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
18
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer
registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the
late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera
Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its
recognition at the national and international level all until her retirement in 2003.
Since 2003, the CRRS together with the Unit of Epidemiology is merged in a single
Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises
the hospital-based Cancer Registry of the IO Ljubljana, which contributes a considerable part of
information to the CRRS and facilitates a more detailed overview of patients treated at the IO
Ljubljana, irrespective of their permanent residence. In the last decade, we have established
national registry in charge of coordinating and monitoring  organised cervical cancer screening
programme (ZORA), while an information system DORA to support organized breast screening
program has been underway since 2007. While the existence of these two new registries
contributes to a higher quality and completeness of CRRS’s data, the latter contribute to the
evaluation of the effectiveness of screening programs.
The data on cancer, that are collected by the CRRS, incidence, survival and prevalence, serve
together with mortality data, collected by the Institute of Public Health,  as the basis for
assessing the cancer burden in the country. They are important for planning and evaluation
of all levels of cancer control, primary prevention, diagnosis, treatment and rehabilitation, for
planning facilities and funding needed for cancer control (personnel, equipment and hospital
capacities) as well as for clinical and epidemiological research in Slovenia and in international
multicentre studies and for evaluation of effectiveness of the cancer screening programs. 
The Annual Reports of CRRS are one of the regular ways of disseminating information on
cancer among professionals and all other groups. As we are limited by the technology of data
collection because of a variety of data sources, data collection, their linking and publication is
rather time consuming (with us and elsewhere) and usually takes two to three years. As
preliminary information on expected incidence in the year when the Annual Report is
published (in this report for the year 2010), estimated numbers and rates are presented; they
are calculated by a special statistical method.
The first annual reports of the CRRS for the period 1951–1955 were issued during the years
1953–1957. The first data analysis for the year 1950 was published in Zdravstveni vestnik in
1951. The data for the period 1957–1971 were appearing in the periodicals Epidemiological
and Vital Statistics Report and World Health Statistics Report, both edited by World Health
Organization. From 1965 onwards, the data have been published regularly in special bi-lingual
(Slovene-English) annual reports, first entitled Cancer in Slovenia (1965–1977), and then Cancer
Incidence in Slovenia (1978–2006). 
Besides Annual Reports, four special publications have been published: Atlas of Cancer
Incidence in Slovenia 1978–1987, Cancer Patients’ Survival in Slovenia 1963–1990, Cancer Patients’
Survival in Slovenia 1983–1997 and Survival of Cancer Patients, diagnosed in 1991–2005 in
Slovenia. The list of other relevant publications in last five years is at the end of this report.
Data of the CRRS are included in several international databases and projects. They have been
published in all nine volumes of the Cancer Incidence in Five Continents issued by International
Agency for Research on Cancer. The data are included in the international databases EUROCIM,
GLOBOCAN and ACCIS. The survival of Slovenian cancer patients is analysed in the international
studies EUROCARE II, EUROCARE III, EUROCARE IV and EUNICE.
The sixtiesth anniversary of CRRS presents a challenge for us, to work on a new, more user-friendly
way of data presentation. Currently, we are preparing an interactive web portal with the name
Introduction
19
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
SLORA, according to the first letters in Slovenian language: “SLOvenia and RAk/cancer”. It will
be available at www.slora.si from this autumn on. It will enable a simple access to data on
cancer in Slovenia, registered in CRRS (incidence, prevalence and survival) or Institute of Public
health (mortality) and comparison with other countries in the European Union and in the
world. It will describe the data and inform users with professional explanations about cancer
risk factors, about screening and early detection and thus contribute also to the evaluation of
National Cancer Control Program. As a communication bridge between professionals and
users, it will contribute to better and objective information about cancer.
20
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
SAVINJSKA
PODRAVSKA
GORENJSKA
POMURSKA
OSREDNJESLOVENSKA
JUGOVZHODNA SLOVENIJA
SPODNJEPOSAVSKA
ZASAVSKA
Data sources and the list of data collected
Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and
prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85;
Official Gazette of RS, No 9/92 and 65/00).  The main sources of data are notifications of cancer,
gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary
health care centres in case the patient has not been referred for further diagnostic
investigations and/or treatment. 
The data, gathered with notifications are identification data, data on the cancer disease (anatomic
cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification)
and basic data on treatment. Additional sources of information are death certificates that we
get from the Institute of Public health of RS. A lot of time of CRRS’s staff is needed for queries
about patients, from who we do not have all data or we get their data at death only.
Calculation of patient survival requires the patient’s vital status (a person may be alive, dead or
lost to follow-up). This data is obtained quarterly from the Central Population Registry for all
persons registered in the CRRS database as alive. In this year, an on-line connection with the
Central Population Registry will be established, through a specially secured web technology,
together with the upgrade of CRRS’s database. This will enable an on-line connection and
up-to-date vital status of all patients registered. In lost persons, the date of last notification or
the date of loss obtained from the Central Population Registry, whichever first, is considered
as date of loss. From 1985, since the uniform personal ID number has been used in Slovenia,
in CRRS the percentage of the lost to follow-up is below 1%, in patients registered in the
decade between 1996–2005 being 0.1%.
When analysing the spatial distribution of cancer, the new law on regional division of Slovenia
is followed, that in the year 2000 introduced the system of division of Slovenian territory at
eleven levels. The exact mapping of patients’ permanent address is also possible, as we maintain
the regular connection with the Registry of spatial units of the Surveying and Mapping
Authority. In this report, in cancer maps, presented in Figures 6–21, the division by administrative
units was used. In the Table 6, the data have been presented by 9 health regions till the Annual
Report 2002, since then, 12 statistical regions have been chosen to present the data.
Statistical regions of Slovenia
Data sources and methods of registration
21
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
PTUJ
TOLMIN
SEŽANA
KOČEVJE
LJUBLJANA
KRANJ
IDRIJA
MOZIRJE
LITIJA
NOVO MESTO
ŽALEC
RADOVLJICA
KRŠKO
CERKNICAPOSTOJNA
KOPER
ČRNOMELJ
NOVA GORICA
KAMNIK
ŠKOFJA LOKA
LAŠKO
CELJE
GROSUPLJE TREBNJE
SEVNICA
RIBNICA
BREŽICE
ILIRSKA BISTRICA
AJDOVŠČINA
DOMŽALE
LOGATEC
MARIBOR
MURSKA SOBOTA
JESENICE
ORMOŽ
LENDAVA
TRŽIČ
LENART
VELENJE
ŠMARJE PRI JELŠAH
RADLJE OB DRAVI
VRHNIKA
SLOVENSKA BISTRICA
LJUTOMER
SLOVENJ GRADEC
RAVNE NA KOROŠKEM
METLIKA
ŠENTJUR PRI CELJU
GORNJA RADGONA
SLOVENSKE KONJICE
DRAVOGRAD
PIRAN
ZAGORJE OB SAVIHRASTNIK
TRBOVLJE
IZOLA
ZAGORJE OB SAVI
Slovenian administrative units
Preparation of data for computer processing 
In CRRS specially trained nurses code the data retrieved from notifications in accordance with
the internationally and in CRRS agreed rules.
Since 1997, cancer sites are coded according to the 10th revision of the International Statistical
Classification of Diseases and Related health Problems (ICD-10); before, the 8th revision was
used (ICD-8). When classifying tumours as malignant, the behaviour digit of the morphology
code of the third edition of International Classification of Diseases for Oncology has been used
since the report for the year 2001. In this edition, some changes were introduced in terms of
morphology and behaviour code. According to this classification, chronic myeloproliferative
disorders and myelodisplastic syndromes are classified as malignant (currently C96.7
topography code), while ovarian tumours of borderline malignancy are currently coded as
D39.1 (and not C56).
In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was
introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was
registered. Thus, the comparison with the data for the period 1961–1992 is not possible.
According to ICD-10, all cervical intraepithelial neoplasm (in situ and CIN III) are coded as D06.
Since 1987, the number of all reported intraepithelial carcinomas of breast and since 1995, all
reported intraepithelial carcinomas of the bladder and all malignant melanomas Clark I have
been registered.
As data on stage of disease by TNM Classification System in cancer notification forms are often
lacking, a simplified definition of stages at diagnosis is used, classifying them in localised,
regional and remote stage of disease. The simplified definition is based on all investigation
methods, including surgery. In case the patient was not treated before death, the autopsy
record is considered as well. In solid tumors, the simplified stage definition generally follows
the TNM classification. Localised stage includes all cancers where the tumour has been
22
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
classified as T1 and T2 (except in breast, malignant melanoma and thyroid cancer, where T3 is
also included, and uterine cervix, uterine corpus and sarcomas, where T1 only is included),
where neither regional node involvement nor distant metastases are found (N0, M0). The
regional stage includes tumours classified as T3 and T4 (exceptions already mentioned) and/or
regional node metastases (N1), without presence of metastases in distant lymph nodes or
organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the
remote stage (M1). Malignant lymphomas are classified according to Ann-Arbor System.
Data quality and completeness of registration
The quality of information can be assessed by the following parameters: the percentage of
microscopically (histologically or cytologically) confirmed cases and the percentage of cancer
cases registered on the basis of death certificates only. The values of these parameters in the
three observation periods are presented in Table 3.
The completeness of registration shows the proportion of all new cancer cases in the region
covered by the registry, which are included in the registry’s data base. It can be measured
directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing
patient record in the hospitals or outpatient clinics in a particular region. In Slovenia, no such
surveys have been carried out so far. However, a considerable contribution towards the
completeness of registration is made by our colleagues – clinicians, who send us the data on
their groups of patients in order to get information about their survival and among them we
often find cases that have not been entered in the CRRS database yet.
The registration is more complete where the registries have access to death certificates, and
can send out additional inquiries about disease for the deceased that have not been entered
into the database yet. This improves the completeness of registration of cancers with poor
prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well in other European
population based cancer registries – registration is less complete in non-melanoma skin cancer
and in malignomas that are treated on the out-patient basis only. 
23
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Incidence and mortality
Incidence and mortality mean absolute number of all newly diagnosed cases of any disease
in a defined population or number of deceased from this disease in one calendar year. New
primary cancers of the same histology in paired organs, e. g. on the left and right breast, are
not comprised in the incidence figures, neither are any new cancers of the same histology
appearing in the same organ, e.g. multiple lesions of the colon. Incidence in CRRS includes all
cancer cases with permanent residence in Slovenia, regardless of the country, where they have
been treated.
The method by Dyba and Hakulinen was used for estimation of incidence in 2010 (presented
in Table 1). This method is suitable for predictions in shorter time period, taking into account
the period of diagnosis and the age structure of the population. For long-term predictions
the cohort effect should be included also.
Crude and age-specific rates
Crude incidence rate is the number of new cases per 100,000 population. More precisely it is
defined as number of new cases in a specified time interval, usually one calendar year, divided
by the number of persons at risk of disease at the beginning of time interval; it is expressed
per 100,000 person-years.  The age-specific rate expresses this relative number in an individual
five-year age group.
Age-standardised rates
When analysing the incidence rate within longer time period (if the age structure of population
changes) or comparing the incidence between populations with different age structure,
age-standardisation is needed to adjust the rate for the effect of age. The age-standardised rate
is a theoretical incidence rate assuming that the age structure in the observed population is
the same as in the standard population. In Table 2, besides crude cancer incidence rates,
age-standardised rates by direct method are presented, using World, European and Slovenian
standard population; the smaller is the proportion of older population in the standard, the
bigger is the difference between crude and standardized rate. In Table 6b the standard is the
age structure of Slovenian 2002 census population. The standard population is always the
same for both sexes that may in some situations result in standardized rate being bigger than
crude in one sex, usually in males that are on average younger and smaller in females. This is
the case in rates standardised to Slovenian standard population in Table 2.
Indirect method of standardisation was used to present cancer maps in four time periods
(Figures 6–21). In this case, the standardised incidence ratio was calculated, which is the ratio
of observed number of cancer cases in every time period and the number that would be expected
if a particular administrative unit in every of the four time periods had the same age-specific
incidence rates as that in the whole Slovenia in the entire observation period (1961–2007).
SIR can be interpreted as the relative risk of cancer in particular administrative unit in a given
time period. The values of SIR were divided in 9 equal class intervals. The administrative units
with low risk have blue cast, those with average yellow, and those with higher risk the red one.
Different colouring of maps in 4 time periods show a time trend in cancer risk on one hand,
and on the other the differences in risk between administrative units compared to Slovenian
average in the entire time period 1961–2007.
Statistical methods
24
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Cumulative incidence rate and cumulative risk
The cumulative incidence rate is five times the sum of the age-specific incidence rates over
five-year age groups up to the age of 74 years, calculated per 100 population. It is presented
in the last column of Table 5. The cumulative rate can be interpreted as a form of direct
age-standardization with the same standard population size in each age group. Thus, it avoids
the arbitrary choice of standard population. The cumulative incidence rate was also used to
present the incidence time trend in the lower part of the Figure 4. The comparison to the
curves of crude incidence per 100,000 population (upper part of Figure 4) indicates that the
increasing cancer incidence rate in both sexes cannot be attributed only to the aging of
Slovenian population, but also to additional risk factors.
The cumulative risk (CR) is the risk an individual would have of developing the disease in
question during a certain age period, e.g. up to the age of 74,  if no other causes of death were
in operation. The cumulative risk is expressed per 100 (per cent). If cumulative rate is lower
than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate
is greater than 10/100, it should be calculated from cumulative risk according to the following
formula: CR = 100 (1 – e–KS/100).
Cumulative incidence rate of breast cancer in females can be used to estimate cumulative risk
of breast cancer that is in this case 7.3%. This means that 7.3% of women born in 2007
(approximately each 14th woman) are expected to develop breast cancer by their age of 75 in
the absence of any other cause of death. 
Prevalence
Prevalence is the number of all cancer patients that are alive on a given date, regardless of
time, when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all
persons living and ever diagnosed with cancer, while partial prevalence counts only those
patients, diagnosed with cancer within a defined period of time (e. g. less than 1 year, 1–4
years, 5–9 years, 10 years or more). In cancer these periods are important, as they reflect the
number of cancer cases in different course of disease, e. g. the one-year prevalence includes
patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up,
while 5–9 and especially 10 and more years prevalence includes predominantly those
considered cured from cancer.
25
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Population data, especially the number and age structure, are important for calculation and
interpretation of most indicators of cancer burden. Census population data are available for the
whole time period since the beginning of cancer registration. Census has been performed
nearly every 10 years, but till 1985 no data were available for intermediate years, so for this
time period it was assumed that the population structure between two censuses was the
same. Since the middle of the eighties, the population data are available for any particular
date from the Central Population Registry. In CRRS Annual Reports, the number of population
on June 30 of a particular year is used, and is obtained from Statistical Office of Republic of
Slovenia. In the following tables, numbers of inhabitants of Slovenia by age and by sex and in
statistical regions are presented. 
Population of Slovenia by age
and by sex, 
June 30, 2007.
Population by Slovenian
statistical regions and by sex,
June 30, 2007.
Population of Slovenia
Age Total Males Females
0–4 92.074 47.251 44.823
5–9 90.658 46.806 43.852
10–14 98.320 50.493 47.827
15–19 116.906 60.324 56.582
20–24 135.658 70.525 65.133
25–29 153.990 80.515 73.475
30–34 151.880 79.094 72.786
35–39 145.716 75.053 70.663
40–44 157.574 80.259 77.315
45–49 154.407 78.825 75.582
50–54 158.637 81.760 76.877
55–59 138.072 69.941 68.131
60–64 101.952 49.044 52.908
65–69 97.647 44.974 52.673
70–74 85.848 36.020 49.828
75–79 70.016 25.789 44.227
80+ 70.051 18.452 51.599
All ages 2.019.406 995.125 1.024.281
Statistical region Total Males Females
Gorenjska 200.585 98.531 102.054
Goriška 119.945 59.605 60.340
JV Slovenija 140.532 70.186 70.346
Koroška 73.594 36.747 36.847
Notranjsko-Kraška 51.830 25.928 25.902
Obalno-Kraška 107.062 53.298 53.764
Osrednjeslovenska 506.829 247.417 259.412
Podravska 320.863 157.765 163.098
Pomurska 121.964 59.164 62.800
Savinjska 260.121 129.234 130.887
Spodnjeposavska 70.839 35.204 35.635
Zasavska 45.242 22.046 23.196
Slovenia 2.019.406 995.125 1.024.281
26
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
In 2007, 11.607 patients were diagnosed with cancer, 6.083 males and 5.524 females, and 5.537
patients died from cancer, 3.146 males and 2.391 females. At the end of December 2007, there
were 76.459 people alive who were diagnosed with cancer at any time since the foundation
of the CRRS (Figure 1). It is estimated, that in 2010, there will be 12.685 Slovenian diagnosed
with cancer, 6.683 males and 6.011 females. The estimated incidence of different cancer sites
together with 5-year average values in the last 10-year period are presented in Table 1.
Cancer incidence varies during lifetime; cancer is more an exception till the age of 19. Less
than 3% of all cancer is in the age group 20–34, and more than three quarters of all cancer
cases occur in patients older than 50 years. The proportion of new cancer patients is a bit
higher among females in the age group 35–49 (11.7% of females and 7.3% of males), while this
ratio is reversed between the age of 50–74 years; after the age of 75, there is again a higher
proportion of cancer among females, also because of their longer life expectancy (Figure 2).
As cancer incidence depends on the age structure of a population, in Table 2 besides crude also
age-standardised rates are presented. For better comparison with other countries and as
different standard populations are used, three standard populations, World, European and
Slovenian were applied.
First five most frequent cancers (skin, colorectal, lung, breast and prostate) comprise 56.6% of
all new cancer cases (Figure 3). In males, the most frequent cancer site in 2007 was prostate
(Figure 3). It replaced lung cancer, which was the most frequent in males from 1967 till 2004.
In females, breast is in the first place with 21% of all new cases, followed by skin, colorectal and
lung (Figure 3).
Since 1950, the crude cancer incidence rate in Slovenia increased for 505% in males and for
320% in females; in the last 10 years for 35% in males and 27% in females. The crude mortality
rate in the last 10 years increased for 18% in males and 16% in females (Figure 4). More than half
of the crude incidence rate increase is a consequence of ageing of population, as cumulative
incidence rate increased in males since 1950 for 230% in males, for 10% in the last 10 years, and
in females for 139% and for 12% in the last 10 years. Age-standardised, cumulative mortality
rate is decreasing since 1985 in both sexes (Figure 4). The decrease in mortality along with
increase in incidence indicates better results of treatment and better survival or cure from
cancer.
The time trend of lung cancer incidence in males was increasing till the nineties of the last
century, when it stabilised around 85/100.000; similarly, head and neck cancer incidence rate
is constant. In females, the incidence of breast, lung and uterine corpus cancer is still increasing,
while cervical cancer incidence rate is decreasing since 2003. In both sexes, the incidence of
colorectal, skin melanoma and other skin cancer is increasing, while incidence of stomach
cancer is decreasing as elsewhere.
Cancer maps in four different time periods in both sexes reflect on one hand the time trend
in particular cancer and on the other, similar or changing geographic pattern of risk in different
parts of Slovenia (Figure 6–21). Thus breast cancer risk is higher in western parts of Slovenia,
while stomach in eastern. In males the surrounding of Kočevje is known as high risk region for
a longer time period, in wine-growing regions of north easter part of Slovenia, the risk of head
and neck cancer is higher.
In the majority of new cases, the diagnosis was confirmed microscopically. Table 3 shows that
in 2007, in 94% from 11.607 newly diagnosed cancer cases, the diagnosis was confirmed by
histology or by cytology, in 5.6% with other investigations and only 0.4% of cases were
registered from death certificate only. This letter percentage has been similar for several years
and represents those patients that, due to advanced age or disease have not been treated in
Cancer in Slovenia 2007
27
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
the hospital. The morphology of tumours in 10,913 cases, diagnosed microscopically, is
presented in Table 7. In this table, cases confirmed by histology (92%) and by cytology only (8%)
are presented separately. 
In Table 6a, the number of new cases of all and selected cancer sites by different statistical
regions is presented. While these data are important for planning health care facilities, the
age-standardised rates in Table 6b indicate the differences in the risk of cancer, as these
differences are not due to different age structure of population in these regions.
Age distribution of extranodal and nodal sites of non-Hodgkin malignant lymphomas is
presented in Table 8. Owing to a small number of extranodal sites, only the absolute numbers
are given.
In Table 9, the distribution of cancer patients by stage at diagnosis is presented. A simplified
definition of stages at diagnosis is used, that takes into account all investigation methods,
including surgery or autopsy in case the patient has not been treated before death.
In this report, data on treatment of cancer patients are presented for the first time. Table 10a
presents the mode of treatment, while Tables 10b and 10c show the hospital where patients
had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at
institute of Oncology Ljubljana only (with few exceptions, that have been irradiated abroad).
Data on prevalence of all and most frequent cancers on December 31, 2007 are presented in
Table 11. In this report, besides lifetime also partial prevalence is presented, including cases
diagnosed in the year before the reference date and in the period 1–4, 5–9 and 10 years or
more before reference date.
Official data on cancer mortality in 2005 are given in Table 12. The table has been prepared at
the Institute of Public Health of the Republic of Slovenia.
Physicians, nurses, and administrative staff from Slovenian hospitals and other health
institutions have provided the data on new cancer patients and their medical history as well
as helped us in obtaining additional information when needed.
Our co-workers at the Hospital Registry of the Institute of Oncology Ljubljana, Ana Dotzauer
and Maruška Ferjančič, have contributed at least a half of the information presented in this
report. 
The long-term collaboration with the Population Registry of the Republic of Slovenia, the
Institute of Public Health of the Republic of Slovenia and the Statistical Office of the Republic
of Slovenia is indispensable for our work.
We thank all of them as well as to all others who have contributed and enabled us to present
the results of our work in this report. 
Editors
Acknowledgement 
28
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
– Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za
leto 1950. Zdrav Vestn 1951; 20: 264–77.
– Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
– World health statistics report. Geneva: World Health Organization, 1970–1974.
– Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
– Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
– Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
– Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for
Research on Cancer, 1970.
– Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International
Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
– Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon:
International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
– Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon:
International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
– Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6.
International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
– Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon:
International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
– Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon:
International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
– Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents.
Vol 9. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 160). 
– European Network of Cancer Registries. EUROCIM version 4.0. European incidence database V2.4, ICD-10
dictionary (2003), Lyon 2001.
– Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide.
IARC CancerBase No. 5, version 2.0. Lyon: IARC Press, 2004.
– Steliarova-Foucher E, Berrino F, Coebergh JW et al. ACCISpass 1.01 software for analysis and presentation of
data on incidence and survival of children and adolescents in Europe. Lyon: ENCR, 2002. 
– Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCARE-2 study.
Lyon: International Agency for Research on Cancer, 1999.
– Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann
Oncol 2003: 14 (Suppl 5).
– Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European
adults diagnosed in 1995–1999: Results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773–83. 
– Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of
cancer incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
– Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer
patients’ survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
– Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients’
survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
– Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v
Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009. 
– Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
– Savezni zavod za zdravstvenu zaštitu. Međunarodna klasifikacija bolesti, povreda i uzroka smrti. 8. revizija. Novi
Sad: Savezni zavod za zdravstvenu zaštitu, 1970.
– Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za
statistične namene. 10. revizija (International statistical classification of diseaseses and related health
problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
– World Health Organisation. International classification of diseases for Oncology. Geneva: World Health
Organisation, 2000.
– Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for
Research on Cancer, 1991. (IARC Sci Publ 95).
– Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research
on Cancer, 1999.
– Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical
comparison of different approaches. Stat Med 2003; 15: 2751–66.
– Statistični letopis republike Slovenije 2007. Ljubljana: Statistični urad Republike Slovenije, 2008.
29
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Reference References
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
30
0 10.000 20.000 30.000 40.000 50.000 60.000 70.000 80.000 90.000
Prevalenca
Prevalence
Umrljivost
Mortality
Incidenca
Incidence
Število
Number
Moški in ženske / Males and females
5.537
11.607
76.676
3.146
2.391
6.083
5.524
29.087
41.589
Ženske / Females
Moški / Males
ŽENSKE - FEMALES
75+
let/
32,4 %
years
50-64
let/
8,12 %
years
20-34
let/
2,5 %
years
0-19
let/
0,7 %
years
65-74
let/
24,7 %
years
0-19
let
0,5 %
/years
35-49
let/
7,3 %
years
50-64
let/
31,7 %
years
75+
let/
25,4 %
years
20-34
let/
2,0 %
years
MOŠKI - MALES
65-74
let/
33,1 %
years
35-49
let/years
11,7 %
Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2007.
Figure 2: Percentage distribution of all cancer sites by age groups and by sex, Slovenia 2007.
Slika 1: Breme raka, Slovenija 2007.
Figure 1: Cancer burden, Slovenia 2007. 
31
Slika 3: Najpogostejše lokacije raka po spolu in pri obeh spolih skupaj, Slovenija 2007.
Figure 3: The leading cancer sites by sex and in both sexes together, Slovenia 2007.
25 0510152030%
Koža, razen melanoma
Debelo črevo in danka*
Pljuča
Dojka
Prostata
Glava in vrat*
Želodec
Koža, melanom
Maternično telo
Ostalo
Trebušna slinavka
Skin, non-melanoma
Colorectum*
Lung
Breast
Prostate
Head and neck*
Stomach
Skin, melanoma
Corpus uteri
Other
Pancreas
MOŠKI IN ŽENSKE - MALES AND FEMALES
15,5
11,9
10,4
9,9
8,8
4,0
3,9
3,7
2,5
2,5
26,2
Prostata
Pljuča
Koža, razen melanoma
Debelo črevo in danka*
Glava in vrat*
Želodec
Mehur
Koža, melanom
Ledvica
Trebušna slinavka
Ostalo
Prostate
Lung
Skin, non-melanoma
Colorectum*
Head and neck*
Stomach
Bladder
Skin, melanoma
Kidney
Pancreas
Other
25 25
ŽENSKE - FEMALES
05 510 1015 1520 2030 30 %
Dojka
Koža, razen melanoma
Debelo črevo in danka*
Pljuča
Maternično telo
Koža, melanom
Jajčnik
Maternični vrat
Želodec
Trebušna slinavka
Ostalo
Breast
Skin, non-melanoma
Colorectum*
Lung
Corpus uteri
Skin, melanoma
Ovary
Cervix uteri
Stomach
Pancreas
Other
MOŠKI - MALES
%
23,6
2,6
2,7
3,1
3,2
4,2
5,3
6,1
11,0
16,9
20,7
2,5
18,4
2,9
3,3
3,3
4,6
6,3
12,8
14,3
14,4
16,9
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
* Pojasnilo – Explanation
Debelo črevo in danka – Colorectum: C18–C20
Glava in vrat – Head and neck: C00–C14, C30–C32
NHL: Ne-Hodgkinovi limfomi – NHL: Non-Hodkgin's lymphoma: C82–C85
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
32
0
100
200
300
400
500
600
G
ro
ba
 s
to
pn
ja
 n
a
10
0.
00
0
C
ru
de
 ra
te
 p
er
10
0,
00
0
19
50
19
56
19
62
19
68
19
74
19
80
19
86
19
92
19
98
20
04
20
07
19
53
19
59
19
65
19
71
19
77
19
83
19
89
19
95
20
01
Le
to
/ 
Ye
ar
Umrljivost moški - Mortality males
Incidenca moški - Incidence males
Umrljivost ženske - Mortality females
Incidenca ženske - Incidence females
Ku
m
ul
at
iv
na
 s
to
pn
ja
 n
a 
10
0
C
um
ul
at
iv
e 
ra
te
 p
er
 1
00
0
10
20
30
40
50
19
50
19
56
19
62
19
68
19
74
19
80
19
86
19
92
19
98
20
04
20
07
19
53
19
59
19
65
19
71
19
77
19
83
19
89
19
95
20
01
Le
to
/ 
Ye
ar
Umrljivost moški - Mortality males
Incidenca moški - Incidence males
Umrljivost ženske - Mortality females
Incidenca ženske - Incidence females
Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu, Slovenija 1950–2007.
Figure 4: Crude and cumulative annual incidence and mortality rates of all cancer sites by sex, Slovenia 1950–2007.
33
Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2007.
Figure 5: Crude annual incidence rate of selected primary cancer sites by sex, Slovenia 1950–2007.
0
10
20
30
40
50
60
70
80
90
100
110
19
50
19
56
19
62
19
68
19
74
19
80
19
86
19
92
19
98
20
04
20
07
19
53
19
59
19
65
19
71
19
77
19
83
19
89
19
95
20
01
Le
to
/ 
Ye
ar
Prostata - (C61)Prostate
Pljuča - (C33–C34)Lung
Koža, melanom - (C43)Skin, melanoma
Debelo črevo in danka - (C18–C20)Colorectum
Koža, razen melanoma - (C44)Skin, non-melanoma
Glava in vrat - (C00–C14,C30–C32)Head and neck
Želodec - (C16)Stomach
Mehur - (C67)Bladder
MOŠKI - MALES
G
ro
ba
 s
to
pn
ja
 n
a
10
0.
00
0
C
ru
de
 ra
te
 p
er
10
0,
00
0
0
10
20
30
40
50
60
70
80
90
100
110
G
ro
ba
 s
to
pn
ja
 n
a
10
0.
00
0
C
ru
de
 ra
te
 p
er
10
0,
00
0
19
50
19
56
19
62
19
68
19
74
19
80
19
86
19
92
19
98
20
04
20
07
19
53
19
59
19
65
19
71
19
77
19
83
19
89
19
95
20
01
Le
to
/ 
Ye
ar
Želodec - (C16)Stomach
Maternični vrat - (C53)Cervix uteri
Maternično telo - (C54)Corpus uteri
Debelo črevo in danka - (C18–C20)Colorectum
Koža, razen melanoma - (C44)Skin, non-melanoma
Koža, melanom - (C43)Skin, melanoma
Pljuča - (C33–C34)Lung
Dojka - (C50)Breast
ŽENSKE - FEMALES
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Koža, brez melanoma – moški
Skin, but melanoma – males
MKB 10/ICD 10: C44
Slika 6: Zemljevidi nemelanomskega kožnega raka pri moških po upravnih enotah; standardizirani količniki
incidence v 4 časovnih obdobjih, Slovenija1961–2007.
Figure 6: Maps of non-melanoma skin cancer in males by administrative units; standardised incidence ratio in
4 time periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
34
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Koža, brez melanoma – ženske
Skin, but melanoma – females
MKB 10/ICD 10: C44
Slika 7: Zemljevidi nemelanomskega kožnega raka pri ženskah po upravnih enotah; standardizirani količniki
incidence v 4 časovnih obdobjih, Slovenija1961–2007.
Figure 7: Maps of non-melanoma skin cancer in females by administrative units; standardised incidence ratio in
4 time periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
35
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Debelo črevo in danka – moški
Colon and rectum – males
MKB 10/ICD 10: C18–C20
Slika 8: Zemljevidi raka debelega črevesa in danke pri moških po upravnih enotah; standardizirani količniki
incidence v 4 časovnih obdobjih, Slovenija1961–2007.
Figure 8: Maps of colorectal cancer in males by administrative units; standardised incidence ratio in 4 time
periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
36
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Debelo črevo in danka – ženske
Colon and rectum – females
MKB 10/ICD 10: C18–C20
Slika 9: Zemljevidi raka debelega črevesa in danke pri ženskah po upravnih enotah ; standardizirani količniki
incidence v 4 časovnih obdobjih, Slovenija1961–2007.
Figure 9: Maps of colorectal cancer in females by administrative units; standardised incidence ratio in 4 time
periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
37
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Pljuča – moški
Lung – males
MKB 10/ICD 10: C33–C34
Slika 10: Zemljevidi pljučnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 10: Maps of lung cancer in males by administrative units; standardised incidence ratio in 4 time periods,
Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
38
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Pljuča – ženske
Lung – females
MKB 10/ICD 10: C33–C34
Slika 11: Zemljevidi pljučnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 11: Maps of lung cancer in females by administrative units; standardised incidence ratio in 4 time periods,
Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
39
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Prostata – moški
Prostate – males
MKB 10/ICD 10: C61
Slika 12: Zemljevidi raka prostate pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 12: Maps of prostate cancer in males by administrative units; standardised incidence ratio in 4 time periods,
Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
40
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Dojka – ženske
Breast – females
MKB 10/ICD 10: C50
Slika 13: Zemljevidi raka dojke pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 13: Maps of breast cancer in females by administrative units; standardised incidence ratio in 4 time periods,
Slovenia 1961–2007. 
1961–1972
1973–1984
1985–1996
1997–2007
41
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Želodec – moški
Stomach – males
MKB 10/ICD 10: C16
Slika 14: Zemljevidi želodčnega raka pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 14: Maps of stomach cancer in males by administrative units; standardised incidence ratio in 4 time periods,
Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
42
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Želodec – ženske
Stomach – females
MKB 10/ICD 10: C16
Slika 15: Zemljevidi želodčnega raka pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 15: Maps of stomach cancer in females by administrative units; standardised incidence ratio in 4 time
periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
43
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Koža, melanom – moški
Skin, melanoma – males
MKB 10/ICD 10: C43
Slika 16: Zemljevidi kožnega melanoma pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 16: Maps of skin melanoma in males by administrative units; standardised incidence ratio in 4 time periods,
Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
44
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Koža, melanom – ženske
Skin, melanoma – females
MKB 10/ICD 10: C43
Slika 17: Zemljevidi kožnega melanoma pri ženskah po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 17: Maps of skin melanoma in females by administrative units; standardised incidence ratio in 4 time
periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
45
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Glava in vrat – moški
Head and neck – males
MKB 10/ICD 10: C00–C14, C30-C32
Slika 18: Zemljevidi raka glave in vratu pri moških po upravnih enotah; standardizirani količniki incidence v 4 časovnih
obdobjih, Slovenija1961–2007.
Figure 18: Maps of head and neck cancer in males by administrative units; standardised incidence ratio in 4 time
periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
46
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Sečni mehur – moški
Bladder – males
MKB 10/ICD 10: C67
Slika 19: Zemljevidi raka sečnega mehurja pri moških po upravnih enotah; standardizirani količniki incidence v
4 časovnih obdobjih, Slovenija1961–2007.
Figure 19: Maps of bladder cancer in males by administrative units; standardised incidence ratio in 4 time periods,
Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
47
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
Maternično telo – ženske
Corpus uteri – females
MKB 10/ICD 10: C54
Slika 20: Zemljevidi raka materničnega telesa pri ženskah po upravnih enotah; standardizirani količniki incidence
v 4 časovnih obdobjih, Slovenija1961–2007.
Figure 20: Maps of uterine corpus cancer in females by administrative units; standardised incidence ratio in 4 time
periods, Slovenia 1961–2007. 
1961–1972
1973–1984
1985–1996
1997–2007
48
Maternični vrat – ženske
Cervix uteri – females
MKB 10/ICD 10: C53
Slika 21: Zemljevidi raka materničnega vratu pri ženskah po upravnih enotah; standardizirani količniki incidence
v 4 časovnih obdobjih, Slovenija1961–2007.
Figure 21: Maps of uterine cervix cancer in females by administrative units; standardised incidence ratio in 4 time
periods, Slovenia 1961–2007.
1961–1972
1973–1984
1985–1996
1997–2007
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
49
Šifra 
MKB
Primarna 
lokacija     Spol
Povprečne letne opazovane 
vrednosti 1998–2002
Povprečne letne opazovane 
vrednosti 2003–2007 Ocena za 2010
Število
Incidenčna 
stopnja na 
100.000
Število
Incidenčna 
stopnja na 
100.000
Število  
(95 % napovedni interval)
Incidenčna stopnja na 
100.000 
 (95 % napovedni interval)
ICD 
code
Primary 
site Sex
Average annual observed 
values 1998–2002
Average annual observed 
values 2003–2007 Estimation for 2010
Number Incidence rate per 100,000 Number
Incidence rate 
per 100,000
Number  
(95% prediction interval)
Incidence rate per 100,000 
(95% prediction interval)
C00–C96
Vse lokacije  
 
All sites    
Skupaj/Total 9687 467,3 11010 549,3 12685 12390–12981 621 607–636
Moški/Males 4765 492,8 5707 580,5 6683 6466–6900 661 639–682
Ženske/Females 4522 443,1 5303 519,2 6011 5508–6214 583 534–603
C00–C14
Usta in žrelo M 263 27,3 253 25,7 252 201–305 25 20–30
Mouth and pharynx Ž 55 5,4 64 6,5 74 52–97 7 5–9
C15    
Požiralnik M 74 7,7 76 7,7 80 56–105 8 6–10
Oesophagus Ž 19 1,8 16 1,5 16 5–26 2 0–3
C16    
Želodec M 293 30,3 290 29,5 277 143–410 27 14–41
Stomach Ž 188 18,5 180 17,7 166 73–266 16 7–26
C18    
Debelo črevo M 331 34,3 389 39,5 455 398–511 45 39–51
Colon Ž 276 27,0 327 32,0 373 322–424 36 31–41
C19–C20
Rektum in rektosigmoidna zveza M 285 29,5 338 34,4 389 337–442 38 33–44
Rectum and rectosigmoid junction Ž 207 20,3 236 23,1 262 219–305 25 21–30
C22    
Jetra in intrahepatični vodi M 83 8,6 103 10,5 134 104–164 13 10–16
Liver and intrahepatic bile ducts Ž 33 3,3 47 4,6 63 42–83 6 4–8
C23–C24
Žolčnik in žolčevodi M 49 5,0 56 5,6 65 43–87 6 4–9
Gallbladder and billiary tract Ž 83 8,1 89 8,7 105 77–134 10 7–13
C25    
Trebušna slinavka M 112 11,6 137 13,9 167 135–203 17 13–20
Pancreas Ž 119 11,7 142 13,9 165 131–198 16 13–19
C32    
Grlo M 104 10,7 96 9,7 94 68–121 9 7–12
Larynx Ž 11 1,1 11 1,0 13 3–23 1 0–2
C33–C34
Sapnik, sapnici in pljuča M 810 83,8 903 91,8 946 862–1029 93 85–102
Trachea, bronchus and lung Ž 239 23,4 305 29,9 383 333–433 37 32–42
C43    
Maligni melanom kože M 120 12,4 174 17,7 223 185–261 22 18–26
Malignant melanoma of skin Ž 138 13,5 194 19,0 252 213–292 24 21–28
C44    
Druge maligne neoplazme kože M 574 59,3 803 81,7 1042 958–1126 103 95–111
Skin, other malignomas Ž 634 62,1 888 87,0 1108 1018–1198 108 99–116
C48–C49
Vezivno in mehko tkivo M 26 2,7 27 2,8 33 17–49 3 2–5
Connective and soft tissue Ž 27 2,6 38 3,7 46 0–106 4 0–10
C50    
Dojka M 8 0,9 8 0,8 8 0–18 1 0–2
Breast Ž 990 97,1 1113 108,9 1218 1127–1310 118 109–127
C53    
Maternični vrat M – – – – – – – –
Cervix uteri Ž 202 19,8 181 17,7 156 124–188 15 12–18
C54    
Maternično telo M – – – – – – – –
Corpus uteri Ž 281 27,5 295 28,9 318 271–365 31 26–35
C56    
Jajčnik M – – – – – – – –
Ovary Ž 180 17,6 179 17,5 179 143–214 17 14–21
C61    
Prostata M 614 63,5 865 88,0 1184 1096–1272 117 108–126
Prostate Ž – – – – – – – –
C62    
Modo M 83 8,6 98 9,9 108 80–135 11 8–13
Testis Ž – – – – – – – –
C64–C65
Ledvica z ledvičnim mehom M 144 14,9 178 18,1 216 178–254 21 18–25
Kidney with renal pelvis Ž 82 8,0 102 10,0 113 85–140 11 8–14
C67    
Sečni mehur M 163 16,8 197 20,0 220 180–260 22 18–26
Bladder Ž 55 5,4 70 6,8 93 33–153 9 3–15
C70–C72
Centralni in avtonomni živčni sistem M 70 7,1 76 7,7 89 64–114 9 6–11
Central and autonomic nervous system Ž 54 5,4 63 6,2 70 48–92 7 5–9
C73    
Ščitnica M 24 2,4 28 2,8 38 4–72 4 0–7
Thyroid gland Ž 69 6,7 105 10,3 130 102–158 13 10–15
C81    
Hodgkinova bolezen M 19 2,0 29 2,9 42 24–59 4 2–6
Hodgkin's disease Ž 23 2,2 19 1,9 22 8–36 2 1–3
C82–C85
Ne-Hodgkinovi limfomi M 110 11,3 113 11,5 125 95–156 12 9–15
Non-Hodgkin's lymphoma Ž 112 11,0 137 13,4 152 119–184 15 12–18
C90    
Difuzni plazmocitom in maligne 
neoplazme plazmocitov M 36 3,7 53 5,4 67 46–88 7 5–9
Multiple myeloma and malignant 
plasma cell neoplasms Ž 47 4,6 55 5,4 60 40–81 6 4–8
C91–C95
Levkemije M 107 11,1 115 11,7 128 98–158 13 10–16
Leukaemias Ž 89 8,7 91 8,9 98 72–125 10 7–12
Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 1998–2007 in 2010.
Table 1: Observed and estimated cancer incidence, Slovenia 1998–2007 and 2010.
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
50
*SSS – starostno standardizirana incidenčna stopnja na 100.000
**ASR – age-standadised incidence rate per 100,000
Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji 
standardizirane incidenčne stopnje raka, Slovenija 2007.
Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard 
population standardised incidence cancer rates, Slovenia 2007.
Šifra MKB 
ICD code
Primarna lokacija 
Primary site
Spol 
Sex
Število 
Number
Groba incidenčna 
stopnja na 100.000 
Crude incidence rate 
per 100,000
SSS* – SVETOVNI 
STANDARD 
ASR** – WORLD 
STANDARD
SSS* – EVROPSKI 
STANDARD 
ASR** – EUROPEAN 
STANDARD
SSS* – SLOVENSKI 
STANDARD 
ASR** – SLOVENIAN 
STANDARD
C00–C96
Vse lokacije  
All sites
Skupaj/Total 11607 574,77 316,19 448,55 529,54
Moški/Males 6083 611,28 374,35 545,55 658,03
Ženske/Females 5524 539,31 277,82 386,19 448,14
C00–C14
Usta in žrelo M 256 25,73 16,41 22,70 25,64
Mouth and pharynx Ž 64 6,25 3,55 4,92 5,45
C15    
Požiralnik M 83 8,34 5,05 7,50 8,76
Oesophagus Ž 14 1,37 0,69 0,98 1,11
C16    
Želodec M 280 28,14 16,74 25,05 30,77
Stomach Ž 181 17,67 7,69 11,37 13,68
C18    
Debelo črevo M 431 43,31 25,59 38,49 47,67
Colon Ž 353 34,46 14,58 21,89 26,75
C19–C20
Rektum in rektosigmoidna zveza M 349 35,07 21,12 31,32 38,15
Rectum and rectosigmoid junction Ž 259 25,29 11,68 17,11 20,30
C22    
Jetra in intrahepatični vodi M 128 12,86 7,87 11,50 13,82
Liver and intrahepatic bile ducts Ž 49 4,78 2,36 3,31 3,78
C23–C24
Žolčnik in žolčevodi M 55 5,53 3,15 4,98 6,35
Gallbladder and billiary tract Ž 99 9,67 3,48 5,49 6,97
C25    
Trebušna slinavka M 154 15,48 9,18 13,57 16,34
Pancreas Ž 146 14,25 6,06 9,13 11,04
C32    
Grlo M 111 11,15 6,79 9,72 10,98
Larynx Ž 10 0,98 0,63 0,84 0,92
C33–C34
Sapnik, sapnici in pljuča M 882 88,63 53,90 79,08 93,96
Trachea, bronchus and lung Ž 341 33,29 16,39 23,70 27,44
C43    
Maligni melanom kože M 201 20,20 13,27 17,88 20,77
Malignant melanoma of skin Ž 236 23,04 15,27 19,27 21,57
C44    
Druge maligne neoplazme kože M 873 87,73 51,21 78,52 97,53
Skin, other malignomas Ž 935 91,28 39,28 58,27 70,56
C48–C49
Vezivno in mehko tkivo M 26 2,61 2,26 2,56 2,78
Connective and soft tissue Ž 40 3,91 2,52 3,21 3,51
C50    
Dojka M 6 0,60 0,34 0,51 0,65
Breast Ž 1147 111,98 63,86 87,07 98,51
C53    
Maternični vrat M – – – – –
Cervix uteri Ž 153 14,94 10,45 13,18 14,40
C54    
Maternično telo M – – – – –
Corpus uteri Ž 296 28,90 15,38 21,76 24,56
C56    
Jajčnik M – – – – –
Ovary Ž 174 16,99 9,72 13,20 15,07
C61    
Prostata M 1032 103,71 61,60 92,33 114,23
Prostate Ž – – – – –
C62    
Modo M 89 8,94 7,80 8,11 8,69
Testis Ž – – – – –
C64–C65
Ledvica z ledvičnim mehom M 197 19,80 12,60 17,62 20,24
Kidney with renal pelvis Ž 103 10,06 5,27 7,22 8,45
C67    
Sečni mehur M 202 20,30 11,75 18,03 22,69
Bladder Ž 76 7,42 3,12 4,75 5,78
C70–C72
Centralni in avtonomni živčni sistem M 81 8,14 6,21 7,53 8,22
Central and autonomic nervous system Ž 64 6,25 4,46 5,16 5,64
C73    
Ščitnica M 29 2,91 1,96 2,55 2,86
Thyroid gland Ž 105 10,25 7,53 9,06 9,84
C81    
Hodgkinova bolezen M 31 3,12 2,59 2,87 3,23
Hodgkin's disease Ž 17 1,66 1,72 1,70 1,78
C82–C85
Ne-Hodgkinovi limfomi M 118 11,86 7,58 10,66 12,74
Non-Hodgkin's lymphoma Ž 130 12,69 6,40 8,90 10,34
C90    
Difuzni plazmocitom in maligne 
neoplazme plazmocitov M 59 5,93 3,65 5,34 6,46
Multiple myeloma and malignant 
plasma cell neoplasms Ž 52 5,08 2,40 3,44 4,06
C91–C95
Levkemije M 127 12,76 8,46 11,73 13,94
Leukaemias Ž 99 9,67 6,76 7,56 7,89
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
51
Nadaljevanje   —>
Continued   —>
Tabela 3:  Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2007.
Table 3:  Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2007.
Šifra MKB* Primarna lokacija Spol
Število 
novih 
primerov
Mikroskopsko potrjeni 
primeri
Ugotovljeni z drugimi 
preiskavami
Registrirani samo iz 
zdravniških poročil  
o vzroku smrti
Število %** Število %** Število %**
ICD No.* Primary site Sex
Number 
of new 
cases
Microscopically 
confirmed cases
Confirmed by other 
investigations
Registered from death 
certificates only
Number %** Number %** Number %**
C00–C96
Vse lokacije
All sites
M+Ž 11607 10913 94,0 650 5,6 44 0,4
M 6083 5721 94,0 343 5,6 19 0,3
Ž 5524 5192 94,0 307 5,6 25 0,5
C00
Ustnica M 17 16 94,1 1 5,9 0 0
Lip Ž 9 8 – 0 – 1 –
C01
Baza jezika M 13 13 – 0 – 0 –
Base of tongue Ž 3 3 – 0 – 0 –
C02
Jezik, drugi deli M 30 30 100 0 0 0 0
Tongue, other & unspecified parts Ž 1 1 – 0 – 0 –
C03
Dlesen M 7 7 – 0 – 0 –
Gum Ž 3 3 – 0 – 0 –
C04
Ustno dno M 29 29 100 0 0 0 0
Floor of mouth Ž 12 12 – 0 – 0 –
C05
Nebo M 10 10 – 0 – 0 –
Palate Ž 6 6 – 0 – 0 –
C06
Usta, drugi deli M 8 8 – 0 – 0 –
Mouth, other & unspecified parts Ž 5 5 – 0 – 0 –
C07
Parotidna žleza M 6 6 – 0 – 0 –
Parotid gland Ž 4 3 – 1 – 0 –
C08
Druge in neopredeljene velike žleze slinavke M 1 1 – 0 – 0 –
Other & unspecified major salivary glands Ž 1 1 – 0 – 0 –
C09
Tonzila M 30  30 100 0 0 0 0
Tonsil Ž 9 9 – 0 – 0 –
C10
Orofarinks M 39 39 100 0 0 0 0
Oropharynx Ž 5 4 – 0 – 1 –
C11
Nazofarinks M 8 8 – 0 – 0 –
Nasopharynx Ž 3 3 – 0 – 0 –
C12
Piriformni sinus M 31 31 100 0 0 0 0
Pyriform sinus Ž 3 3 – 0 – 0 –
C13
Hipofarinks M 26 24 92,3 2 7,7 0 0
Hypopharynx Ž 0 0 – 0 – 0 –
C14
Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu M 1 0 – 0 – 1 –
Other and ill-defined sites in the lip, oral cavity and pharynx Ž 0 0 – 0 – 0 –
C15
Požiralnik M 83 76 91,6 7 8,4 0 0
Oesophagus Ž 14 13 – 1 – 0 –
C16
Želodec M 280 269 96,1 10 3,6 1 0,4
Stomach Ž 181 175 96,7 3 1,7 3 1,7
C17
Tanko črevo M 14 14 – 0 – 0 –
Small intestine Ž 9 9 – 0 – 0 –
C18
Debelo črevo M 431 422 97,9 9 2,1 0 0
Colon Ž 353 338 95,8 12 3,4 3 0,8
C19
Rektosigmoidna zveza M 79 79 100 0 0 0 0
Rectosigmoid junction Ž 66 65 98,5 1 1,5 0 0
C20
Rektum M 270 267 98,9 3 1,1 0 0
Rectum Ž 193 190 98,4 3 1,6 0 0
C21
Anus in analni kanal M 11 11 – 0 – 0 –
Anus and anal canal Ž 14 14 – 0 – 0 –
C22
Jetra in intrahepatični vodi M 128 75 58,6 52 40,6 1 0,8
Liver and intrahepatic bile ducts Ž 49 31 63,6 17 34,7 1 2,0
C23
Žolčnik M 16 9 56,3 7 43,8 0 0
Gallbladder Ž 45 27 60,0 17 37,8 1 2,2
C24
Drugi in neopredeljeni deli biliarnega trakta M 39 26 66,7 13 33,3 0 0
Billiary tract, other and unspecified parts Ž 54 23 42,6 31 57,4 0 0
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
52
Nadaljevanje   —>
Continued   —>
Tabela 3:  Nadaljevanje.
Table 3:  Continued.
Šifra MKB* Primarna lokacija Spol
Število 
novih 
primerov
Mikroskopsko potrjeni 
primeri
Ugotovljeni z drugimi 
preiskavami
Registrirani samo iz 
zdravniških poročil  
o vzroku smrti
Število %** Število %** Število %**
ICD No.* Primary site Sex
Number 
of new 
cases
Microscopically 
confirmed cases
Confirmed by other 
investigations
Registered from death 
certificates only
Number %** Number %** Number %**
C25
Trebušna slinavka M 154 100 64,9 53 34,4 1 0,6
Pancreas Ž 146 74 50,7 68 46,6 4 2,7
C26
Druga in slabo opredeljena mesta v prebavnih organih M 0 0 – 0 – 0 –
Other and ill-defined digestive organs Ž 3 2 – 1 – 0 –
C30
Nosna votlina in srednje uho M 9 9 – 0 – 0 –
Nasal cavity and middle ear Ž 4 4 – 0 – 0 –
C31
Obnosni sinusi M 9 9 – 0 – 0 –
Accessory sinuses Ž 2 2 – 0 – 0 –
C32
Grlo M 111 111 100 0 0 0 0
Larynx Ž 10 10 – 0 – 0 –
C33
Sapnik M 5 5 – 0 – 0 –
Trachea Ž 2 2 – 0 – 0 –
C34
Sapnica in pljuča M 877 800 91,2 71 8,1 6 0,7
Bronchus and lung Ž 339 312 92,0 26 7,7 1 0,3
C37
Timus M 2 2 – 0 – 0 –
Thymus Ž 1 1 – 0 – 0 –
C38
Srce, mediastinum, plevra M 4 4 – 0 – 0 –
Heart, mediastinum, pleura Ž 0 0 – 0 – 0 –
C39
Druga in slabo opredeljena mesta v dihalih in prsnih organih M 0 0 – 0 – 0 –
Other and ill-defined sites in the respiratory system and intrathoracic organs Ž 0 0 – 0 – 0 –
C40
Kosti, sklepni hrustanec udov M 3 3 – 0 – 0 –
Bone and articular cartilage of limbs Ž 3 3 – 0 – 0 –
C41
Kosti, sklepni hrustanec, drugje M 3 2 – 1 – 0 –
Bone and articular cartilage of other and unspecified parts Ž 4 4 – 0 – 0 –
C43
Maligni melanom kože M 201 201 100 0 0 0 0
Malignant melanoma of skin Ž 236 236 100 0 0 0 0
C44
Druge maligne neoplazme kože M 873 873 100 0 0 0 0
Skin, other malignomas Ž 935 930 99,5 4 0,4 1 0,1
C45
Mezoteliom M 26 25 96,2 1 3,8 0 0
Mesothelioma Ž 3 3 – 0 – 0 –
C46
Kaposijev sarkom M 2 2 – 0 – 0 –
Kaposi's sarcoma Ž 0 0 – 0 – 0 –
C47
Periferni živci in avtonomno živčevje M 5 5 – 0 – 0 –
Peripheral nerves and autonomic nervous system Ž 1 1 – 0 – 0 –
C48
Peritonej in retroperitonej M 7 7 – 0 – 0 –
Retroperitoneum and peritoneum Ž 20 20 100 0 0 0 0
C49
Drugo vezivno in mehko tkivo M 19 19 100 0 0 0 0
Other connective and soft tissue Ž 20 20 100 0 0 0 0
C50
Dojka M 6 5 – 1 – 0 –
Breast Ž 1147 1126 98,2 19 1,7 2 0,2
C51
Žensko zunanje spolovilo M – – – – – – –
Vulva Ž 53 52 98,1 1 1,9 0 0
C52
Nožnica M – – – – – – –
Vagina Ž 15 15 100 0 0 0 0
C53
Maternični vrat M – – – – – – –
Cervix uteri Ž 153 153 100 0 0 0 0
C54
Maternično telo M – – – – – – –
Corpus uteri Ž 296 295 99,7 1 0,3 0 0
C55
Maternica, neopredeljeno M – – – – – – –
Uterus, unspecified Ž 6 4 – 1 – 1 –
C56
Jajčnik M – – – – – – –
Ovary Ž 174 166 95,4 7 4,0 1 0,6
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
53
Nadaljevanje   —>
Continued   —>
Tabela 3:  Nadaljevanje.
Table 3:  Continued.
Šifra MKB* Primarna lokacija Spol
Število 
novih 
primerov
Mikroskopsko potrjeni 
primeri
Ugotovljeni z drugimi 
preiskavami
Registrirani samo iz 
zdravniških poročil  
o vzroku smrti
Število %** Število %** Število %**
ICD No.* Primary site Sex
Number 
of new 
cases
Microscopically 
confirmed cases
Confirmed by other 
investigations
Registered from death 
certificates only
Number %** Number %** Number %**
C57
Drugi in neopredeljeni ženski spolni organi M – – – – – – –
Other and unspecified parts of female genital organs Ž 14 14 – 0 – 0 –
C58
Posteljica M – – – – – – –
Placenta Ž 0 0 – 0 – 0 –
C60
Penis M 7 7 – 0 – 0 –
Penis Ž – – – – – – –
C61
Prostata M 1032 980 95,0 48 4,7 4 0,4
Prostate Ž – – – – – – –
C62
Modo M 89 89 100 0 0 0 0
Testis Ž – – – – – – –
C63
Drugi in neopredeljeni moški spolni organi M 1 1 – 0 – 0 –
Other and unspecified male genital organs Ž – – – – – – –
C64
Ledvica razen meha M 177 167 94,4 9 5,1 1 0,6
Kidney, except renal pelvis Ž 95 81 85,3 13 13,7 1 1,1
C65
Ledvični meh M 20 20 100 0 0 0 0
Renal pelvis Ž 8 7 – 1 – 0 –
C66
Sečevod M 6 6 – 0 – 0 –
Ureter Ž 4 4 – 0 – 0 –
C67
Sečni mehur M 202 192 95,0 10 5,0 0 0
Bladder Ž 76 73 96,1 3 3,9 0 0
C68
Drugi in neopredeljeni sečni organi M 3 3 – 0 – 0 –
Other and unspecified urinary organs Ž 1 1 – 0 – 0 –
C69
Oko in očesni adneksi M 7 6 – 1 – 0 –
Eye and adnexa Ž 9 8 – 1 – 0 –
C70
Meninge M 0 0 – 0 – 0 –
Meninges Ž 1 1 – 0 – 0 –
C71
Možgani M 81 75 92,6 4 4,9 2 2,5
Brain Ž 63 53 84,1 9 14,3 1 1,6
C72
Hrbtni mozeg, možganski živci in drugi deli CŽS M 0 0 – 0 – 0 –
Spinal cord, cranial nerves and other parts of CNS Ž 0 0 – 0 – 0 –
C73
Ščitnica M 29 29 100 0 0 0 0
Thyroid gland Ž 105 105 100 0 0 0 0
C74
Nadledvična žleza M 2 2 – 0 – 0 –
Adrenal gland Ž 6 4 – 2 – 0 –
C75
Druge endokrine žleze in sorodne strukture M 0 0 – 0 – 0 –
Other endocrine glands and related structures Ž 1 1 – 0 – 0 –
C76
Druga in slabo opredeljena mesta M 3 2 – 1 – 0 –
Other and ill-defined sites Ž 23 12 52,2 11 47,8 0 0
C77
Metastaza in neopredeljena maligna neoplazma bezgavk M 14 14 – 0 – 0 –
Metastasis and unspecified malignant neoplasm of lymph nodes Ž 19 19 100 0 0 0 0
C78
Metastaze dihal in prebavil M 37 19 51,4 17 45,9 1 2,7
Metastases of respiratory and digestive organs Ž 64 35 54,7 28 43,8 1 1,6
C79
Metastaze, drugje M 14 9 – 5 – 0 –
Metastases of other sites Ž 14 8 – 5 – 1 –
C80
Maligna neoplazma brez opredeljenega mesta M 48 30 62,5 17 35,4 1 2,1
Malignant neoplasm without specification of site Ž 42 21 50,0 20 47,6 1 2,4
C81
Hodgkinova bolezen M 31 31 100 0 0 0 0
Hodgkin's disease Ž 17 17 100 0 0 0 0
C82
Folikularni ne-Hodgkinov limfom M 26 26 100 0 0 0 0
Follicular non-Hodgkin's lymphoma Ž 34 34 100 0 0 0 0
C83
Difuzni ne-Hodgkinov limfom M 72 72 100 0 0 0 0
Diffuse non-Hodgkin's lymphoma Ž 76 76 100 0 0 0 0
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
54
Tabela 3:  Nadaljevanje.
Table 3:  Continued.
* MKB – Mednarodna klasifikacija bolezni, deseta revizija, 1995
* ICD – International Classification of Diseases, Tenth Revision, 1995
** Odstotki niso računani, če je število novih primerov manjše od 15
** Percentages are not calculated when number of new cases is less than 15
Šifra MKB* Primarna lokacija Spol
Število 
novih 
primerov
Mikroskopsko potrjeni 
primeri
Ugotovljeni z drugimi 
preiskavami
Registrirani samo iz 
zdravniških poročil  
o vzroku smrti
Število %** Število %** Število %**
ICD No.* Primary site Sex
Number 
of new 
cases
Microscopically 
confirmed cases
Confirmed by other 
investigations
Registered from death 
certificates only
Number %** Number %** Number %**
C84
Limfomi celic T in kožni limfom celic T M 11 11 – 0 – 0 –
Peripheral and cutaneous T-cell lymphomas Ž 9 9 – 0 – 0 –
C85
Druge in neopredeljene vrste ne-Hodgkinovega limfoma M 9 9 – 0 – 0 –
Other and unspecified types of non-Hodgkin's lymphoma Ž 11 11 – 0 – 0 –
C88
Maligne imunoproliferativne bolezni M 0 0 – 0 – 0 –
Malignant immunoproliferative diseases Ž 0 0 – 0 – 0 –
C90
Difuzni plazmocitom in maligne neoplazme plazmocitov M 59 59 100 0 0 0 0
Multiple myeloma and malignant plasma cell neoplasms Ž 52 52 100 0 0 0 0
C91.0
Limfatična levkemija, akutna M 9 9 – 0 – 0 –
Lymphoblastic leukaemia, acute Ž 11 11 – 0 – 0 –
C91.1–C91.9
Limfatična levkemija, druga M 54 54 100 0 0 0 0
Lymphoid leukaemia, other Ž 43 43 100 0 0 0 0
C92
Mieloična levkemija M 54 54 100 0 0 0 0
Myeloid leukaemia Ž 35 35 100 0 0 0 0
C93
Monocitna levkemija M 2 2 – 0 – 0 –
Monocytic leukaemia Ž 4 4 – 0 – 0 –
C94
Druge opredeljene levkemije M 0 0 – 0 – 0 –
Other leukaemias of specified cells Ž 1 1 – 0 – 0 –
C95
Levkemija z neopredeljenim celičnim tipom M 8 8 – 0 – 0 –
Leukaemia, unspecified cell type Ž 5 5 – 0 – 0 –
C96
Druge in neopredeljene maligne neoplazme limfatičnega, 
krvotvornega ali sorodnega tkiva M 53 53 100 0 0 0 0
Other and unspecified malignant neoplasms of lymphoid, 
haematopoietic and related tissue Ž 66 66 100 0 0 0 0
Zgoraj neupoštevani
Not included above
Šifra MKB* Primarna lokacija Spol
Število 
novih 
primerov
Mikroskopsko potrjeni 
primeri
Ugotovljeni z drugimi 
preiskavami
Registrirani samo iz 
zdravniških poročil  
o vzroku smrti
Število %** Število %** Število %**
ICD No.* Primary site Sex
Number 
of new 
cases
Microscopically 
confirmed cases
Confirmed by other 
investigations
Registered from death 
certificates only
Number %** Number %** Number %**
D03
Melanom, in situ M 54 54 100 0 0 0 0
Melanoma, in situ Ž 66 66 100 0 0 0 0
D05
Dojka, in situ M 0 0 – 0 – 0 –
Breast, in situ Ž 86 86 100 0 0 0 0
D06
Maternični vrat, CIN III M – – – – – – –
Cervix uteri, in situ Ž 1114 1114 100 0 0 0 0
D09.0
Sečni mehur, in situ M 129 129 100 0 0 0 0
Bladder, in situ Ž 41 41 100 0 0 0 0
D32.0
Meninge, benigna neoplazma M 14 14 – 0 – 0 –
Benign neoplasm of meninges Ž 53 49 92,5 4 7,5 0 0
D33.0–D33.2
Možgani, benigna neoplazma M 2 2 – 0 – 0 –
Benign neopasm of brain Ž 2 1 – 1 – 0 –
D39.1
Jajčnik, neopl. negotovega značaja M – – – – – – –
Ovary, neopl. of uncertain behavior Ž 38 38 100 0 0 0 0
D43.0–D43.2
Možgani, neopredeljeno M 6 1 – 5 –  0 –
CNS, uncertain or unknown Ž 7 1 – 5 – 1 –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
55
Nadaljevanje   —>
Continued   —>
Tabela 4:  Incidenca raka po lokaciji, spolu in starosti, Slovenija 2007.
Table 4:  Cancer incidence by site, by sex and by age, Slovenia 2007.
Šifra MKB Primarna lokacija Spol Vse starosti
Starosti
Age
ICD code Primary site Sex All ages 0 –5 –10 –15 –20 –25 –30 –35 –40 –45 –50 –55 –60 –65 –70 –75 80+
C00–C96
Vse lokacije
All sites
M+Ž 11607    20 9 14 22 56 82 122 214 314 561 948 1215 1320 1555 1820 1599 1736
M 6083 5 5 7 12 31 40 53 81 125 239 464 684 780 960 1053 898 646
Ž 5524 15 4 7 10 25 42 69 133 189 322 484 531 540 595 767 701 1090
C00
Ustnica M 17 0 0 0 0 0 0 0 0 0 0 3 1 1 4 3 3 2
Lip Ž 9 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 2 4
C01
Baza jezika M 13 0 0 0 0 0 0 0 0 1 3 2 1 2 2 1 1 0
Base of tongue Ž 3 0 0 0 0 0 0 0 0 1 0 0 2 0 0 0 0 0
C02
Jezik, drugi deli M 30 0 0 0 0 0 0 0 1 4 5 2 0 5 5 4 2 2
Tongue, other & unspecified parts Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
C03
Dlesen M 7 0 0 0 0 0 0 0 0 0 0 0 2 2 2 0 1 0
Gum Ž 3 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 0
C04
Ustno dno M 29 0 0 0 0 0 0 0 0 0 4 5 9 2 4 4 0 1
Floor of mouth Ž 12 0 0 0 0 0 0 0 0 1 1 3 2 2 0 3 0 0
C05
Nebo M 10 0 0 0 0 0 0 0 0 0 3 2 2 1 2 0 0 0
Palate Ž 6 0 0 0 0 0 1 0 1 0 0 0 1 1 0 1 1 0
C06
Usta, drugi deli M 8 0 0 0 0 0 0 0 0 0 2 2 0 1 1 0 1 1
Mouth, other & unspecified parts Ž 5 0 0 0 0 0 0 0 0 0 0 1 0 2 0 1 1 0
C07
Parotidna žleza M 6 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 2
Parotid gland Ž 4 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 0
C08
Druge in neopredeljene velike 
žleze slinavke M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
Other & unspecified major 
salivary glands Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
C09 Tonzila M 30 0 0 0 0 0 0 0 0 2 3 6 8 1 5 2 3 0Tonsil Ž 9 0 0 0 0 0 0 0 0 0 0 3 3 1 1 1 0 0
C10 Orofarinks M 39 0 0 0 0 0 0 0 0 3 6 9 8 4 1 4 3 1Oropharynx Ž 5 0 0 0 0 0 0 0 0 1 0 3 0 0 0 1 0 0
C11 Nazofarinks M 8 0 0 0 0 1 0 0 0 2 1 0 0 1 2 0 1 0Nasopharynx Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1
C12 Piriformni sinus M 31 0 0 0 0 0 0 0 0 0 3 9 5 7 3 3 1 0Pyriform sinus Ž 3 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0
C13 Hipofarinks M 26 0 0 0 0 0 0 0 0 2 1 5 7 1 4 4 1 1Hypopharynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C14
Druga in slabo opredeljena 
mesta na ustnici, v ustni votlini 
in farinksu
M 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
Other and ill-defined sites in the 
lip, oral cavity and pharynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C15 Požiralnik M 83 0 0 0 0 0 1 0 1 0 4 11 15 9 12 9 9 12Oesophagus Ž 14 0 0 0 0 0 0 0 0 0 0 2 1 4 1 1 1 4
C16 Želodec M 280 0 0 0 0 1 4 1 0 8 9 15 30 33 44 48 50 37Stomach Ž 181 0 0 0 1 0 0 1 3 3 7 11 15 12 19 30 25 54
C17 Tanko črevo M 14 0 0 0 0 0 0 0 0 0 0 3 3 2 3 3 0 0Small intestine Ž 9 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1 2 3
C18 Debelo črevo M 431 0 0 0 0 0 2 1 9 5 11 23 42 44 78 93 68 55Colon Ž 353 0 0 0 0 0 1 1 1 3 6 20 24 32 46 68 58 93
C19 Rektosigmoidna zveza M 79 0 0 0 0 0 0 0 1 1 3 5 9 8 12 14 16 10Rectosigmoid junction Ž 66 0 0 0 0 0 0 1 0 1 2 4 9 9 6 12 9 13
C20 Rektum M 270 0 0 0 0 0 0 1 3 2 12 22 24 48 40 50 40 28Rectum Ž 193 0 0 0 0 0 0 1 1 2 3 9 19 25 25 42 22 44
C21 Anus in analni kanal M 11 0 0 0 0 0 0 0 0 0 0 2 1 2 0 1 2 3Anus and anal canal Ž 14 0 0 0 0 0 0 0 0 0 1 0 1 1 2 4 1 4
C22 Jetra in intrahepatični vodi M 128 0 0 0 0 0 0 0 0 0 5 8 15 23 26 23 17 11Liver and intrahepatic bile ducts Ž 49 1 0 0 0 0 0 0 0 0 0 3 7 5 8 7 7 11
C23 Žolčnik M 16 0 0 0 0 0 0 0 0 0 0 0 1 2 2 5 5 1Gallbladder Ž 45 0 0 0 0 0 0 0 0 1 2 2 1 2 1 12 11 13
C24
Drugi in neopredeljeni deli 
biliarnega trakta M 39 0 0 0 0 0 0 0 0 0 2 1 3 5 3 9 6 10
Billiary tract, other and 
unspecified parts Ž 54 0 0 0 0 0 0 1 0 1 0 1 3 3 4 9 7 25
C25 Trebušna slinavka M 154 0 0 0 0 0 0 0 2 2 7 16 22 14 29 26 24 12Pancreas Ž 146 0 0 0 0 0 0 0 0 2 5 11 11 16 12 21 30 38
C26
Druga in slabo opredeljena mesta 
v prebavnih organih M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other and ill-defined digestive 
organs Ž 3 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
56
Nadaljevanje   —>
Continued   —>
Tabela 4:  Nadaljevanje.
Table 4:  Continued.
Šifra MKB Primarna lokacija Spol Vse starosti
Starosti
Age
ICD code Primary site Sex All ages 0 –5 –10 –15 –20 –25 –30 –35 –40 –45 –50 –55 –60 –65 –70 –75 80+
C30
Nosna votlina in srednje uho M 9 0 0 0 0 0 0 0 0 1 1 2 3 0 1 0 1 0
Nasal cavity and middle ear Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1
C31
Obnosni sinusi M 9 0 0 0 0 1 0 0 0 1 2 2 2 0 1 0 0 0
Accessory sinuses Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
C32
Grlo M 111 0 0 0 0 0 0 0 0 2 4 17 29 10 20 19 7 3
Larynx Ž 10 0 0 0 0 0 0 0 0 0 3 1 2 2 0 1 1 0
C33
Sapnik M 5 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 1 0
Trachea Ž 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0
C34
Sapnica in pljuča M 877 0 0 0 0 0 1 0 4 13 30 96 119 139 131 151 109 84
Bronchus and lung Ž 339 0 0 0 0 0 1 0 2 6 22 41 47 27 39 46 52 56
C37
Timus M 2 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0
Thymus Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
C38
Srce, mediastinum, plevra M 4 0 0 0 0 0 1 2 0 0 0 0 0 1 0 0 0 0
Heart, mediastinum, pleura Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C39
Druga in slabo opredeljena  
mesta v dihalih in prsnih organih M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other and ill-defined sites in 
the respiratory system and 
intrathoracic organs
Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C40
Kosti, sklepni hrustanec udov M 3 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0
Bone and articular cartilage 
of limbs Ž 3 0 0 0 1 0 0 0 0 0 2 0 0 0 0 0 0 0
C41
Kosti, sklepni hrustanec, drugje M 3 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0
Bone and articular cartilage of 
other and unspecified parts Ž 4 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0
C43 Maligni melanom kože M 201 0 0 0 0 4 3 8 12 12 16 25 19 19 31 27 16 9Malignant melanoma of skin Ž 236 0 0 0 1 2 12 9 26 19 28 23 22 19 22 17 18 18
C44 Druge maligne neoplazme kože M 873 0 0 0 0 0 4 2 13 9 25 43 85 102 129 156 166 139Skin, other malignomas Ž 935 0 0 1 0 3 0 9 11 20 35 59 56 79 96 128 162 276
C45 Mezoteliom M 26 0 0 0 0 0 0 0 0 0 0 2 8 1 8 4 1 2Mesothelioma Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1
C46 Kaposijev sarkom M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0Kaposi's sarcoma Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C47
Periferni živci in avtonomno 
živčevje M 5 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 1 0
Peripheral nerves and autonomic 
nervous system Ž 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
C48
Peritonej in retroperitonej M 7 0 0 0 0 0 1 1 1 1 1 0 0 1 1 0 0 0
Retroperitoneum and 
peritoneum Ž 20 0 0 0 0 0 0 0 0 0 1 2 5 2 3 4 3 0
C49 Drugo vezivno in mehko tkivo M 19 0 2 2 0 0 0 1 1 1 1 1 1 2 0 2 3 2Other connective and soft tissue Ž 20 0 1 0 0 2 1 0 0 2 1 4 2 1 1 2 1 2
C50 Dojka M 6 0 0 0 0 0 0 0 0 0 0 1 0 0 2 2 1 0Breast Ž 1147 0 0 0 0 0 5 15 41 71 104 126 141 141 129 134 100 140
C51 Žensko zunanje spolovilo M – – – – – – – – – – – – – – – – – –Vulva Ž 53 0 0 0 0 0 0 0 0 1 1 2 2 4 8 8 10 17
C52 Nožnica M – – – – – – – – – – – – – – – – – –Vagina Ž 15 0 0 0 0 0 0 0 0 2 1 0 2 2 2 2 0 4
C53 Maternični vrat M – – – – – – – – – – – – – – – – – –Cervix uteri Ž 153 0 0 0 0 0 4 18 14 20 21 25 14 9 7 8 7 6
C54 Maternično telo M – – – – – – – – – – – – – – – – – –Corpus uteri Ž 296 0 0 0 0 0 1 1 1 7 15 38 47 38 43 32 36 37
C55 Maternica, neopredeljeno M – – – – – – – – – – – – – – – – – –Uterus, unspecified Ž 6 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 3
C56 Jajčnik M – – – – – – – – – – – – – – – – – –Ovary Ž 174 0 0 0 0 1 2 1 7 7 14 25 16 23 17 26 17 18
C57
Drugi in neopredeljeni ženski 
spolni organi M – – – – – – – – – – – – – – – – – –
Other and unspecified parts of 
female genital organs Ž 14 0 0 0 0 0 0 0 0 1 2 1 3 2 3 1 1 0
C58 Posteljica M – – – – – – – – – – – – – – – – – –Placenta Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C60 Penis M 7 0 0 0 0 0 0 0 0 0 0 0 2 2 0 1 2 0Penis Ž – – – – – – – – – – – – – – – – – –
C61 Prostata M 1032 0 0 0 0 0 0 0 0 1 9 37 97 166 214 232 170 106Prostate Ž – – – – – – – – – – – – – – – – – –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
57
Nadaljevanje   —>
Continued   —>
Tabela 4:  Nadaljevanje.
Table 4:  Continued.
Šifra MKB Primarna lokacija Spol Vse starosti
Starosti
Age
ICD code Primary site Sex All ages 0 –5 –10 –15 –20 –25 –30 –35 –40 –45 –50 –55 –60 –65 –70 –75 80+
C62
Modo M 89 0 0 0 3 12 17 21 15 10 6 3 1 0 1 0 0 0
Testis Ž – – – – – – – – – – – – – – – – – –
C63
Drugi in neopredeljeni moški 
spolni organi M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
Other and unspecified male 
genital organs Ž – – – – – – – – – – – – – – – – – –
C64
Ledvica razen meha M 177 2 0 0 0 0 0 2 2 8 14 24 28 20 27 24 16 10
Kidney, except renal pelvis Ž 95 1 0 0 0 0 0 0 4 3 4 5 6 9 19 19 5 20
C65
Ledvični meh M 20 0 0 0 0 0 0 0 0 0 0 0 6 2 2 4 4 2
Renal pelvis Ž 8 0 0 0 0 0 0 0 0 0 1 2 1 0 1 1 1 1
C66
Sečevod M 6 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 2 1
Ureter Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3
C67
Sečni mehur M 202 0 0 0 0 0 0 0 1 1 5 7 15 31 30 40 47 25
Bladder Ž 76 0 0 0 0 0 0 0 0 0 5 7 8 2 7 14 16 17
C68
Drugi in neopredeljeni sečni 
organi M 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1
Other and unspecified urinary 
organs Ž 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
C69
Oko in očesni adneksi M 7 0 0 0 0 0 0 0 0 0 2 1 0 0 3 1 0 0
Eye and adnexa Ž 9 0 0 0 0 0 0 1 0 1 0 1 0 0 3 1 1 1
C70
Meninge M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Meninges Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
C71
Možgani M 81 1 1 2 1 4 2 3 3 7 6 8 11 9 7 9 4 3
Brain Ž 63 3 1 0 3 0 0 0 2 1 7 4 4 6 6 12 9 5
C72
Hrbtni mozeg, možganski živci in 
drugi deli CŽS M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Spinal cord, cranial nerves and 
other parts of CNS Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C73
Ščitnica M 29 0 0 0 0 1 0 1 2 5 3 4 4 2 3 1 3 0
Thyroid gland Ž 105 0 0 3 0 6 6 7 12 5 8 11 16 4 7 9 9 2
C74
Nadledvična žleza M 2 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Adrenal gland Ž 6 1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 2
C75
Druge endokrine žleze in sorodne 
strukture M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other endocrine glands and 
related structures Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
C76
Druga in slabo opredeljena mesta M 3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1
Other and ill-defined sites Ž 23 0 0 0 0 1 0 0 1 0 0 0 1 2 2 6 3 7
C77
Metastaza in neopredeljena 
maligna neoplazma bezgavk M 14 0 0 0 0 1 0 0 0 0 1 0 5 2 1 0 3 1
Metastasis and unspecified 
malignant neoplasm of lymph 
nodes
Ž 19 0 0 0 0 0 0 0 0 2 0 2 3 3 1 3 2 3
C78
Metastaze dihal in prebavil M 37 0 0 0 0 0 0 0 0 0 2 3 5 2 1 6 9 9
Metastases of respiratory and 
digestive organs Ž 64 0 0 0 0 0 0 0 0 0 0 2 2 1 3 12 11 33
C79
Metastaze, drugje M 14 0 0 0 0 0 0 0 0 1 0 0 2 2 2 2 3 2
Metastases of other sites Ž 14 0 0 0 0 0 0 0 0 0 0 1 0 0 2 3 5 3
C80
Maligna neoplazma brez 
opredeljenega mesta M 48 0 0 0 0 0 0 0 0 1 4 2 4 7 5 8 11 6
Malignant neoplasm without 
specification of site Ž 42 0 0 0 0 0 0 0 0 0 1 4 2 3 2 11 6 13
C81
Hodgkinova bolezen M 31 0 0 0 5 2 2 1 3 2 3 2 1 2 2 1 5 0
Hodgkin's disease Ž 17 0 0 1 0 7 2 0 1 0 0 1 2 1 2 0 0 0
C82
Folikularni ne-Hodgkinov 
limfom M 26 0 0 0 0 0 0 2 1 5 1 4 3 6 1 1 0 2
Follicular non-Hodgkin's 
lymphoma Ž 34 0 0 0 0 0 0 0 1 0 5 4 6 5 2 4 4 3
C83
Difuzni ne-Hodgkinov limfom M 72 0 0 0 1 1 0 0 3 2 5 6 6 3 10 14 14 7
Diffuse non-Hodgkin's lymphoma Ž 76 0 0 0 2 0 1 0 0 1 3 1 7 8 9 14 8 22
C84
Limfomi celic T in kožni limfom 
celic T M 11 0 0 0 0 1 1 0 0 3 0 0 2 0 1 0 2 1
Peripheral and cutaneous T-cell 
lymphomas Ž 9 0 0 1 0 0 0 0 0 0 0 1 1 2 2 0 2 0
C85
Druge in neopredeljene vrste 
ne-Hodgkinovega limfoma M 9 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 5
Other and unspecified types of 
non-Hodgkin's lymphoma Ž 11 0 0 0 0 0 0 0 0 0 0 1 0 2 0 0 3 5
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
58
Tabela 4:  Nadaljevanje.
Table 4:  Continued.
Šifra MKB Primarna lokacija Spol Vse starosti
Starosti
Age
ICD code Primary site Sex All ages 0 –5 –10 –15 –20 –25 –30 –35 –40 –45 –50 –55 –60 –65 –70 –75 80+
C88
Maligne imunoproliferativne 
bolezni M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Malignant immunoproliferative 
diseases Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C90
Difuzni plazmocitom in maligne 
neoplazme plazmocitov M 59 0 0 0 0 0 0 0 0 1 4 6 4 7 14 9 6 8
Multiple myeloma and malignant 
plasma cell neoplasms Ž 52 0 0 0 0 0 0 1 0 0 3 4 1 11 4 7 5 16
C91.0 Limfatična levkemija, akutna M 9 0 1 3 1 0 0 2 0 0 0 0 1 0 0 0 1 0Lymphoblastic leukaemia, acute Ž 11 5 1 0 0 0 1 0 0 0 0 1 0 0 2 0 0 1
C91.1–91.9 Limfatična levkemija, druga M 54 0 0 0 0 0 0 0 0 0 2 6 6 6 12 11 4 7Lymphoid leukaemia, other Ž 43 0 0 0 0 0 0 0 0 0 0 3 2 2 6 11 5 14
C92 Mieloična levkemija M 54 0 1 0 1 0 1 0 1 2 3 4 4 5 4 8 11 9Myeloid leukaemia Ž 35 3 0 0 2 1 0 0 2 1 0 1 3 4 4 1 6 7
C93 Monocitna levkemija M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1Monocytic leukaemia Ž 4 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1
C94
Druge opredeljene levkemije M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other leukaemias of specified 
cells Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
C95
Levkemija z neopredeljenim 
celičnim tipom M 8 0 0 0 0 0 0 0 0 0 2 1 0 1 1 0 2 1
Leukaemia, unspecified cell type Ž 5 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 2
C96
Druge in neopredeljene maligne 
neoplazme limfatičnega, 
krvotvornega ali sorodnega tkiva
M 53 0 0 0 0 1 0 2 1 2 1 1 0 5 8 9 13 10
Other and unspecified malignant 
neoplasms of lymphoid, 
haematopoietic and related 
tissue
Ž 66 0 0 0 0 2 2 2 1 1 6 3 3 4 5 7 10 20
Zgoraj neupoštevani
Not included above
Šifra MKB Primarna lokacija Spol Vse starosti
Starosti
Age
ICD code Primary site Sex All ages 0 –5 –10 –15 –20 –25 –30 –35 –40 –45 –50 –55 –60 –65 –70 –75 80+
D03 Melanom, in situ M 54 0 0 0 0 0 2 5 4 0 6 5 7 6 6 6 6 1Melanoma, in situ Ž 66 0 0 0 0 2 3 4 6 9 6 5 3 7 6 7 7 1
D05 Dojka, in situ M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0Breast, in situ Ž 86 0 0 0 0 0 0 0 1 4 10 27 18 5 13 6 1 1
D06 Maternični vrat, CIN III M – – – – – – – – – – – – – – – – – –Cervix uteri, in situ Ž 1114 0 0 0 4 74 260 258 184 128 99 39 27 21 8 8 1 3
D09.0 Sečni mehur, in situ M 129 0 0 0 0 0 0 1 0 2 6 9 13 19 23 24 22 10Bladder, in situ Ž 41 0 0 0 0 0 0 0 1 0 2 2 10 3 8 4 6 5
D32.0 Meninge, benigna neoplazma M 14 0 0 0 0 0 0 1 0 0 0 1 2 1 1 1 2 5Benign neoplasm of meninges Ž 53 0 0 0 0 0 1 0 4 2 7 3 6 5 6 7 6 6
D33.0–33.2 Možgani, benigna neoplazma M 2 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0Benign neopasm of brain Ž 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1
D39.1
Jajčnik, neopl. negotovega 
značaja M – – – – – – – – – – – – – – – – – –
Ovary, neopl. of uncertain 
behavior Ž 38 0 0 0 0 1 2 2 2 6 8 2 3 2 3 5 1 1
D43.0–43.2 Možgani, neopredeljeno M 6 0 0 0 0 1 0 0 0 0 0 0 0 0 0 3 0 2CNS, uncertain or unknown Ž 7 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 3
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
59
Nadaljevanje   —>
Continued   —>
Tabela 5:  Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) 
po lokaciji in spolu, Slovenija 2007.
Table 5:  Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, 
Slovenia 2007.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti
Starost
Age
KS
CR
ICD 
code Primary site Sex
All 
ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80+ 0–74
C00–
C96
Vse lokacije
All sites
M+Ž 574,8 21,7 9,9 14,2 18,8 41,3 53,3 80,3 146,9 199,3 363,3 597,6 880,0 1294,7 1592,5 2120,0 2283,8 2478,2 37,2
M 611,3 10,6 10,7 13,9 19,9 44,0 49,7 67,0 107,9 155,7 303,2 567,5 978,0 1590,4 2134,6 2923,4 3482,1 3501,0 44,9
Ž 539,3 33,5 9,1 14,6 17,7 38,4 57,2 94,8 188,2 244,5 426,0 629,6 779,4 1020,6 1129,6 1539,3 1585,0 2112,4 31,1
C00
Ustnica M 1,7 0 0 0 0 0 0 0 0 0 0 3,7 1,4 2,0 8,9 8,3 11,6 10,8 0,1
Lip Ž 0,9 0 0 0 0 0 0 0 1,4 0 0 0 1,5 1,9 0 0 4,5 7,8 0,0
C01
Baza jezika M 1,3 0 0 0 0 0 0 0 0 1,2 3,8 2,4 1,4 4,1 4,4 2,8 3,9 0 0,1
Base of tongue Ž 0,3 0 0 0 0 0 0 0 0 1,3 0 0 2,9 0 0 0 0 0 0,0
C02
Jezik, drugi deli M 3,0 0 0 0 0 0 0 0 1,3 5,0 6,3 2,4 0 10,2 11,1 11,1 7,8 10,8 0,2
Tongue, other & 
unspecified parts Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0 0 0 0,0
C03
Dlesen M 0,7 0 0 0 0 0 0 0 0 0 0 0 2,9 4,1 4,4 0 3,9 0 0,1
Gum Ž 0,3 0 0 0 0 0 0 0 0 0 0 1,3 0 0 1,9 0 2,3 0 0,0
C04
Ustno dno M 2,9 0 0 0 0 0 0 0 0 0 5,1 6,1 12,9 4,1 8,9 11,1 0 5,4 0,2
Floor of mouth Ž 1,2 0 0 0 0 0 0 0 0 1,3 1,3 3,9 2,9 3,8 0 6,0 0 0 0,1
C05
Nebo M 1,0 0 0 0 0 0 0 0 0 0 3,8 2,4 2,9 2,0 4,4 0 0 0 0,1
Palate Ž 0,6 0 0 0 0 0 1,4 0 1,4 0 0 0 1,5 1,9 0 2,0 2,3 0 0,0
C06
Usta, drugi deli M 0,8 0 0 0 0 0 0 0 0 0 2,5 2,4 0 2,0 2,2 0 3,9 5,4 0,0
Mouth, other & 
unspecified parts Ž 0,5 0 0 0 0 0 0 0 0 0 0 1,3 0 3,8 0 2,0 2,3 0 0,0
C07
Parotidna žleza M 0,6 0 0 0 0 0 0 0 0 0 0 1,2 0 2,0 2,2 0 3,9 10,8 0,0
Parotid gland Ž 0,4 0 0 0 0 0 0 0 0 1,3 1,3 0 0 0 1,9 0 2,3 0 0,0
C08
Druge in neopredeljene 
velike žleze slinavke M 0,1 0 0 0 0 0 0 0 0 0 0 1,2 0 0 0 0 0 0 0,0
Other & unspecified 
major salivary glands Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0,0
C09
Tonzila M 3,0 0 0 0 0 0 0 0 0 2,5 3,8 7,3 11,4 2,0 11,1 5,6 11,6 0 0,2
Tonsil Ž 0,9 0 0 0 0 0 0 0 0 0 0 3,9 4,4 1,9 1,9 2,0 0 0 0,1
C10
Orofarinks M 3,9 0 0 0 0 0 0 0 0 3,7 7,6 11,0 11,4 8,2 2,2 11,1 11,6 5,4 0,3
Oropharynx Ž 0,5 0 0 0 0 0 0 0 0 1,3 0 3,9 0 0 0 2,0 0 0 0,0
C11
Nazofarinks M 0,8 0 0 0 0 1,4 0 0 0 2,5 1,3 0 0 2,0 4,4 0 3,9 0 0,1
Nasopharynx Ž 0,3 0 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0 2,3 1,9 0,0
C12
Piriformni sinus M 3,1 0 0 0 0 0 0 0 0 0 3,8 11,0 7,1 14,3 6,7 8,3 3,9 0 0,3
Pyriform sinus Ž 0,3 0 0 0 0 0 0 0 0 0 0 2,6 1,5 0 0 0 0 0 0,0
C13
Hipofarinks M 2,6 0 0 0 0 0 0 0 0 2,5 1,3 6,1 10,0 2,0 8,9 11,1 3,9 5,4 0,2
Hypopharynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C14
Druga in slabo opredeljena 
mesta na ustnici, v ustni 
votlini in farinksu
M 0,1 0 0 0 0 0 0 0 0 0 0 0 0 2,0 0 0 0 0 0,0
Other and ill-defined 
sites in the lip, oral 
cavity and pharynx
Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C15
Požiralnik M 8,3 0 0 0 0 0 1,2 0 1,3 0 5,1 13,5 21,4 18,4 26,7 25,0 34,9 65,0 0,6
Oesophagus Ž 1,4 0 0 0 0 0 0 0 0 0 0 2,6 1,5 7,6 1,9 2,0 2,3 7,8 0,1
C16
Želodec M 28,1 0 0 0 0 1,4 5,0 1,3 0 10,0 11,4 18,3 42,9 67,3 97,8 133,3 193,9 200,5 1,9
Stomach Ž 17,7 0 0 0 1,8 0 0 1,4 4,2 3,9 9,3 14,3 22,0 22,7 36,1 60,2 56,5 104,7 0,9
C17
Tanko črevo M 1,4 0 0 0 0 0 0 0 0 0 0 3,7 4,3 4,1 6,7 8,3 0 0 0,1
Small intestine Ž 0,9 0 0 0 0 0 1,4 0 0 0 0 0 0 1,9 1,9 2,0 4,5 5,8 0,0
C18
Debelo črevo M 43,3 0 0 0 0 0 2,5 1,3 12,0 6,2 14,0 28,1 60,1 89,7 173,4 258,2 263,7 298,1 3,2
Colon Ž 34,5 0 0 0 0 0 1,4 1,4 1,4 3,9 7,9 26,0 35,2 60,5 87,3 136,5 131,1 180,2 1,8
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
60
Nadaljevanje   —>
Continued   —>
Tabela 5:  Nadaljevanje.
Table 5:  Continued.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti
Starost
Age
KS
CR
ICD 
code Primary site Sex
All 
ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80+ 0–74
C19
Rektosigmoidna zveza M 7,9 0 0 0 0 0 0 0 1,3 1,2 3,8 6,1 12,9 16,3 26,7 38,9 62,0 54,2 0,5
Rectosigmoid junction Ž 6,4 0 0 0 0 0 0 1,4 0 1,3 2,6 5,2 13,2 17,0 11,4 24,1 20,3 25,2 0,4
C20
Rektum M 27,1 0 0 0 0 0 0 1,3 4,0 2,5 15,2 26,9 34,3 97,9 88,9 138,8 155,1 151,7 2,0
Rectum Ž 18,8 0 0 0 0 0 0 1,4 1,4 2,6 4,0 11,7 27,9 47,3 47,5 84,3 49,7 85,3 1,1
C21
Anus in analni kanal M 1,1 0 0 0 0 0 0 0 0 0 0 2,4 1,4 4,1 0 2,8 7,8 16,3 0,1
Anus and anal canal Ž 1,4 0 0 0 0 0 0 0 0 0 1,3 0 1,5 1,9 3,8 8,0 2,3 7,8 0,1
C22
Jetra in intrahepatični 
vodi M 12,9 0 0 0 0 0 0 0 0 0 6,3 9,8 21,4 46,9 57,8 63,9 65,9 59,6 1,0
Liver and intrahepatic 
bile ducts Ž 4,8 2,2 0 0 0 0 0 0 0 0 0 3,9 10,3 9,5 15,2 14,0 15,8 21,3 0,3
C23
Žolčnik M 1,6 0 0 0 0 0 0 0 0 0 0 0 1,4 4,1 4,4 13,9 19,4 5,4 0,1
Gallbladder Ž 4,4 0 0 0 0 0 0 0 0 1,3 2,6 2,6 1,5 3,8 1,9 24,1 24,9 25,2 0,2
C24
Drugi in neopredeljeni 
deli biliarnega trakta M 3,9 0 0 0 0 0 0 0 0 0 2,5 1,2 4,3 10,2 6,7 25,0 23,3 54,2 0,2
Billiary tract, other and 
unspecified parts Ž 5,3 0 0 0 0 0 0 1,4 0 1,3 0 1,3 4,4 5,7 7,6 18,1 15,8 48,5 0,2
C25
Trebušna slinavka M 15,5 0 0 0 0 0 0 0 2,7 2,5 8,9 19,6 31,5 28,5 64,5 72,2 93,1 65,0 1,2
Pancreas Ž 14,3 0 0 0 0 0 0 0 0 2,6 6,6 14,3 16,1 30,2 22,8 42,1 67,8 73,6 0,7
C26
Druga in slabo 
opredeljena mesta v 
prebavnih organih
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Other and ill-defined 
digestive organs Ž 0,3 0 0 0 0 0 0 0 0 0 1,3 0 0 0 0 2,0 0 1,9 0,0
C30
Nosna votlina in srednje 
uho M 0,9 0 0 0 0 0 0 0 0 1,2 1,3 2,4 4,3 0 2,2 0 3,9 0 0,1
Nasal cavity and middle 
ear Ž 0,4 0 0 0 0 0 0 0 0 0 0 0 0 1,9 1,9 2,0 0 1,9 0,0
C31
Obnosni sinusi M 0,9 0 0 0 0 1,4 0 0 0 1,2 2,5 2,4 2,9 0 2,2 0 0 0 0,1
Accessory sinuses Ž 0,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,3 1,9 0,0
C32
Grlo M 11,2 0 0 0 0 0 0 0 0 2,5 5,1 20,8 41,5 20,4 44,5 52,7 27,1 16,3 0,9
Larynx Ž 1,0 0 0 0 0 0 0 0 0 0 4,0 1,3 2,9 3,8 0 2,0 2,3 0 0,1
C33
Sapnik M 0,5 0 0 0 0 0 0 0 0 0 1,3 0 1,4 2,0 0 2,8 3,9 0 0,0
Trachea Ž 0,2 0 0 0 0 0 0 0 0 0 0 0 1,5 0 0 2,0 0 0 0,0
C34
Sapnica in pljuča M 88,1 0 0 0 0 0 1,2 0 5,3 16,2 38,1 117,4 170,1 283,4 291,3 419,2 422,7 455,2 6,7
Bronchus and lung Ž 33,1 0 0 0 0 0 1,4 0 2,8 7,8 29,1 53,3 69,0 51,0 74,0 92,3 117,6 108,5 1,9
C37
Timus M 0,2 0 0 0 0 0 0 0 0 0 0 0 1,4 2,0 0 0 0 0 0,0
Thymus Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0 0 0 0,0
C38
Srce, mediastinum, 
plevra M 0,4 0 0 0 0 0 1,2 2,5 0 0 0 0 0 2,0 0 0 0 0 0,0
Heart, mediastinum, 
pleura Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C39
Druga in slabo 
opredeljena mesta 
v dihalih in prsnih 
organih
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Other and ill-defined 
sites in the respiratory 
system and 
intrathoracic organs
Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C40
Kosti, sklepni hrustanec 
udov M 0,3 0 0 0 0 1,4 0 0 1,3 0 0 0 0 0 2,2 0 0 0 0,0
Bone and articular 
cartilage of limbs Ž 0,3 0 0 0 1,8 0 0 0 0 0 2,6 0 0 0 0 0 0 0 0,0
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
61
Nadaljevanje   —>
Continued   —>
Tabela 5:  Nadaljevanje.
Table 5:  Continued.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti
Starost
Age
KS
CR
ICD 
code Primary site Sex
All 
ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80+ 0–74
C41
Kosti, sklepni hrustanec, 
drugje M 0,3 0 0 0 0 0 0 1,3 0 0 0 0 1,4 0 0 0 3,9 0 0,0
Bone and articular 
cartilage of other and 
unspecified parts
Ž 0,4 0 2,3 2,1 0 0 1,4 0 0 0 0 0 0 0 0 0 2,3 0 0,0
C43
Maligni melanom kože M 20,2 0 0 0 0 5,7 3,7 10,1 16,0 15,0 20,3 30,6 27,2 38,7 68,9 75,0 62,0 48,8 1,6
Malignant melanoma 
of skin Ž 23,0 0 0 0 1,8 3,1 16,3 12,4 36,8 24,6 37,0 29,9 32,3 35,9 41,8 34,1 40,7 34,9 1,5
C44
Druge maligne 
neoplazme kože M 87,7 0 0 0 0 0 5,0 2,5 17,3 11,2 31,7 52,6 121,5 208,0 286,8 433,1 643,7 753,3 5,8
Skin, other malignomas Ž 91,3 0 0 2,1 0 4,6 0 12,4 15,6 25,9 46,3 76,7 82,2 149,3 182,3 256,9 366,3 534,9 4,3
C45
Mezoteliom M 2,6 0 0 0 0 0 0 0 0 0 0 2,4 11,4 2,0 17,8 11,1 3,9 10,8 0,2
Mesothelioma Ž 0,3 0 0 0 0 0 0 0 0 0 0 0 0 0 1,9 2,0 0 1,9 0,0
C46
Kaposijev sarkom M 0,2 0 0 0 0 0 0 0 0 0 0 0 0 2,0 0 2,8 0 0 0,0
Kaposi's sarcoma Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C47
Periferni živci in 
avtonomno živčevje M 0,5 0 0 0 0 0 0 1,3 0 1,2 1,3 1,2 0 0 0 0 3,9 0 0,0
Peripheral nerves and 
autonomic nervous 
system
Ž 0,1 0 0 0 0 0 0 0 0 1,3 0 0 0 0 0 0 0 0 0,0
C48
Peritonej in 
retroperitonej M 0,7 0 0 0 0 0 1,2 1,3 1,3 1,2 1,3 0 0 2,0 2,2 0 0 0 0,1
Retroperitoneum and 
peritoneum Ž 2,0 0 0 0 0 0 0 0 0 0 1,3 2,6 7,3 3,8 5,7 8,0 6,8 0 0,1
C49
Drugo vezivno in mehko 
tkivo M 1,9 0 4,3 4,0 0 0 0 1,3 1,3 1,2 1,3 1,2 1,4 4,1 0 5,6 11,6 10,8 0,1
Other connective and 
soft tissue Ž 2,0 0 2,3 0 0 3,1 1,4 0 0 2,6 1,3 5,2 2,9 1,9 1,9 4,0 2,3 3,9 0,1
C50
Dojka M 0,6 0 0 0 0 0 0 0 0 0 0 1,2 0 0 4,4 5,6 3,9 0 0,1
Breast Ž 112,0 0 0 0 0 0 6,8 20,6 58,0 91,8 137,6 163,9 207,0 266,5 244,9 268,9 226,1 271,3 7,3
C51
Žensko zunanje 
spolovilo M – – – – – – – – – – – – – – – – – – –
Vulva Ž 5,2 0 0 0 0 0 0 0 0 1,3 1,3 2,6 2,9 7,6 15,2 16,1 22,6 32,9 0,2
C52
Nožnica M – – – – – – – – – – – – – – – – – – –
Vagina Ž 1,5 0 0 0 0 0 0 0 0 2,6 1,3 0 2,9 3,8 3,8 4,0 0 7,8 0,1
C53
Maternični vrat M – – – – – – – – – – – – – – – – – – –
Cervix uteri Ž 14,9 0 0 0 0 0 5,4 24,7 19,8 25,9 27,8 32,5 20,5 17,0 13,3 16,1 15,8 11,6 1,0
C54
Maternično telo M – – – – – – – – – – – – – – – – – – –
Corpus uteri Ž 28,9 0 0 0 0 0 1,4 1,4 1,4 9,1 19,8 49,4 69,0 71,8 81,6 64,2 81,4 71,7 1,8
C55
Maternica, 
neopredeljeno M – – – – – – – – – – – – – – – – – – –
Uterus, unspecified Ž 0,6 0 0 0 0 0 0 0 0 0 0 0 1,5 0 1,9 2,0 0 5,8 0,0
C56
Jajčnik M – – – – – – – – – – – – – – – – – – –
Ovary Ž 17,0 0 0 0 0 1,5 2,7 1,4 9,9 9,1 18,5 32,5 23,5 43,5 32,3 52,2 38,4 34,9 1,1
C57
Drugi in neopredeljeni 
ženski spolni organi M – – – – – – – – – – – – – – – – – – –
Other and unspecified 
parts of female genital 
organs
Ž 1,4 0 0 0 0 0 0 0 0 1,3 2,6 1,3 4,4 3,8 5,7 2,0 2,3 0 0,1
C58
Posteljica M – – – – – – – – – – – – – – – – – – –
Placenta Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C60
Penis M 0,7 0 0 0 0 0 0 0 0 0 0 0 2,9 4,1 0 2,8 7,8 0 0,0
Penis Ž – – – – – – – – – – – – – – – – – – –
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
62
Nadaljevanje   —>
Continued   —>
Tabela 5:  Nadaljevanje.
Table 5:  Continued.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti
Starost
Age
KS
CR
ICD 
code Primary site Sex
All 
ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80+ 0–74
C61
Prostata M 103,7 0 0 0 0 0 0 0 0 1,2 11,4 45,3 138,7 338,5 475,8 644,1 659,2 574,5 8,3
Prostate Ž – – – – – – – – – – – – – – – – – – –
C62
Modo M 8,9 0 0 0 5,0 17,0 21,1 26,6 20,0 12,5 7,6 3,7 1,4 0 2,2 0 0 0 0,6
Testis Ž – – – – – – – – – – – – – – – – – – –
C63
Drugi in neopredeljeni 
moški spolni organi M 0,1 0 0 0 0 0 0 0 0 0 0 1,2 0 0 0 0 0 0 0,0
Other and unspecified 
male genital organs Ž – – – – – – – – – – – – – – – – – – –
C64
Ledvica razen meha M 17,8 4,2 0 0 0 0 0 2,5 2,7 10,0 17,8 29,4 40,0 40,8 60,0 66,6 62,0 54,2 1,4
Kidney, except renal 
pelvis Ž 9,3 2,2 0 0 0 0 0 0 5,7 3,9 5,3 6,5 8,8 17,0 36,1 38,1 11,3 38,8 0,6
C65
Ledvični meh M 2,0 0 0 0 0 0 0 0 0 0 0 0 8,6 4,1 4,4 11,1 15,5 10,8 0,1
Renal pelvis Ž 0,8 0 0 0 0 0 0 0 0 0 1,3 2,6 1,5 0 1,9 2,0 2,3 1,9 0,0
C66
Sečevod M 0,6 0 0 0 0 0 0 0 0 0 0 1,2 0 2,0 2,2 0 7,8 5,4 0,0
Ureter Ž 0,4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2,0 0 5,8 0,0
C67
Sečni mehur M 20,3 0 0 0 0 0 0 0 1,3 1,2 6,3 8,6 21,4 63,2 66,7 111,0 182,2 135,5 1,4
Bladder Ž 7,4 0 0 0 0 0 0 0 0 0 6,6 9,1 11,7 3,8 13,3 28,1 36,2 32,9 0,4
C68
Drugi in neopredeljeni 
sečni organi M 0,3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5,6 0 5,4 0,0
Other and unspecified 
urinary organs Ž 0,1 0 0 0 0 0 0 0 0 0 0 1,3 0 0 0 0 0 0 0,0
C69
Oko in očesni adneksi M 0,7 0 0 0 0 0 0 0 0 0 2,5 1,2 0 0 6,7 2,8 0 0 0,1
Eye and adnexa Ž 0,9 0 0 0 0 0 0 1,4 0 1,3 0 1,3 0 0 5,7 2,0 2,3 1,9 0,1
C70
Meninge M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Meninges Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0 0 0 0 0,0
C71
Možgani M 8,1 2,1 2,1 4,0 1,7 5,7 2,5 3,8 4,0 8,7 7,6 9,8 15,7 18,4 15,6 25,0 15,5 16,3 0,6
Brain Ž 6,2 6,7 2,3 0 5,3 0 0 0 2,8 1,3 9,3 5,2 5,9 11,3 11,4 24,1 20,3 9,7 0,4
C72
Hrbtni mozeg, 
možganski živci in drugi 
deli CŽS
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Spinal cord, cranial 
nerves and other parts 
of CNS
Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C73
Ščitnica M 2,9 0 0 0 0 1,4 0 1,3 2,7 6,2 3,8 4,9 5,7 4,1 6,7 2,8 11,6 0 0,2
Thyroid gland Ž 10,3 0 0 6,3 0 9,2 8,2 9,6 17,0 6,5 10,6 14,3 23,5 7,6 13,3 18,1 20,3 3,9 0,7
C74
Nadledvična žleza M 0,2 2,1 0 0 0 0 0 0 0 1,2 0 0 0 0 0 0 0 0 0,0
Adrenal gland Ž 0,6 2,2 0 0 0 0 0 0 0 0 0 0 0 1,9 1,9 2,0 0 3,9 0,0
C75
Druge endokrine žleze 
in sorodne strukture M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Other endocrine glands 
and related structures Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0 0 0 0,0
C76
Druga in slabo 
opredeljena mesta M 0,3 0 0 0 0 0 0 0 0 0 0 0 0 2,0 0 0 3,9 5,4 0,0
Other and ill-defined 
sites Ž 2,2 0 0 0 0 1,5 0 0 1,4 0 0 0 1,5 3,8 3,8 12,0 6,8 13,6 0,1
C77
Metastaza in 
neopredeljena maligna 
neoplazma bezgavk
M 1,4 0 0 0 0 1,4 0 0 0 0 1,3 0 7,1 4,1 2,2 0 11,6 5,4 0,1
Metastasis and 
unspecified malignant 
neoplasm of lymph 
nodes
Ž 1,9 0 0 0 0 0 0 0 0 2,6 0 2,6 4,4 5,7 1,9 6,0 4,5 5,8 0,1
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
63
Nadaljevanje   —>
Continued   —>
Tabela 5:  Nadaljevanje.
Table 5:  Continued.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti
Starost
Age
KS
CR
ICD 
code Primary site Sex
All 
ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80+ 0–74
C78
Metastaze dihal in 
prebavil M 3,7 0 0 0 0 0 0 0 0 0 2,5 3,7 7,1 4,1 2,2 16,7 34,9 48,8 0,2
Metastases of 
respiratory and 
digestive organs
Ž 6,2 0 0 0 0 0 0 0 0 0 0 2,6 2,9 1,9 5,7 24,1 24,9 64,0 0,2
C79
Metastaze, drugje M 1,4 0 0 0 0 0 0 0 0 1,2 0 0 2,9 4,1 4,4 5,6 11,6 10,8 0,1
Metastases of other 
sites Ž 1,4 0 0 0 0 0 0 0 0 0 0 1,3 0 0 3,8 6,0 11,3 5,8 0,1
C80
Maligna neoplazma 
brez opredeljenega 
mesta
M 4,8 0 0 0 0 0 0 0 0 1,2 5,1 2,4 5,7 14,3 11,1 22,2 42,7 32,5 0,3
Malignant neoplasm 
without specification 
of site
Ž 4,1 0 0 0 0 0 0 0 0 0 1,3 5,2 2,9 5,7 3,8 22,1 13,6 25,2 0,2
C81
Hodgkinova bolezen M 3,1 0 0 0 8,3 2,8 2,5 1,3 4,0 2,5 3,8 2,4 1,4 4,1 4,4 2,8 19,4 0 0,2
Hodgkin's disease Ž 1,7 0 0 2,1 0 10,7 2,7 0 1,4 0 0 1,3 2,9 1,9 3,8 0 0 0 0,1
C82
Folikularni ne-Hodgkinov 
limfom M 2,6 0 0 0 0 0 0 2,5 1,3 6,2 1,3 4,9 4,3 12,2 2,2 2,8 0 10,8 0,2
Follicular non-Hodgkin's 
lymphoma Ž 3,3 0 0 0 0 0 0 0 1,4 0 6,6 5,2 8,8 9,5 3,8 8,0 9,0 5,8 0,2
C83
Difuzni ne-Hodgkinov 
limfom M 7,2 0 0 0 1,7 1,4 0 0 4,0 2,5 6,3 7,3 8,6 6,1 22,2 38,9 54,3 37,9 0,5
Diffuse non-Hodgkin's 
lymphoma Ž 7,4 0 0 0 3,5 0 1,4 0 0 1,3 4,0 1,3 10,3 15,1 17,1 28,1 18,1 42,6 0,4
C84
Limfomi celic T in kožni 
limfom celic T M 1,1 0 0 0 0 1,4 1,2 0 0 3,7 0 0 2,9 0 2,2 0 7,8 5,4 0,1
Peripheral and 
cutaneous T-cell 
lymphomas
Ž 0,9 0 0 2,1 0 0 0 0 0 0 0 1,3 1,5 3,8 3,8 0 4,5 0 0,1
C85
Druge in neopredeljene 
vrste ne-Hodgkinovega 
limfoma
M 0,9 2,1 0 0 0 0 0 0 0 0 0 0 0 0 0 2,8 7,8 27,1 0,0
Other and unspecified 
types of non-Hodgkin's 
lymphoma
Ž 1,1 0 0 0 0 0 0 0 0 0 0 1,3 0 3,8 0 0 6,8 9,7 0,0
C88
Maligne 
imunoproliferativne 
bolezni
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Malignant 
immunoproliferative 
diseases
Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
C90
Difuzni plazmocitom 
in maligne neoplazme 
plazmocitov
M 5,9 0 0 0 0 0 0 0 0 1,2 5,1 7,3 5,7 14,3 31,1 25,0 23,3 43,4 0,4
Multiple myeloma and 
malignant plasma cell 
neoplasms
Ž 5,1 0 0 0 0 0 0 1,4 0 0 4,0 5,2 1,5 20,8 7,6 14,0 11,3 31,0 0,3
C91.0
Limfatična levkemija, 
akutna M 0,9 0 2,1 5,9 1,7 0 0 2,5 0 0 0 0 1,4 0 0 0 3,9 0 0,1
Lymphoblastic 
leukaemia, acute Ž 1,1 11,2 2,3 0 0 0 1,4 0 0 0 0 1,3 0 0 3,8 0 0 1,9 0,1
C91.1
–91.9
Limfatična levkemija, 
druga M 5,4 0 0 0 0 0 0 0 0 0 2,5 7,3 8,6 12,2 26,7 30,5 15,5 37,9 0,4
Lymphoid leukaemia, 
other Ž 4,2 0 0 0 0 0 0 0 0 0 0 3,9 2,9 3,8 11,4 22,1 11,3 27,1 0,2
C92
Mieloična levkemija M 5,4 0 2,1 0 1,7 0 1,2 0 1,3 2,5 3,8 4,9 5,7 10,2 8,9 22,2 42,7 48,8 0,3
Myeloid leukaemia Ž 3,4 6,7 0 0 3,5 1,5 0 0 2,8 1,3 0 1,3 4,4 7,6 7,6 2,0 13,6 13,6 0,2
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
64
Tabela 5:  Nadaljevanje.
Table 5:  Continued.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti
Starost
Age
KS
CR
ICD 
code Primary site Sex
All 
ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80+ 0–74
C93
Monocitna levkemija M 0,2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3,9 5,4 0,0
Monocytic leukaemia Ž 0,4 2,2 0 0 0 0 0 0 0 0 0 1,3 1,5 0 0 0 0 1,9 0,0
C94
Druge opredeljene 
levkemije M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Other leukaemias of 
specified cells Ž 0,1 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0 0 0 0 0,0
C95
Levkemija z 
neopredeljenim 
celičnim tipom
M 0,8 0 0 0 0 0 0 0 0 0 2,5 1,2 0 2,0 2,2 0 7,8 5,4 0,0
Leukaemia, unspecified 
cell type Ž 0,5 0 0 0 0 0 0 0 0 0 0 0 0 1,9 0 4,0 0 3,9 0,0
C96
Druge in neopredeljene 
maligne neoplazme 
limfatičnega, 
krvotvornega ali 
sorodnega tkiva
M 5,3 0 0 0 0 1,4 0 2,5 1,3 2,5 1,3 1,2 0 10,2 17,8 25,0 50,4 54,2 0,3
Other and unspecified 
malignant neoplasms 
of lymphoid, 
haematopoietic and 
related tissue
Ž 6,4 0 0 0 0 3,1 2,7 2,7 1,4 1,3 7,9 3,9 4,4 7,6 9,5 14,0 22,6 38,8 0,3
Zgoraj neupoštevani
Not included above
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti
Starost
Age
KS
CR
ICD 
code Primary site Sex
All 
ages 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80+ 0–74
D03
Melanom, in situ M 5,4 0 0 0 0 0 2,5 6,3 5,3 0 7,6 6,1 10,0 12,2 13,3 16,7 23,3 5,4 0,4
Melanoma, in situ Ž 6,4 0 0 0 0 3,1 4,1 5,5 8,5 11,6 7,9 6,5 4,4 13,2 11,4 14,0 15,8 1,9 0,5
D05
Dojka, in situ M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0
Breast, in situ Ž 8,4 0 0 0 0 0 0 0 1,4 5,2 13,2 35,1 26,4 9,5 24,7 12,0 2,3 1,9 0,6
D06
Maternični vrat, CIN III M – – – – – – – – – – – – – – – – – – –
Cervix uteri, in situ Ž 108,8 0 0 0 7,1 113,6 353,9 354,5 260,4 165,6 131,0 50,7 39,6 39,7 15,2 16,1 2,3 5,8 7,7
D09.0
Sečni mehur, in situ M 13,0 0 0 0 0 0 0 1,3 0 2,5 7,6 11,0 18,6 38,7 51,1 66,6 85,3 54,2 1,0
Bladder, in situ Ž 4,0 0 0 0 0 0 0 0 1,4 0 2,6 2,6 14,7 5,7 15,2 8,0 13,6 9,7 0,3
D32.0
Meninge, benigna 
neoplazma M 1,4 0 0 0 0 0 0 1,3 0 0 0 1,2 2,9 2,0 2,2 2,8 7,8 27,1 0,1
Benign neoplasm of 
meninges Ž 5,2 0 0 0 0 0 1,4 0 5,7 2,6 9,3 3,9 8,8 9,5 11,4 14,0 13,6 11,6 0,3
D33.0
–33.2
Možgani, benigna 
neoplazma M 0,2 0 0 0 0 1,4 0 0 0 1,2 0 0 0 0 0 0 0 0 0,0
Benign neopasm of 
brain Ž 0,2 0 0 0 0 0 0 0 0 0 1,3 0 0 0 0 0 0 1,9 0,0
D39.1
Jajčnik, neopl. 
negotovega značaja M – – – – – – – – – – – – – – – – – – –
Ovary, neopl. of 
uncertain behavior Ž 3,7 0 0 0 0 1,5 2,7 2,7 2,8 7,8 10,6 2,6 4,4 3,8 5,7 10,0 2,3 1,9 0,3
D43.0
–43.2
Možgani, neopredeljeno M 0,6 0 0 0 0 1,4 0 0 0 0 0 0 0 0 0 8,3 0 10,8 0,0
CNS, uncertain or 
unknown Ž 0,7 0 0 0 0 0 0 0 0 0 0 1,3 1,5 1,9 0 2,0 0 5,8 0,0
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
65
Tabela 6a:  Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2007.
Table 6a:  Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2007.
Statistična regija
Statistical region
Spol 
Sex
Skupaj
All sites
Lokacija (šifre MKB-10)
Site (ICD-10 codes) Drugo 
Other
C00-C96 C16 C18 C19 C20 C34 C44 C50 C53 C54 C61 D06**
Slovenija, skupaj
Slovenia, total
M 6083 280 431 79 270 877 873 6 – – 1032 2232 –
Ž 5524 181 353 66 193 339 935 1147 153 296 – 1860 1114
Pomurska
M 393 15 24 10 20 47 63 0 – – 92 122 –
Ž 360 15 24 3 17 10 79 68 12 17 – 115 58
Podravska
M 895 61 63 8 34 137 95 1 – – 168 328 –
Ž 758 41 59 12 38 41 87 181 25 43 – 231 204
Koroška
M 237 18 16 3 11 37 35 0 – – 39 78 –
Ž 184 7 5 1 6 14 50 28 6 10 – 57 50
Savinjska
M 637 36 54 11 32 90 73 0 – – 100 241 –
Ž 645 23 39 7 25 42 70 131 26 40 – 242 170
Zasavska
M 151 6 9 2 5 26 23 0 – – 23 57 –
Ž 126 2 15 1 4 14 12 26 5 7 – 40 27
Spodnjeposavska
M 208 11 25 2 13 25 24 1 – – 35 72 –
Ž 160 8 9 4 10 10 11 37 5 10 – 56 37
Jugovzhodna 
Slovenija
M 436 15 26 13 24 61 63 1 – – 76 157 –
Ž 376 15 28 1 12 23 76 68 4 23 – 126 81
Osrednjeslovenska
M 1646 71 102 11 67 231 261 3 – – 296 601 –
Ž 1570 34 104 17 52 111 296 321 36 80 – 518 319
Gorenjska
M 673 20 44 5 29 112 128 0 – – 97 238 –
Ž 579 12 28 6 12 32 147 114 13 26 – 189 69
Notranjsko-kraška
M 154 5 13 5 4 27 15 0 – – 25 60 –
Ž 129 1 6 4 1 6 22 33 5 8 – 43 19
Goriška
M 362 14 30 7 13 47 53 0 – – 48 150 –
Ž 346 6 21 6 8 25 40 68 8 21 – 143 35
Obalno-kraška
M 291 8 25 2 18 37 40 0 – – 33 128 –
Ž 291 17 15 4 8 11 45 72 8 11 – 100 45
Opis šifer MKB/Description of the ICD code
C16 Želodec
 Stomach
C18 Debelo črevo
 Colon
C19 Rektosigmoidna zveza
 Rectosigmoid junction
C20 Rektum
 Rectum
C34 Sapnica in pljuča
 Bronchus and lung
C44 Druge maligne neoplazme kože
 Skin, other malignomas
C50 Dojka
 Breast
C53 Maternični vrat
 Cervix uteri
C54 Maternično telo
 Corpus uteri
C61 Prostata
 Prostate
D06 Maternični vrat, in situ (CIN III)
 Cervix uteri, in situ (CIN III)
* Neupoštevano v skupnem številu: D06 – Maternični vrat, in situ (CIN III)
* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)
** Standard – prebivalstvo Slovenije po popisu 2002
** Standard – population of Slovenia according to census 2002
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
66
Tabela 6b:  Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in 
spolu, Slovenija 2007.
Table 6b:  Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex, 
Slovenia 2007.
Statistična regija
Statistical region
Spol 
Sex
Skupaj
All sites
Lokacija (šifre MKB-10)
Site (ICD-10 codes) Drugo 
Other
C00-C96 C16 C18 C19 C20 C34 C44 C50 C53 C54 C61 D06**
Slovenija, skupaj
Slovenia, total
M 658,0 30,8 47,7 8,7 29,5 93,4 97,5 0,7 – – 114,2 235,6 –
Ž 448,1 13,7 26,8 5,2 15,1 27,3 70,6 98,5 14,4 24,6 – 152,1 114,2
Pomurska
M 721,4 28,2 46,9 19,0 34,9 83,3 119,4 0,0 – – 179,9 209,9 –
Ž 439,8 18,9 29,6 3,9 20,8 12,4 84,2 92,2 17,4 23,6 – 136,9 97,6
Podravska
M 598,1 41,7 43,9 5,9 22,8 87,3 66,0 0,7 – – 117,2 212,7 –
Ž 382,3 18,8 26,6 5,8 18,7 21,4 40,3 96,2 15,1 21,5 – 118,0 130,4
Koroška
M 721,1 61,8 47,3 9,0 31,8 112,9 113,2 0,0 – – 111,2 234,0 –
Ž 435,3 16,5 9,7 2,5 14,8 34,8 111,0 71,1 16,7 25,1 – 133,1 139,9
Savinjska
M 553,6 33,2 49,7 10,0 27,9 77,2 64,4 0,0 – – 85,2 205,9 –
Ž 427,9 14,7 23,6 4,2 15,9 27,6 44,0 90,6 19,2 27,0 – 161,0 135,8
Zasavska
M 721,3 31,9 42,1 7,5 24,2 124,1 108,7 0,0 – – 113,1 269,7 –
Ž 429,3 7,0 53,5 3,9 15,3 48,0 34,7 93,4 20,3 21,8 – 131,5 125,9
Spodnjeposavska
M 620,3 35,3 75,9 6,6 37,2 72,2 74,0 3,3 – – 106,6 209,2 –
Ž 363,2 16,4 19,4 8,2 21,6 22,7 21,0 91,8 13,4 21,8 – 127,0 109,8
Jugovzhodna 
Slovenija
M 714,0 25,2 43,4 21,0 40,5 98,9 108,9 1,6 – – 128,8 245,8 –
Ž 477,6 17,5 33,2 1,3 14,4 30,0 92,1 90,9 6,5 29,5 – 162,1 122,4
Osrednjeslovenska
M 717,9 29,7 45,6 5,4 30,1 100,4 116,9 1,3 – – 131,6 256,9 –
Ž 510,0 10,3 32,0 5,6 16,8 34,2 90,6 109,4 13,4 26,3 – 171,6 128,3
Gorenjska
M 736,0 22,6 48,2 5,3 31,0 120,2 143,8 0,0 – – 108,6 256,3 –
Ž 481,0 9,5 22,0 4,4 8,4 27,4 115,4 102,8 12,8 22,5 – 155,9 71,0
Notranjsko-kraška
M 616,9 18,3 52,6 20,8 16,9 107,0 60,0 0,0 – – 104,0 237,2 –
Ž 391,1 3,6 18,1 11,1 1,7 14,2 57,9 112,4 17,8 25,1 – 129,2 76,9
Goriška
M 620,0 24,2 50,4 11,2 23,0 82,9 92,4 0,0 – – 84,2 251,7 –
Ž 445,3 7,1 23,0 7,9 8,5 34,4 44,0 90,0 13,4 28,2 – 188,9 62,5
Obalno-kraška
M 547,6 14,8 48,0 2,5 34,2 67,0 76,8 0,0 – – 62,0 242,3 –
Ž 423,5 19,8 21,2 6,6 10,0 14,3 63,4 109,0 12,2 16,2 – 150,8 88,2
Opis šifer MKB/Description of the ICD code
C16 Želodec
 Stomach
C18 Debelo črevo
 Colon
C19 Rektosigmoidna zveza
 Rectosigmoid junction
C20 Rektum
 Rectum
C34 Sapnica in pljuča
 Bronchus and lung
C44 Druge maligne neoplazme kože
 Skin, other malignomas
C50 Dojka
 Breast
C53 Maternični vrat
 Cervix uteri
C54 Maternično telo
 Corpus uteri
C61 Prostata
 Prostate
D06 Maternični vrat, in situ (CIN III)
 Cervix uteri, in situ (CIN III)
* Neupoštevano v skupnem številu: D06 – Maternični vrat, in situ (CIN III)
* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)
** Standard – prebivalstvo Slovenije po popisu 2002
** Standard – population of Slovenia according to census 2002
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
67
Nadaljevanje   —>
Continued   —>
Tabela 7:  Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, 
Slovenija 2007.
Table 7:  Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type 
and by site, Slovenia 2007.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C00 C01 C02 C03 C04 C05 C06 C07 C08 C09
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 24 0 16 0 31 0 10 0 40 1 16 0 13 0 9 0 2 0 39 0
Small cell carcinoma 162 59 – – – – – – – – – – – – – – – – – – – –
Non-small cell carcinoma 51 37 – – – – – – – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 22 – 14 – 31 – 9 – 39 1 11 – 11 – 2 – – – 38 –
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – – – – – – – –
Transitional cel carcinoma 286 0 – – – – – – – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 1 – – – – – 1 – 1 – 2 – 1 – 5 – 1 – – –
Other specified carcinomas 166 22 – – – – – – – – – – 3 – 1 – – – 1 – – –
Carcinoma, unspecified 162 133 1 – 2 – – – – – – – – – – – 2 – – – – –
Malignant thymoma 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 – – – – – – – – – – – – – – – – – – – –
Fibrosarcoma 5 0 – – – – – – – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – – – – – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – – – – – – – – – – – – – – – – – – –
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – – – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – 1 –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – – – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – – – – – – – – – – –
Other specified sarcomas 4 0 – – – – – – – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – – – – – – – – – – – – – – – – –
Malignant complex mixed and stromal tumors 27 1 – – – – – – – – – – – – – – – – – – – –
Malignat fibroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – – – – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 – – – – – – – – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – – – – – – – – – – – – – – – – – –
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
68
Nadaljevanje   —>
Continued   —>
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 43 0 11 0 34 0 23 1 0 0 89 0 437 7 23 0 754 6 144 0
Small cell carcinoma 162 59 – – – – – – – – – – – – 1 – 1 – 2 – – –
Non-small cell carcinoma 51 37 – – – – – – – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 41 – 10 – 34 – 23 1 – – 70 – 2 – – – – – – –
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – – – – – – – –
Transitional cel carcinoma 286 0 – – – – – – – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 – – 1 – – – – – – – 16 – 412 1 19 – 725 2 140 –
Other specified carcinomas 166 22 2 – – – – – – – – – 1 – 1 – – – 2 – – –
Carcinoma, unspecified 162 133 – – – – – – – – – – 2 – 15 5 1 – 25 4 3 –
Malignant thymoma 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 – – – – – – – – – – – – – – – – – – – –
Fibrosarcoma 5 0 – – – – – – – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – – – – – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – – – – – – – – – – – – – – – – – 1 –
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – – – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – – – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – – – – – – – – – – –
Other specified sarcomas 4 0 – – – – – – – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – – – – – – – – – – – – – – – – –
Malignant complex mixed and stromal tumors 27 1 – – – – – – – – – – – – 6 1 2 – – – – –
Malignat fibroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – – – – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 – – – – – – – – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – – – – – – – – – – – – – – – – – –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
69
Nadaljevanje   —>
Continued   —>
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C20 C21 C22 C23 C24 C25 C26 C30 C31 C32
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 456 1 25 0 83 23 31 5 45 4 140 34 1 1 13 0 11 0 120 1
Small cell carcinoma 162 59 – – – – – – – – – – 3 – – – – – – – – –
Non-small cell carcinoma 51 37 – – – – – – – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 – – 15 – – – – – – – – – – – 4 – 5 – 115 1
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – – – – – – – –
Transitional cel carcinoma 286 0 – – 2 – – – – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 444 1 7 – 80 21 28 4 43 2 126 25 1 1 3 – 2 – 1 –
Other specified carcinomas 166 22 1 – – – – – 2 – – – – – – – 1 – 3 – 1 –
Carcinoma, unspecified 162 133 8 – – – – 2 1 1 2 1 9 9 – – – – 1 – 3 –
Malignant thymoma 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 1 – 1 – – – – – – – – – – – 4 – – – – –
Fibrosarcoma 5 0 – – – – – – – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – – – – – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – – – – – – – – – – – – – 1 – – – – –
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – – – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – 1 – – – – – – – – – – – – – – –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – – – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – – – – – – – – – – –
Other specified sarcomas 4 0 – – – – 2 – – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – – – – – – – – – – – – – – – – –
Malignant complex mixed and stromal tumors 27 1 2 – – – – – – – – – 1 – – – – – – – – –
Malignat fibroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – – – – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 – – – – – – – – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – – – – – – – 1 1 – – – – – – – – –
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
70
Nadaljevanje   —>
Continued   —>
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C33 C34 C37 C38 C39 C40 C41 C43 C44 C45
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 7 0 874 238 3 0 4 0 0 0 6 0 6 0 432 5 1752 51 26 2
Small cell carcinoma 162 59 1 – 143 59 – – – – – – – – – – – – – – – –
Non-small cell carcinoma 51 37 – – 51 36 – – – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 5 – 283 50 – – – – – – – – – – – – 355 11 – –
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – – – – 1376 39 – –
Transitional cel carcinoma 286 0 – – – – – – – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 – – 307 59 1 – – – – – – – – – – – 16 – – –
Other specified carcinomas 166 22 1 – 69 21 – – – – – – – – – – – – – – – –
Carcinoma, unspecified 162 133 – – 17 12 – – – – – – – – – – – – – 1 – –
Malignant thymoma 2 0 – – – – 2 – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 – – – – – – – – – – – – – – 432 5 – – – –
Fibrosarcoma 5 0 – – 1 – – – – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – 1 – – – – – 4 – – –
Liposarcoma 16 0 – – – – – – – – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – – – – – – – – – – – – – – – 1 – – –
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – 1 – – – 1 – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – 1 – – – – – – –
Chondrosarcoma 9 0 – – 1 – – – – – – – 4 – 3 – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – 1 – 2 – – – – – – –
Other specified sarcomas 4 0 – – – – – – – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – 1 – – – – – – – – – – – – – – – – –
Malignant complex mixed and stromal tumors 27 1 – – – – – – – – – – – – – – – – – – – –
Malignat fibroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – 26 2
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – – – – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 – – – – – – 1 – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – 1 – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – 1 – – 1 – – – – – – – – – – – – –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
71
Nadaljevanje   —>
Continued   —>
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C46 C47 C48 C49 C50 C51 C52 C53 C54 C55
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 2 0 6 0 27 0 38 1 1053 78 52 0 15 0 153 0 294 1 4 0
Small cell carcinoma 162 59 – – – – – – – – 1 – – – – – – – – – – –
Non-small cell carcinoma 51 37 – – – – – – – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 – – – – – – – – 1 – 36 – 12 – 121 – – – – –
Basal cell carcinoma 1389 39 – – – – – – – – – – 11 – 1 – 1 – – – – –
Transitional cel carcinoma 286 0 – – – – – – – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 – – – – 13 – – – 1019 8 – – – – 23 – 243 1 – –
Other specified carcinomas 166 22 – – – – – – – – 9 – – – 1 – 6 – 41 – – –
Carcinoma, unspecified 162 133 – – – – – – – – 22 70 – – 1 – 1 – 1 – – –
Malignant thymoma 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 – – – – – – – – – – 5 – – – – – – – – –
Fibrosarcoma 5 0 – – – – – – 4 – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – 1 – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – 7 – 8 – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – – – 2 – 2 – – – – – – – – – 2 – 3 –
Rhabdomyosarcoma 1 0 – – – – – – 1 – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – 6 1 – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – 1 – – – – – – – – – – – – –
Kaposi sarcoma 2 0 2 – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – 1 – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – 2 – – – – – – – – – – – – –
Other specified sarcomas 4 0 – – – – – – 1 – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – 1 – 8 – – – – – – – – – 1 – – –
Malignant complex mixed and stromal tumors 27 1 – – – – 1 – – – – – – – – – 1 – 6 – 1 –
Malignat fibroepithelial tumors 2 0 – – – – – – – – 1 – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – 3 – – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 – – – – – – – – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – 6 – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – 2 – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – – – – 1 – – – – – – – – – – – – –
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
72
Nadaljevanje   —>
Continued   —>
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C56 C57 C58 C60 C61 C62 C63 C64 C65 C66
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 161 5 14 0 0 0 7 0 976 4 89 0 1 0 234 14 27 0 10 0
Small cell carcinoma 162 59 – – – – – – – – – – – – – – – – – – – –
Non-small cell carcinoma 51 37 – – – – – – – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 – – – – – – 6 – – – – – – – – – – – 1 –
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – – – – – – – –
Transitional cel carcinoma 286 0 – – – – – – – – 2 – – – – – – – 27 – 9 –
Adenocarcinoma 5216 171 146 1 11 – – – – – 950 3 – – – – 228 11 – – – –
Other specified carcinomas 166 22 7 – 1 – – – 1 – – – – – – – – – – – – –
Carcinoma, unspecified 162 133 1 4 2 – – – – – 24 1 – – – – 2 3 – – – –
Malignant thymoma 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 – – – – – – – – – – – – – – – – – – – –
Fibrosarcoma 5 0 – – – – – – – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – – – – – – – – – 1 – – – – – – –
Leiomyosarcoma 14 1 – – – – – – – – – – – – – – 1 – – – – –
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – – – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – – – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – – – – – – – – – – –
Other specified sarcomas 4 0 1 – – – – – – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – – – – – – – – – – – – – – – – –
Malignant complex mixed and stromal tumors 27 1 3 – – – – – – – – – – – – – 3 – – – – –
Malignat fibroepithelial tumors 2 0 1 – – – – – – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 1 – – – – – – – – – 44 – – – – – – – – –
Other malignant germ cell tumors 38 0 1 – – – – – – – – – 35 – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – 10 – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – – – – – – – – – – – – – – – – – –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
73
Nadaljevanje   —>
Continued   —>
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C67 C68 C69 C70 C71 C72 C73 C74 C75 C76
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 265 0 4 0 14 0 1 0 125 3 0 0 132 2 6 0 1 0 9 5
Small cell carcinoma 162 59 3 – – – – – – – – – – – – – – – – – – –
Non-small cell carcinoma 51 37 – – – – – – – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 7 – – – – – – – – – – – – – – – – – 1 –
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – – – – – – – –
Transitional cel carcinoma 286 0 243 – 3 – – – – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 5 – 1 – 2 – – – – – – – 131 1 3 – 1 – 5 3
Other specified carcinomas 166 22 4 – – – – – – – – – – – 1 1 – – – – – –
Carcinoma, unspecified 162 133 3 – – – – – – – – – – – – – – – – – 1 1
Malignant thymoma 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 – – – – 11 – – – – – – – – – – – – – – –
Fibrosarcoma 5 0 – – – – – – – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – – – – – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – – – – – – – – – – – – – – – – – – 1
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – – – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – – – – – – – – – 1 – – – – –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – – – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – – – – – – – – – – –
Other specified sarcomas 4 0 – – – – – – – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – 1 – – – – – – – – – – – – – 1 –
Malignant complex mixed and stromal tumors 27 1 – – – – – – – – – – – – – – – – – – 1 –
Malignat fibroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – – – – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 – – – – – – – – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – 125 3 – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – 2 – – – – –
Malignant meningioma 1 0 – – – – – – 1 – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – – – – – – – – – – – – – – – – – –
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
74
Nadaljevanje   —>
Continued   —>
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C77 C78 C79 C80 C81 C82 C83 C84 C85 C88
H C H C H C H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 24 9 29 25 15 2 29 22 44 4 53 7 136 12 18 2 12 8 0 0
Small cell carcinoma 162 59 2 – – – 2 – 3 – – – – – – – – – – – – –
Non-small cell carcinoma 51 37 – – – – – – – 1 – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 10 4 2 – – – 2 1 – – – – – – – – – – – –
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – – – – – – – –
Transitional cel carcinoma 286 0 – – – – – – – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 6 4 22 13 6 2 17 8 – – – – – – – – – – – –
Other specified carcinomas 166 22 2 – – – 2 – 2 – – – – – – – – – – – – –
Carcinoma, unspecified 162 133 1 1 4 10 3 – 4 8 – – – – – – – – – – – –
Malignant thymoma 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – – – – – – – –
Malignant melanoma 459 7 2 – – 1 2 – 1 1 – – – – – – – – – – – –
Fibrosarcoma 5 0 – – – – – – – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – – – – – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – 1 – – – – – – – – – – – – – – – – –
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – – – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – – – – – – – – – – – – – – –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – – – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – – – – – – – – – – –
Other specified sarcomas 4 0 – – – – – – – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – – – – – – – – – – – – – – – – –
Malignant complex mixed and stromal tumors 27 1 – – – – – – – – – – – – – – – – – – – –
Malignat fibroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – – – – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 1 – – – – – – – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – 53 7 136 12 18 2 12 8 – –
Hodgkin lymphoma 44 4 – – – – – – – – 44 4 – – – – – – – – – –
Plasma cell tumors 98 13 – – – – – – – – – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – – – – – – – – – – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – – – – – – – – – – – – – – – – – – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – – – – – – – – –
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – – – – – – – – –
Other specified malignant tumors 2 0 – – – – – – – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – 1 – – – 3 – – – – – – – – – – – –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
75
Tabela 7:  Nadaljevanje.
Table 7:  Continued.
Histološka vrsta
Hystologic type
Skupaj
All sites
Lokacija (šifre MKB–10)
Site (ICD–10 codes)
C00–C96 C90 C91 C92 C93 C94 C95 C96
H C H C H C H C H C H C H C H C
Vse vrste/All types 10151 762 98 13 62 55 66 23 5 1 1 0 7 6 39 80
Small cell carcinoma 162 59 – – – – – – – – – – – – – –
Non-small cell carcinoma 51 37 – – – – – – – – – – – – – –
Squamous cell carcinoma 1338 69 – – – – – – – – – – – – – –
Basal cell carcinoma 1389 39 – – – – – – – – – – – – – –
Transitional cel carcinoma 286 0 – – – – – – – – – – – – – –
Adenocarcinoma 5216 171 – – – – – – – – – – – – – –
Other specified carcinomas 166 22 – – – – – – – – – – – – – –
Carcinoma, unspecified 162 133 – – – – – – – – – – – – – –
Malignant thymoma 2 0 – – – – – – – – – – – – – –
Malignant paraganglioma/pheochromocytoma 0 0 – – – – – – – – – – – – – –
Malignant melanoma 459 7 – – – – – – – – – – – – – –
Fibrosarcoma 5 0 – – – – – – – – – – – – – –
Fibrohistiocytic sarcoma 6 0 – – – – – – – – – – – – – –
Liposarcoma 16 0 – – – – – – – – – – – – – –
Leiomyosarcoma 14 1 – – – – – – – – – – – – – –
Rhabdomyosarcoma 1 0 – – – – – – – – – – – – – –
Synovial sarcoma 8 1 – – – – – – – – – – – – – –
Angiosarcoma 4 0 – – – – – – – – – – – – – –
Kaposi sarcoma 2 0 – – – – – – – – – – – – – –
Osteosarcoma 1 0 – – – – – – – – – – – – – –
Chondrosarcoma 9 0 – – – – – – – – – – – – – –
Ewing sarcoma/PNET 5 0 – – – – – – – – – – – – – –
Other specified sarcomas 4 0 – – – – – – – – – – – – – –
Sarcoma, unspecified 13 0 – – – – – – – – – – – – – –
Malignant complex mixed and stromal tumors 27 1 – – – – – – – – – – – – – –
Malignat fibroepithelial tumors 2 0 – – – – – – – – – – – – – –
Malignant mesothelioma 26 2 – – – – – – – – – – – – – –
Malignant gonadal stromal tumors 0 0 – – – – – – – – – – – – – –
Dysgerminoma and seminoma 48 0 – – – – – – – – – – – – – –
Other malignant germ cell tumors 38 0 – – – – – – – – – – – – – –
Malignant trophoblastic tumors 11 0 – – – – – – – – – – – – – –
Malignant gliomas 125 3 – – – – – – – – – – – – – –
Malignant neuroepithelial tumors 2 0 – – – – – – – – – – – – – –
Malignant meningioma 1 0 – – – – – – – – – – – – – –
Malignant nerve sheath tumors 6 0 – – – – – – – – – – – – – –
Non Hodgkin lymphoma 219 29 – – – – – – – – – – – – – –
Hodgkin lymphoma 44 4 – – – – – – – – – – – – – –
Plasma cell tumors 98 13 98 13 – – – – – – – – – – – –
Chronic lymphoid leukemia 45 46 – – 45 46 – – – – – – – – – –
Leukemia except chronic lymphoid 96 39 – – 17 9 66 23 5 1 1 – 7 6 – –
Other lymphoreticular neoplasms 0 0 – – – – – – – – – – – – – –
Chronic myeloproliferative diseases 18 46 – – – – – – – – – – – – 18 46
Myelodysplastic syndromes 21 34 – – – – – – – – – – – – 21 34
Other specified malignant tumors 2 0 – – – – – – – – – – – – – –
Malignant tumor, unspecified 3 6 – – – – – – – – – – – – – –
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
76
* Vključeni so samo citološko in histološko potrjeni primeri
* All cases included have been verified citologically and histologically
Tabela 8:  Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2007.
Table 8:  Incidence of non-Hodgkin´s malignant lymphomas* by site, by sex and by age, Slovenia 2007.
Šifra 
MKB–8
 
ICD–8 
code
Lokacija
Site
Spol
Sex
Vse 
starosti
All ages
Starosti
Age
0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80+
Vse lokacije
All sites
Skupaj
Total 248 1 0 1 3 2 2 2 5 11 14 17 25 26 25 34 35 45
Moški
Male 118 1 0 0 1 2 1 2 4 10 6 10 11 9 12 16 18 15
 Ženske
Female 130 0 0 1 2 0 1 0 1 1 8 7 14 17 13 18 17 30
143
Dlesni M 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
Gum Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
146
Orofarinks M 7 0 0 0 0 0 0 0 0 0 1 2 1 0 0 1 2 0
Oropharynx Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1
149
Žrelo, neoznačeno M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pharynx, not specified Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
150
Požiralnik M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Oesophagus Ž 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
151
Želodec M 11 0 0 0 0 0 0 0 0 1 0 0 0 2 3 2 2 1
Stomach Ž 14 0 0 0 0 0 0 0 0 0 0 0 2 3 2 3 1 3
152
Tanko črevo M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0
Small intestine Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
153
Debelo črevo M 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0
Colon Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
157
Trebušna slinavka M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pancreas Ž 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
160
Nos, obnosne votline, drugo M 2 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0
Nose, sinuses, etc. Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0
161
Grlo M 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
Larynx Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
162
Sapnik, sapnica, pljuča M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Trachea, bronchus, lung Ž 2 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1
170
Kosti M 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
Bone Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
171
Mehka tkiva M 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
Soft tissues Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2
173
Koža, drugi malignomi M 3 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0
Skin, other malignancies Ž 4 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2
174
Dojka M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Breast Ž 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
182
Maternica, telo, drugo M – – – – – – – – – – – – – – – – – –
Uterus, corpus, etc. Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
183
Jajčnik, jajcevod, drugo M – – – – – – – – – – – – – – – – – –
Ovary, Fallopian tube, other Ž 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
186
Modo M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0
Testis Ž – – – – – – – – – – – – – – – – – –
190
Oko M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1
Eye Ž 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0
191
Možgani M 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
Brain Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0
193
Ščitnica M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Thyroid Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
202
Bezgavke M 81 1 0 0 1 1 1 2 4 6 4 7 9 3 7 12 11 12
Lymph nodes Ž 87 0 0 0 0 0 1 0 1 1 7 7 9 10 10 11 12 18
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
77
Nadaljevanje   —>
Continued   —>
Tabela 9:  Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, 
lokaciji in spolu, Slovenija 2007.
Table 9:  Cancer incidence (without cases registered from death certificates only) by stage, by site and by 
sex, Slovenia 2007.
Š i f r a 
M K B
ICD 
code
Primarna lokacija
Primary site
S t a n j e
Spol
Število 
novih 
primerov
Omejen Razširjen Razsejan Neznan
Število %* Število %* Število %* Število %*
S t a g e
Sex Number of new cases
Localized Regional Distant Unknown
Number %* Number %* Number %* Number %*
C00 
–
C96
Vse lokacije
All sites
M+Ž 11563 5315 46,0 3179 27,5 2660 23,0 409 3,5
M 6064 2686 44,3 1676 27,6 1455 24,0 247 4,1
Ž 5499 2629 47,8 1503 27,3 1205 21,9 162 2,9
C00
Ustnica M 17 13 76,5 3 17,6 0 0 1 5,9
Lip Ž 8 8 – 0 – 0 – 0 –
C01
Baza jezika M 13 4 – 9 – 0 – 0 –
Base of tongue Ž 3 0 – 3 – 0 – 0 –
C02
Jezik, drugi deli M 30 12 40,0 18 60,0 0 0 0 0
Tongue, other & unspecified parts Ž 1 1 – 0 – 0 – 0 –
C03
Dlesen M 7 1 – 6 – 0 – 0 –
Gum Ž 3 3 – 0 – 0 – 0 –
C04
Ustno dno M 29 11 37,9 16 55,2 2 6,9 0 0
Floor of mouth Ž 12 2 – 10 – 0 – 0 –
C05
Nebo M 10 4 – 6 – 0 – 0 –
Palate Ž 6 6 – 0 – 0 – 0 –
C06
Usta, drugi deli M 8 3 – 5 – 0 – 0 –
Mouth, other & unspecified parts Ž 5 4 – 1 – 0 – 0 –
C07
Parotidna žleza M 6 1 – 5 – 0 – 0 –
Parotid gland Ž 4 2 – 2 – 0 – 0 –
C08
Druge in neopredeljene velike žleze slinavke M 1 1 – 0 – 0 – 0 –
Other & unspecified major salivary glands Ž 1 1 – 0 – 0 – 0 –
C09
Tonzila M 30 12 40,0 17 56,7 1 3,3 0 0
Tonsil Ž 9 0 – 8 – 1 – 0 –
C10
Orofarinks M 39 9 23,1 30 76,9 0 0 0 0
Oropharynx Ž 4 0 – 3 – 1 – 0 –
C11
Nazofarinks M 8 3 – 4 – 1 – 0 –
Nasopharynx Ž 3 0 – 3 – 0 – 0 –
C12
Piriformni sinus M 31 2 6,5 29 93,5 0 0 0 0
Pyriform sinus Ž 3 1 – 2 – 0 – 0 –
C13
Hipofarinks M 26 1 3,8 22 84,6 2 7,7 1 3,8
Hypopharynx Ž 0 0 – 0 – 0 – 0 –
C14
Druga in slabo opredeljena mesta na ustnici, v ustni votlini 
in farinksu M 0 0 – 0 – 0 – 0 –
Other and ill-defined sites in the lip, oral cavity and 
pharynx Ž 0 0 – 0 – 0 – 0 –
C15
Požiralnik M 83 19 22,9 34 41,0 24 28,9 6 7,2
Oesophagus Ž 14 2 – 6 – 5 – 1 –
C16
Želodec M 279 49 17,6 105 37,6 109 39,1 16 5,7
Stomach Ž 178 42 23,6 57 32,0 58 32,6 21 11,8
C17
Tanko črevo M 14 1 – 8 – 5 – 0 –
Small intestine Ž 9 2 – 2 – 5 – 0 –
C18
Debelo črevo M 431 42 9,7 260 60,3 117 27,1 12 2,8
Colon Ž 350 40 11,4 218 62,3 83 23,7 9 2,6
C19
Rektosigmoidna zveza M 79 13 16,5 49 62,0 16 20,3 1 1,3
Rectosigmoid junction Ž 66 8 12,1 36 54,5 20 30,3 2 3,0
C20
Rektum M 270 35 13,0 160 59,3 62 23,0 13 4,8
Rectum Ž 193 35 18,1 112 58,0 37 19,2 9 4,7
C21
Anus in analni kanal M 11 5 – 5 – 1 – 0 –
Anus and anal canal Ž 14 10 – 3 – 0 – 1 –
C22
Jetra in intrahepatični vodi M 127 45 35,4 14 11,0 46 36,2 22 17,3
Liver and intrahepatic bile ducts Ž 48 10 20,8 7 14,6 26 54,2 5 10,4
C23
Žolčnik M 16 2 12,5 2 12,5 10 62,5 2 12,5
Gallbladder Ž 44 4 9,1 15 34,1 22 50,0 3 6,8
C24
Drugi in neopredeljeni deli biliarnega trakta M 39 10 25,6 17 43,6 8 20,5 4 10,3
Billiary tract, other and unspecified parts Ž 54 12 22,2 18 33,3 9 16,7 15 27,8
C25
Trebušna slinavka M 153 7 4,6 50 32,7 80 52,3 16 10,5
Pancreas Ž 142 5 3,5 51 35,9 72 50,7 14 9,9
C26
Druga in slabo opredeljena mesta v prebavnih organih M 0 0 – 0 – 0 – 0 –
Other and ill-defined digestive organs Ž 3 1 – 1 – 1 – 0 –
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
78
Nadaljevanje   —>
Continued   —>
Tabela 9:  Nadaljevanje.
Table 9:  Continued.
Š i f r a 
M K B
ICD 
code
Primarna lokacija
Primary site
S t a n j e
Spol
Število 
novih 
primerov
Omejen Razširjen Razsejan Neznan
Število %* Število %* Število %* Število %*
S t a g e
Sex Number of new cases
Localized Regional Distant Unknown
Number %* Number %* Number %* Number %*
C30
Nosna votlina in srednje uho M 9 3 – 6 – 0 – 0 –
Nasal cavity and middle ear Ž 4 1 – 2 – 1 – 0 –
C31
Obnosni sinusi M 9 1 – 5 – 3 – 0 –
Accessory sinuses Ž 2 0 – 2 – 0 – 0 –
C32
Grlo M 111 67 60,4 41 36,9 2 1,8 1 0,9
Larynx Ž 10 7 – 3 – 0 – 0 –
C33
Sapnik M 5 1 – 4 – 0 – 0 –
Trachea Ž 2 0 – 1 – 1 – 0 –
C34
Sapnica in pljuča M 871 125 14,4 308 35,4 401 46,0 37 4,2
Bronchus and lung Ž 338 52 15,4 131 38,8 142 42,0 13 3,8
C37
Timus M 2 1 – 0 – 1 – 0 –
Thymus Ž 1 0 – 0 – 0 – 1 –
C38
Srce, mediastinum, plevra M 4 0 – 2 – 2 – 0 –
Heart, mediastinum, pleura Ž 0 0 – 0 – 0 – 0 –
C39
Druga in slabo opredeljena mesta v dihalih in prsnih 
organih M 0 0 – 0 – 0 – 0 –
Other and ill-defined sites in the respiratory system and 
intrathoracic organs Ž 0 0 – 0 – 0 – 0 –
C40
Kosti, sklepni hrustanec udov M 3 0 – 3 – 0 – 0 –
Bone and articular cartilage of limbs Ž 3 1 – 2 – 0 – 0 –
C41
Kosti, sklepni hrustanec, drugje M 3 1 – 1 – 1 – 0 –
Bone and articular cartilage of other and unspecified parts Ž 4 1 – 2 – 1 – 0 –
C43
Maligni melanom kože M 201 160 79,6 30 14,9 4 2,0 7 3,5
Malignant melanoma of skin Ž 236 196 83,1 34 14,4 4 1,7 2 0,8
C44
Druge maligne neoplazme kože M 873 849 97,3 20 2,3 1 0,1 3 0,3
Skin, other malignomas Ž 934 914 97,9 18 1,9 0 0 2 0,2
C45
Mezoteliom M 26 12 46,2 7 26,9 5 19,2 2 7,7
Mesothelioma Ž 3 0 – 2 – 1 – 0 –
C46
Kaposijev sarkom M 2 2 – 0 – 0 – 0 –
Kaposi's sarcoma Ž 0 0 – 0 – 0 – 0 –
C47
Periferni živci in avtonomno živčevje M 5 2 – 3 – 0 – 0 –
Peripheral nerves and autonomic nervous system Ž 1 1 – 0 – 0 – 0 –
C48
Peritonej in retroperitonej M 7 2 – 4 – 1 – 0 –
Retroperitoneum and peritoneum Ž 20 1 5,0 6 30,0 11 55,0 2 10,0
C49
Drugo vezivno in mehko tkivo M 19 8 42,1 7 36,8 4 21,1 0 0
Other connective and soft tissue Ž 20 8 40,0 8 40,0 3 15,0 1 5,0
C50
Dojka M 6 3 – 2 – 1 – 0 –
Breast Ž 1145 575 50,2 477 41,7 87 7,6 6 0,5
C51
Žensko zunanje spolovilo M – – – – – – – – –
Vulva Ž 53 29 54,7 22 41,5 2 3,8 0 0
C52
Nožnica M – – – – – – – – –
Vagina Ž 15 6 40,0 8 53,3 0 0 1 6,7
C53
Maternični vrat M – – – – – – – – –
Cervix uteri Ž 153 93 60,8 51 33,3 8 5,2 1 0,7
C54
Maternično telo M – – – – – – – – –
Corpus uteri Ž 296 209 70,6 63 21,3 18 6,1 6 2,0
C55
Maternica, neopredeljeno M – – – – – – – – –
Uterus, unspecified Ž 5 1 – 3 – 0 – 1 –
C56
Jajčnik M – – – – – – – – –
Ovary Ž 173 30 17,3 15 8,7 126 72,8 2 1,2
C57
Drugi in neopredeljeni ženski spolni organi M – – – – – – – – –
Other and unspecified parts of female genital organs Ž 14 6 – 1 – 7 – 0 –
C58
Posteljica M – – – – – – – – –
Placenta Ž 0 0 – 0 – 0 – 0 –
C60
Penis M 7 4 – 3 – 0 – 0 –
Penis Ž – – – – – – – – –
C61
Prostata M 1028 661 64,3 237 23,1 64 6,2 66 6,4
Prostate Ž – – – – – – – – –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
79
Tabela 9:  Nadaljevanje.
Table 9:  Continued.
* Odstotki niso računani pri številih pod 15
* Percentages are not calculated for less than 15 cases
Š i f r a 
M K B
ICD 
code
Primarna lokacija
Primary site
S t a n j e
Spol
Število 
novih 
primerov
Omejen Razširjen Razsejan Neznan
Število %* Število %* Število %* Število %*
S t a g e
Sex Number of new cases
Localized Regional Distant Unknown
Number %* Number %* Number %* Number %*
C62
Modo M 89 67 75,3 13 14,6 9 10,1 0 0
Testis Ž – – – – – – – – –
C63
Drugi in neopredeljeni moški spolni organi M 1 1 – 0 – 0 – 0 –
Other and unspecified male genital organs Ž – – – – – – – – –
C64
Ledvica razen meha M 176 115 65,3 24 13,6 37 21,0 0 0
Kidney, except renal pelvis Ž 94 57 60,6 14 14,9 19 20,2 4 4,3
C65
Ledvični meh M 20 8 40,0 6 30,0 5 25,0 1 5,0
Renal pelvis Ž 8 3 – 4 – 1 – 0 –
C66
Sečevod M 6 3 – 3 – 0 – 0 –
Ureter Ž 4 3 – 1 – 0 – 0 –
C67
Sečni mehur M 202 148 73,3 37 18,3 12 5,9 5 2,5
Bladder Ž 76 44 57,9 19 25,0 11 14,5 2 2,6
C68
Drugi in neopredeljeni sečni organi M 3 1 – 2 – 0 – 0 –
Other and unspecified urinary organs Ž 1 1 – 0 – 0 – 0 –
C69
Oko in očesni adneksi M 7 7 – 0 – 0 – 0 –
Eye and adnexa Ž 9 6 – 3 – 0 – 0 –
C70
Meninge M 0 0 – 0 – 0 – 0 –
Meninges Ž 1 1 – 0 – 0 – 0 –
C71
Možgani M 79 79 100 0 0 0 0 0 0
Brain Ž 62 62 100 0 0 0 0 0 0
C72
Hrbtni mozeg, možganski živci in drugi deli CŽS M 0 0 – 0 – 0 – 0 –
Spinal cord, cranial nerves and other parts of CNS Ž 0 0 – 0 – 0 – 0 –
C73
Ščitnica M 29 15 51,7 12 41,4 2 6,9 0 0
Thyroid gland Ž 105 89 84,8 12 11,4 3 2,9 1 1,0
C74
Nadledvična žleza M 2 0 – 0 – 2 – 0 –
Adrenal gland Ž 6 2 – 2 – 2 – 0 –
C75
Druge endokrine žleze in sorodne strukture M 0 0 – 0 – 0 – 0 –
Other endocrine glands and related structures Ž 1 1 – 0 – 0 – 0 –
C76
Druga in slabo opredeljena mesta M 3 0 – 1 – 2 – 0 –
Other and ill-defined sites Ž 23 0 0 7 30,4 11 47,8 5 21,7
C77
Metastaza in neopredeljena maligna neoplazma bezgavk M 14 0 – 0 – 0 – 14 –
Metastasis and unspecified malignant neoplasm of lymph 
nodes Ž 19 0 0 0 0 4 21,1 15 78,9
C78
Metastaze dihal in prebavil M 36 0 0 0 0 36 100 0 0
Metastases of respiratory and digestive organs Ž 63 0 0 0 0 63 100 0 0
C79
Metastaze, drugje M 14 0 – 0 – 14 – 0 –
Metastases of other sites Ž 13 0 – 0 – 13 – 0 –
C80
Maligna neoplazma brez opredeljenega mesta M 47 0 0 0 0 47 100 0 0
Malignant neoplasm without specification of site Ž 41 0 0 0 0 41 100 0 0
Šifra 
MKB Primarna lokacija
S t a d i j  ( A n n – A r b o r )
Spol Število primerov
I II III+IV Neznan
Število %* Število %* Število %* Število %*
ICD 
code Primary site
S t a g e  ( A n n – A r b o r )
Sex Number of new cases
I II III+IV Unknown
Number %* Number %* Number %* Number %*
C81
Hodgkinova bolezen M 31 7 22,6 4 12,9 19 61,3 1 3,2
Hodgkin's disease Ž 17 0 0 7 41,2 10 58,8 0 0
C82–
C85
Ne-Hodgkinov limfom M 118 27 22,9 17 14,4 58 49,2 16 13,6
Non-Hodgkin's lymphoma Ž 130 29 22,3 25 19,2 59 45,4 17 13,1
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
80
* Odstotki niso računani, če je število zdravljenih manjše od 15
* Percentages are not calculated for less then 15 new cases
Tabela 10a: Število in deleži bolnikov, zbolelih leta 2007, ki so bili v okviru prvega zdravljenja operirani, 
zdravljeni s sitemsko terapijo ali obsevani.
Table 10a: Number of patients diagnosed in 2007, that were treated by surgery, sistemic therapy or 
radiotherapy during their first treatment.
Šifra MKB 
ICD code
Primarna lokacija 
Primary site
Število novih 
primerov 
Number of new 
cases
Število operiranih 
Number of treated by surgery
Število zdravljenih s sitemsko 
terapijo 
Number of treated sistemic 
therapy
Število obsevanih 
Number of treated by 
radiotherapy
Število 
Number %*
Število 
Number %*
Število 
Number %*
C00–C96 Vse lokacije All sites 11607 7125 61,4 3598 31,0 2368 20,4
C00–C14 Usta in žrelo Mouth and pharynx 320 180 56,3 71 22,2 219 68,4
C15 Požiralnik Oesophagus 97 20 20,6 26 26,8 32 33,0
C16 Želodec Stomach 461 226 49,0 114 24,7 67 14,5
C18 Debelo črevo  Colon 784 661 84,3 203 25,9 10 –
C19–C20 Rektum in rektosigmoidna zveza  Rectum and rectosigmoid junction 608 479 78,8 252 41,4 212 34,9
C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts  177 18 10,2 22 12,4 3 –
C23–C24 Žolčnik in žolčevodi  Gallbladder and billiary tract 154 48 31,2 4 – 0 –
C25 Trebušna slinavka  Pancreas 300 53 17,7 49 16,3 6 –
C32 Grlo  Larynx 121 41 33,9 14 – 111 91,7
C33–C34 Sapnik, sapnici in pljuča  Trachea, bronchus and lung 1223 214 17,5 448 36,6 501 41,0
C43 Maligni melanom kože  Malignant melanoma of skin 437 431 98,6 4 – 19 4,3
C44 Druge maligne neoplazme kože  Skin, other malignomas 1808 1634 90,4 12 – 98 5,4
C48–C49 Vezivno in mehko tkivo  Connective and soft tissue 66 54 81,8 21 31,8 24 36,4
C50 Dojka  Breast 1153 988 85,7 973 84,4 538 46,7
C53 Maternični vrat  Cervix uteri 153 104 68,0 21 13,7 37 24,2
C54 Maternično telo  Corpus uteri 296 256 86,5 7 – 68 23,0
C56 Jajčnik  Ovary 174 147 84,5 122 70,1 1 –
C61 Prostata  Prostate 1032 510 49,4 509 49,3 81 7,8
C62 Modo  Testis 89 88 98,9 54 60,7 1 –
C64–C65 Ledvica z ledvičnim mehom Kidney with renal pelvis  300 238 79,3 22 7,3 7 –
C67 Sečni mehur  Bladder 278 246 88,5 44 15,8 23 8,3
C70–C72 Centralni in avtonomni živčni sistem  Central and autonomic nervous system 145 105 72,4 59 40,7 74 51,0
C73 Ščitnica  Thyroid gland 134 128 95,5 119 88,8 11 –
C81 Hodgkinova bolezen  Hodgkin's disease 48 1 – 42 87,5 23 47,9
C82–C85 Ne-Hodgkinovi limfomi  Non-Hodgkin's lymphoma 248 41 16,5 151 60,9 75 30,2
C90
Difuzni plazmocitom in maligne neoplazme 
plazmocitov  
Multiple myeloma and malignant plasma cell 
neoplasms 
111 4 – 59 53,2 28 25,2
C91–C95 Levkemije  Leukaemias 226 2 – 82 36,3 9 –
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
81
* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo 
* Patients that undergone multiple surgery procedures in the corse of first treatment were included with first procedure only
** V posamezni ustanovi so operirali manj kot 30 bolnikov
** Less then 30 patients were treated by surgery in indivdual institution
Tabela 10b: Število bolnikov, zbolelih v letu 2007, ki so bili v okviru prvega zdravljenja operirani*, po lokaciji 
raka in bolnišnici posega.
Table 10b: Number of patients, diagnosed in 2007, that were treated by surgery during their first treatment* 
by primary sites and tretament institution.
Šifra 
MKB 
ICD code
Primarna lokacija 
Primary site
Št
ev
ilo
 n
ov
ih
 pr
im
er
ov
 
Nu
m
be
r o
f n
ew
 ca
as
es
Št
ev
ilo
 op
er
ira
ni
h 
Nu
m
be
r o
f t
re
at
ed
 by
 su
rg
er
y
Sp
lo
šn
a b
ol
ni
šn
ica
 Ce
lje
Sp
lo
šn
a b
ol
ni
šn
ica
 Je
se
ni
ce
Sp
lo
šn
a b
ol
ni
šn
ica
 Iz
ol
a
Un
ive
rz
ite
tn
i k
lin
ičn
i c
en
te
r 
Lju
bl
jan
a
On
ko
lo
šk
i in
šti
tu
t L
ju
bl
jan
a
Un
ive
rz
ite
tn
i k
lin
ičn
i c
en
te
r 
M
ar
ib
or
Sp
lo
šn
a b
ol
ni
šn
ica
 M
ur
sk
a S
ob
ot
a
Sp
lo
šn
a b
ol
ni
šn
ica
 N
ov
a G
or
ica
Sp
lo
šn
a b
ol
ni
šn
ica
 N
ov
o m
es
to
Sp
lo
šn
a b
ol
ni
šn
ica
 Sl
ov
en
j G
ra
de
c
Za
se
bn
e o
rd
in
ac
ije
 
Pr
iva
te
 cl
in
ics
Os
ta
le 
us
ta
no
ve
**
 
Ot
he
r i
ns
tit
ut
io
ns
**
C00–
C96
Vse lokacije 
All sites 11607 7125 422 207 141 2574 1046 1085 277 267 273 396 329 108
C00–
C14
Usta in žrelo 
Mouth and pharynx 320 180 2 0 0 124 1 47 4 2 0 0 0 0
C15 Požiralnik Oesophagus 97 20 0 0 0 17 0 3 0 0 0 0 0 0
C16 Želodec Stomach 461 226 11 8 11 98 9 59 5 3 4 11 1 6
C18 Debelo črevo  Colon 784 661 51 51 36 226 21 105 38 39 36 30 10 18
C19–
C20
Rektum in rektosigmoidna zveza  
Rectum and rectosigmoid junction 608 479 33 22 20 166 55 74 28 17 21 16 16 11
C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts  177 18 0 0 0 10 1 7 0 0 0 0 0 0
C23–
C24
Žolčnik in žolčevodi  
Gallbladder and billiary tract 154 48 0 2 7 25 0 8 1 0 0 2 2 1
C25 Trebušna slinavka  Pancreas 300 53 0 0 8 32 0 12 0 0 0 0 0 1
C32 Grlo  Larynx 121 41 0 0 0 27 0 13 0 0 1 0 0 0
C33–
C34
Sapnik, sapnici in pljuča  
Trachea, bronchus and lung 1223 214 0 1 0 152 3 51 0 0 1 0 3 3
C43 Maligni melanom kože  Malignant melanoma of skin 437 431 44 11 4 162 72 36 11 5 18 10 41 17
C44 Druge maligne neoplazme kože  Skin, other malignomas 1808 1634 99 97 5 600 38 156 126 67 110 76 250 10
C48–
C49
Vezivno in mehko tkivo  
Connective and soft tissue 66 54 2 2 1 7 34 4 1 0 0 1 1 1
C50 Dojka  Breast 1153 988 48 2 12 4 602 198 6 69 14 30 1 2
C53 Maternični vrat  Cervix uteri 153 104 4 1 3 51 9 14 2 1 2 3 0 14
C54 Maternično telo  Corpus uteri 296 256 23 2 5 124 31 37 4 7 4 9 0 10
C56 Jajčnik  Ovary 174 147 15 1 2 52 32 28 3 3 3 3 0 5
C61 Prostata  Prostate 1032 510 36 0 3 184 0 82 23 10 23 148 0 1
C62 Modo  Testis 89 88 3 0 5 45 0 17 4 1 5 7 0 1
C64–
C65
Ledvica z ledvičnim mehom 
Kidney with renal pelvis  300 238 16 0 4 120 0 34 10 12 13 29 0 0
C67 Sečni mehur  Bladder 278 246 20 0 7 128 0 41 7 22 8 13 0 0
C70–
C72
Centralni in avtonomni živčni sistem  
Central and autonomic nervous system 145 105 0 0 0 85 0 20 0 0 0 0 0 0
C73 Ščitnica  Thyroid gland 134 128 0 0 2 15 102 5 0 0 0 1 3 0
C81 Hodgkinova bolezen  Hodgkin's disease 48 1 0 0 0 0 0 0 0 0 0 1 0 0
C82–
C85
Ne-Hodgkinovi limfomi  
Non-Hodgkin's lymphoma 248 41 4 4 3 16 5 4 0 2 3 0 0 0
C90
Difuzni plazmocitom in maligne 
neoplazme plazmocitov 
Multiple myeloma and malignant plasma 
cell neoplasms
111 4 0 0 0 2 0 1 0 0 1 0 0 0
C91–
C95
Levkemije  
Leukaemias 226 2 0 1 0 0 0 0 1 0 0 0 0 0
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
82
* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat
* Patients that undergone multiple systemic tretaments in the corse of first treatment were included with first tretament only
** V posamezni ustanovi so zdravili manj kot 10 bolnikov
** Less then 10 patients were treated in indivdual institution
Tabela 10c: Število bolnikov, zbolelih v letu 2007, ki so v okviru prvega zdravljenja prejeli sistemsko terapijo*, 
po lokacijah raka in bolnišnici posega.
Table 10c: Number of patients diagnosed in 2007, that were treated by sistemic therapy during their first 
treatment* by primary sites and tretament institution.
Šifra 
MKB 
ICD code
Primarna lokacija 
Primary site
Št
ev
ilo
 n
ov
ih
 pr
im
er
ov
 
Nu
m
be
r o
f n
ew
 ca
as
es
Št
ev
ilo
 zd
ra
vlj
en
ih
 s 
sis
te
m
sk
o 
te
ra
pi
jo
 
Nu
m
be
r o
f t
re
at
ed
 si
ste
m
ic 
th
er
ap
y
Sp
lo
šn
a b
ol
ni
šn
ica
 Ce
lje
Bo
ln
išn
ica
 G
ol
ni
k
Sp
lo
šn
a b
ol
ni
šn
ica
 Iz
ol
a
Un
ive
rz
ite
tn
i k
lin
ičn
i c
en
te
r 
Lju
bl
jan
a
On
ko
lo
šk
i in
šti
tu
t L
ju
bl
jan
a
Un
ive
rz
ite
tn
i k
lin
ičn
i c
en
te
r 
M
ar
ib
or
Sp
lo
šn
a b
ol
ni
šn
ica
 M
ur
sk
a S
ob
ot
a
Sp
lo
šn
a b
ol
ni
šn
ica
 N
ov
a G
or
ica
Sp
lo
šn
a b
ol
ni
šn
ica
 N
ov
o m
es
to
Sp
lo
šn
a b
ol
ni
šn
ica
 Sl
ov
en
j G
ra
de
c 
Za
se
bn
e o
rd
in
ac
ije
 
Pr
iva
te
 cl
in
ics
Os
ta
le 
us
ta
no
ve
**
 
Ot
he
r i
ns
tit
ut
io
ns
**
C00–
C96
Vse lokacije 
All sites 11607 3598 129 79 15 300 2511 357 34 57 25 30 42 19
C00–
C14
Usta in žrelo 
Mouth and pharynx 320 71 1 0 0 1 69 0 0 0 0 0 0 0
C15 Požiralnik Oesophagus 97 26 0 0 0 0 26 0 0 0 0 0 0 0
C16 Želodec Stomach 461 114 0 0 0 0 111 0 0 0 0 2 0 1
C18 Debelo črevo  Colon 784 203 19 0 0 3 175 1 0 0 0 5 0 0
C19–
C20
Rektum in rektosigmoidna zveza  
Rectum and rectosigmoid junction 608 252 9 0 1 1 239 1 0 0 0 1 0 0
C22 Jetra in intrahepatični vodi Liver and intrahepatic bile ducts  177 22 1 0 0 12 3 6 0 0 0 0 0 0
C23–
C24
Žolčnik in žolčevodi  
Gallbladder and billiary tract 154 4 0 0 0 0 3 1 0 0 0 0 0 0
C25 Trebušna slinavka  Pancreas 300 49 0 0 0 6 41 1 0 0 0 0 0 1
C32 Grlo  Larynx 121 14 0 0 0 1 13 0 0 0 0 0 0 0
C33–
C34
Sapnik, sapnici in pljuča  
Trachea, bronchus and lung 1223 448 0 77 0 0 355 14 0 0 0 0 0 2
C43 Maligni melanom kože  Malignant melanoma of skin 437 4 0 0 0 0 4 0 0 0 0 0 0 0
C44 Druge maligne neoplazme kože  Skin, other malignomas 1808 12 3 0 0 0 1 5 0 0 1 0 2 0
C48–
C49
Vezivno in mehko tkivo  
Connective and soft tissue 66 21 1 0 0 2 17 0 1 0 0 0 0 0
C50 Dojka  Breast 1153 973 25 1 3 1 719 187 0 25 1 5 2 4
C53 Maternični vrat  Cervix uteri 153 21 0 0 0 0 21 0 0 0 0 0 0 0
C54 Maternično telo  Corpus uteri 296 7 0 0 0 0 3 4 0 0 0 0 0 0
C56 Jajčnik  Ovary 174 122 0 0 0 0 102 20 0 0 0 0 0 0
C61 Prostata  Prostate 1032 509 48 0 8 162 80 97 22 26 18 5 36 7
C62 Modo  Testis 89 54 0 0 0 0 54 0 0 0 0 0 0 0
C64–
C65
Ledvica z ledvičnim mehom 
Kidney with renal pelvis  300 22 0 0 0 9 10 2 0 1 0 0 0 0
C67 Sečni mehur  Bladder 278 44 2 0 0 10 29 0 2 0 1 0 0 0
C70–
C72
Centralni in avtonomni živčni sistem  
Central and autonomic nervous system 145 59 0 0 0 7 52 0 0 0 0 0 0 0
C73 Ščitnica  Thyroid gland 134 119 0 0 1 2 113 0 0 0 0 1 2 0
C81 Hodgkinova bolezen  Hodgkin's disease 48 42 0 0 0 4 38 0 0 0 0 0 0 0
C82–
C85
Ne-Hodgkinovi limfomi  
Non-Hodgkin's lymphoma 248 151 1 1 0 7 135 2 2 1 0 1 0 1
C90
Difuzni plazmocitom in maligne 
neoplazme plazmocitov 
Multiple myeloma and malignant plasma 
cell neoplasms
111 59 8 0 0 19 5 6 7 2 3 6 0 3
C91–
C95
Levkemije  
Leukaemias 226 82 11 0 2 45 7 10 0 2 1 4 0 0
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
83
* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah 
skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat
*  For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the 
all sites group each person is counted once only
Tabela 11:  Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2007.
Table 11:  Prevalence of cancer patients by sex and by selected primary site, Slovenia, December 31, 2007.
Šifra MKB 
ICD code
Primarna lokacija* 
Primary site*
Spol 
Sex
Leta po diagnozi
Years after diagnosis
Celokupna 
prevalenca
Overall 
prevalence
<1 1–4 5–9 10+ 31.12.2007
C00 
– 
C96
Vse lokacije  
 
All sites
Skupaj 7963 21720 16549 24444 70676Total
Moški 4036 10056 6884 8111 29087Males
Ženske 3927 11664 9665 16333 41589Females
C00–C14
Usta in žrelo M 216 474 305 488 1483
Mouth and pharynx Ž 54 163 135 169 521
C15    
Požiralnik M 46 32 16 30 124
Oesophagus Ž 7 10 6 7 30
C16    
Želodec M 167 308 205 339 1019
Stomach Ž 112 212 162 314 800
C18    
Debelo črevo M 331 813 553 460 2157
Colon Ž 269 698 504 592 2063
C19–C20
Rektum in rektosigmoidna zveza M 284 727 450 426 1887
Rectum and rectosigmoid junction Ž 212 486 344 500 1542
C22    
Jetra in intrahepatični vodi M 53 38 5 11 107
Liver and intrahepatic bile ducts Ž 14 16 4 13 47
C23 
–C24
Žolčnik in žolčevodi M 29 29 21 21 100
Gallbladder and billiary tract Ž 48 39 15 25 127
C25    
Trebušna slinavka M 67 29 16 14 126
Pancreas Ž 54 41 14 14 123
C32    
Grlo M 102 240 219 308 869
Larynx Ž 10 29 27 45 111
C33–C34
Sapnik, sapnici in pljuča M 473 589 248 354 1664
Trachea, bronchus and lung Ž 204 228 109 106 647
C43    
Maligni melanom kože M 197 523 347 324 1391
Malignant melanoma of skin Ž 232 601 480 718 2031
C44    
Druge maligne neoplazme kože M 855 2711 1945 2151 7662
Skin, other malignomas Ž 922 3082 2211 2909 9124
C48–C49
Vezivno in mehko tkivo M 23 64 59 136 282
Connective and soft tissue Ž 36 87 57 161 341
C50    
Dojka M 5 20 21 21 67
Breast Ž 1093 3664 3094 4135 11986
C53    
Maternični vrat M – – – – –
Cervix uteri Ž 143 590 679 2280 3692
C54    
Maternično telo M – – – – –
Corpus uteri Ž 280 934 953 1715 3882
C56    
Jajčnik M – – – – –
Ovary Ž 155 387 320 659 1521
C61    
Prostata M 952 2311 1299 355 4917
Prostate Ž – – – – –
C62    
Modo M 88 375 387 773 1623
Testis Ž – – – – –
C64–C65
Ledvica z ledvičnim mehom M 163 419 280 293 1155
Kidney with renal pelvis Ž 76 239 188 283 786
C67    
Sečni mehur M 162 423 225 282 1092
Bladder Ž 58 138 81 112 389
C70–C72
Centralni in avtonomni živčni sistem M 49 83 55 148 335
Central and autonomic nervous system Ž 34 57 50 111 252
C73    
Ščitnica M 27 94 79 109 309
Thyroid gland Ž 100 383 276 425 1184
C81    
Hodgkinova bolezen M 28 99 74 261 462
Hodgkin's disease Ž 17 67 91 227 402
C82–C85
Ne-Hodgkinovi limfomi M 93 264 217 321 895
Non-Hodgkin's lymphoma Ž 108 347 219 310 984
C90    
Difuzni plazmocitom in maligne neoplazme plazmocitov M 45 97 36 21 199
Multiple myeloma and malignant plasma cell neoplasms Ž 37 81 31 24 173
C91–C95
Levkemije M 87 200 178 198 663
Leukaemias Ž 64 140 134 240 578
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
84
Nadaljevanje   —>
Continued   —>
Tabela 12:  Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2007.
Table 12:  Mortality by site, by sex and by age, Slovenia 2007.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti Starosti
ICD 
code Primary site Sex
All 
ages
Age
0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80–
C00
–
C97
Vse lokacije
All sites
M+Ž 5537 5 0 3 6 6 10 22 38 81 145 307 486 534 705 894 966 1329
M 3146 3 0 2 4 4 7 13 23 43 84 192 308 349 448 560 547 559
Ž 2391 2 0 1 2 2 3 9 15 38 61 115 178 185 257 334 419 770
C00 Ustnica M 4 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 1Lip Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
C01 Baza jezika M 3 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0Base of tongue Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C02 Jezik, drugi deli M 13 0 0 0 0 0 0 0 0 0 1 2 1 2 2 1 2 2Tongue, other & unspecified parts Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1
C04 Ustno dno M 9 0 0 0 0 0 0 0 0 0 1 1 1 1 3 2 0 0Floor of mouth Ž 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1
C05 Nebo M 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0Palate Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C06 Usta, drugi deli M 11 0 0 0 0 0 0 0 0 0 0 2 1 2 2 0 2 2Mouth, other & unspecified parts Ž 3 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0
C07 Parotidna žleza M 6 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 3Parotid gland Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
C08 Druge in neopredeljene velike žleze slinavke M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1Other & unspecified major salivary glands Ž 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
C09 Tonzila M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0Tonsil Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C10 Orofarinks M 38 0 0 0 0 0 0 0 0 1 4 8 5 9 6 1 3 1Oropharynx Ž 6 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 2
C11 Nazofarinks M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0Nasopharynx Ž 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
C12 Piriformni sinus M 4 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 1Pyriform sinus Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C13 Hipofarinks M 24 0 0 0 0 0 1 0 0 0 2 4 4 6 3 2 2 0Hypopharynx Ž 4 0 0 0 0 0 0 0 0 0 1 2 0 0 1 0 0 0
C14
Druga in slabo opredeljena mesta na ustnici, v 
ustni votlini in farinksu M 10 0 0 0 0 0 0 0 0 0 0 2 2 2 1 1 2 0
Other and ill-defined sites in the lip, oral cavity 
and pharynx Ž 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0
C15 Požiralnik M 84 0 0 0 0 0 0 0 0 2 5 8 15 9 12 8 11 14Oesophagus Ž 15 0 0 0 0 0 0 0 0 0 0 0 2 3 0 1 3 6
C16 Želodec M 218 0 0 0 0 0 2 2 1 3 4 9 14 27 43 38 31 44Stomach Ž 142 0 0 0 0 0 0 1 1 0 6 6 5 7 14 19 25 58
C17 Tanko črevo M 6 0 0 0 0 0 0 0 0 0 0 2 1 0 2 1 0 0Small intestine Ž 7 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 5
C18 Debelo črevo M 256 0 0 0 0 0 1 0 1 1 5 13 17 27 40 54 44 53Colon Ž 200 0 0 0 0 0 0 1 1 0 0 3 14 13 29 25 42 72
C19 Rektosigmoidna zveza M 42 0 0 0 0 0 0 0 0 0 1 1 2 4 4 6 18 6Rectosigmoid junction Ž 29 0 0 0 0 0 0 0 0 0 0 1 2 4 1 3 6 12
C20 Rektum M 134 0 0 0 0 0 0 0 0 2 3 5 5 17 14 36 31 21Rectum Ž 114 0 0 0 0 0 0 0 0 0 1 3 6 7 13 16 20 48
C21 Anus in analni kanal M 4 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1 1 0Anus and anal canal Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C22 Jetra in intrahepatični vodi M 114 0 0 0 0 0 0 0 0 0 4 4 14 14 16 26 21 15Liver and intrahepatic bile ducts Ž 68 0 0 0 0 0 0 0 0 0 1 3 4 7 6 12 15 20
C23 Žolčnik M 17 0 0 0 0 0 0 0 0 0 0 0 0 0 4 1 8 4Gallbladder Ž 52 0 0 0 0 0 0 0 0 0 0 2 5 2 3 10 11 19
C24 Drugi in neopredeljeni deli biliarnega trakta M 23 0 0 0 0 0 0 0 0 1 0 0 2 2 4 6 4 4Billiary tract, other and unspecified parts Ž 41 0 0 0 0 0 0 0 0 0 0 2 2 0 4 6 10 17
C25 Trebušna slinavka M 158 0 0 0 0 0 0 0 1 2 9 19 23 17 19 22 27 19Pancreas Ž 141 0 0 0 0 0 0 0 0 1 0 3 9 17 13 27 29 42
C26
Druga in slabo opredeljena mesta v prebavnih 
organih M 10 0 0 0 0 0 0 0 0 0 1 1 0 1 0 1 4 2
Other and ill-defined digestive organs Ž 12 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 1 8
C30 Nosna votlina in srednje uho M 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0Nasal cavity and middle ear Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
C31 Obnosni sinusi M 3 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0Accessory sinuses Ž 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
C32 Grlo M 45 0 0 0 0 0 0 0 0 0 0 4 8 8 8 4 6 7Larynx Ž 5 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0 2 0
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
85
Nadaljevanje   —>
Continued   —>
Tabela 12:  Nadaljevanje.
Table 12:  Continued.
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti Starosti
ICD 
code Primary site Sex
All 
ages
Age
0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80–
C33 Sapnik M 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0Trachea Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0
C34 Sapnica in pljuča M 830 0 0 0 0 0 0 0 2 10 17 66 118 105 139 156 124 93Bronchus and lung Ž 295 0 0 0 0 0 0 0 3 9 7 20 32 26 38 39 50 71
C37 Timus M 4 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 1 0Thymus Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C38 Srce, mediastinum, plevra M 9 0 0 0 0 0 0 0 0 0 1 1 0 0 1 2 1 3Heart, mediastinum, pleura Ž 8 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 1 3
C40 Kosti, sklepni hrustanec udov M 5 0 0 0 0 0 1 1 1 0 0 0 1 0 0 0 0 1Bone and articular cartilage of limbs Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
C41
Kosti, sklepni hrustanec, drugje M 9 0 0 0 0 1 0 1 0 2 1 0 0 3 0 0 1 0
Bone and articular cartilage of other and 
unspecified parts Ž 3 0 0 0 0 0 0 0 2 0 0 0 0 0 0 1 0 0
C43 Maligni melanom kože M 64 0 0 0 0 0 1 0 3 2 3 5 6 8 9 10 9 8Malignant melanoma of skin Ž 41 0 0 0 0 1 1 1 1 3 2 4 0 4 3 5 3 13
C44 Druge maligne neoplazme kože M 12 0 0 0 0 0 0 1 0 0 0 0 0 1 0 3 2 5Skin, other malignomas Ž 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 6
C45 Mezoteliom M 25 0 0 0 0 0 0 0 0 0 0 1 9 3 7 1 3 1Mesothelioma Ž 8 0 0 0 0 0 0 0 0 1 0 0 0 1 3 0 0 3
C46 Kaposijev sarkom M 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0Kaposi's sarcoma Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C47 Periferni živci in avtonomno živčevje M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0Peripheral and authonomic nervous system Ž 2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0
C48 Peritonej in retroperitonej M 4 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 0 1Retroperitoneum and peritoneum Ž 17 0 0 0 0 0 0 0 0 0 0 0 0 1 2 3 7 4
C49 Drugo vezivno in mehko tkivo M 3 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 1Other connective and soft tissue Ž 9 0 0 0 0 0 0 0 0 1 1 3 1 0 0 0 0 3
C50 Dojka M 3 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0Breast Ž 399 0 0 0 0 0 0 2 2 13 14 17 35 34 41 36 86 119
C51 Žensko zunanje spolovilo M – – – – – – – – – – – – – – – – – –Vulva Ž 20 0 0 0 0 0 0 0 0 0 0 1 0 1 2 3 5 8
C52 Nožnica M – – – – – – – – – – – – – – – – – –Vagina Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0
C53 Maternični vrat M – – – – – – – – – – – – – – – – – –Cervix uteri Ž 44 0 0 0 0 0 0 1 1 1 6 4 6 3 3 3 5 11
C54 Maternično telo M – – – – – – – – – – – – – – – – – –Corpus uteri Ž 45 0 0 0 0 0 0 0 0 0 0 1 3 6 7 9 5 14
C55 Maternica, neopredeljeno M – – – – – – – – – – – – – – – – – –Uterus, unspecified Ž 34 0 0 0 0 0 0 0 0 1 1 0 8 1 3 6 2 12
C56 Jajčnik M – – – – – – – – – – – – – – – – – –Ovary Ž 133 0 0 0 0 0 0 1 0 3 8 10 12 10 15 28 22 24
C57 Drugi in neopredeljeni ženski spolni organi M – – – – – – – – – – – – – – – – – –Other and unspecified parts of female genital organs Ž 11 0 0 0 0 0 0 0 0 0 0 0 1 2 0 2 3 3
C60 Penis M 3 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1Penis Ž – – – – – – – – – – – – – – – – – –
C61 Prostata M 347 0 0 0 0 0 0 0 0 0 0 0 6 15 38 75 73 140Prostate Ž – – – – – – – – – – – – – – – – – –
C62 Modo M 9 0 0 0 0 1 0 0 2 2 0 1 0 1 0 1 1 0Testis Ž – – – – – – – – – – – – – – – – – –
C64 Ledvica razen meha M 80 0 0 0 0 0 0 0 2 4 2 6 11 11 12 7 17 8Kidney, except renal pelvis Ž 52 0 0 0 0 1 0 0 0 0 0 2 2 4 5 10 6 22
C65 Ledvični meh M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0Renal pelvis Ž 3 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 0
C66 Sečevod M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0Ureter Ž 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2
C67 Sečni mehur M 130 0 0 0 0 0 0 0 0 0 2 4 6 6 9 33 38 32Bladder Ž 38 0 0 0 0 0 0 0 0 0 3 1 0 1 1 6 5 21
C68 Drugi in neopredeljeni sečni organi M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1Other and unspecified urinary organs Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
C69 Oko in očesni adneksi M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0Eye and adnexa Ž 2 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0
C70 Meninge M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0Meninges Ž 7 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 4
C71 Možgani M 82 3 0 1 2 0 1 3 3 3 8 10 13 10 2 10 4 9Brain Ž 55 0 0 0 0 0 0 1 1 3 2 8 0 5 10 12 5 8
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
86
Tabela 12:  Nadaljevanje.
Table 12:  Continued.
* Vir: Inštitut za varovanje zdravja RS
 * Source: Institute of Public Health RS
Šifra 
MKB Primarna lokacija Spol
Vse 
starosti Starosti
ICD 
code Primary site Sex
All 
ages
Age
0– 5– 10– 15– 20– 25– 30– 35– 40– 45– 50– 55– 60– 65– 70– 75– 80–
C72
Hrbtni mozeg, možganski živci in drugi deli CŽS M 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Spinal cord, cranial nerves and other parts 
of CNS Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
C73 Ščitnica
M 5 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0 1 1
Thyroid gland Ž 7 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 3
C74 Nadledvična žleza
M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0
Adrenal gland Ž 7 0 0 0 0 0 0 1 1 0 1 0 1 0 0 0 1 2
C75 Druge endokrine žleze in sorodne strukture
M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1
Other endocrine glands and related structures Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C76 Druga in slabo opredeljena mesta
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other and ill-defined sites Ž 7 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 4
C77
Metastaza in neopredeljena maligna 
neoplazma bezgavk M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
Metastasis and unspecified malignant 
neoplasm of lymph nodes Ž 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1
C78 Metastaze dihal in prebavil
M 25 0 0 0 0 0 0 0 1 0 1 1 3 2 2 2 4 9
Metastases of respiratory and digestive organs Ž 36 0 0 0 0 0 0 0 0 0 0 1 2 0 6 6 4 17
C79 Metastaze, drugje
M 10 0 0 0 0 0 0 0 0 1 1 0 0 3 2 1 1 1
Metastases of other sites Ž 9 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 2 4
C80
Maligna neoplazma brez opredeljenega mesta M 24 0 0 0 0 0 0 0 1 0 1 1 3 2 2 6 5 3
Malignant neoplasm without specification 
of site Ž 29 0 0 0 0 0 0 0 0 0 1 3 4 3 3 4 4 7
C81 Hodgkinova bolezen
M 8 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 5 0
Hodgkin's disease Ž 2 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0
C82 Folikularni ne-Hodgkinov limfom
M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
Follicular non-Hodgkin's lymphoma Ž 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4
C83 Difuzni ne-Hodgkinov limfom
M 8 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1 3 1
Diffuse non-Hodgkin's lymphoma Ž 8 0 0 0 0 0 0 0 0 0 0 1 2 0 0 1 2 2
C84 Limfomi celic T in kožni limfom celic T
M 10 0 0 0 1 0 0 0 0 1 0 0 1 0 2 2 2 1
Peripheral and cutaneous T-cell lymphomas Ž 3 0 0 0 0 0 0 0 0 0 0 0 2 0 0 1 0 0
C85
Druge in neopredeljene vrste ne-Hodgkinovega 
limfoma M 51 0 0 0 0 0 0 1 1 2 1 1 5 5 6 8 9 12
Other and unspecified types of non-Hodgkin's 
lymphoma Ž 45 0 0 0 0 0 0 0 0 1 1 2 5 4 6 8 4 14
C88 Maligne imunoproliferativne bolezni
M 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
Malignant immunoproliferative diseases Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
C90
Difuzni plazmocitom in maligne neoplazme 
plazmocitov M 30 0 0 0 0 0 0 0 0 0 2 1 0 5 7 6 2 7
Multiple myeloma and malignant plasma cell 
neoplasms Ž 52 0 0 0 0 0 0 0 0 0 0 0 3 5 5 10 11 18
C91 Limfatična levkemija
M 36 0 0 1 1 1 0 2 1 2 1 1 2 3 4 1 9 7
Lymphoid leukaemia Ž 20 1 0 0 0 0 0 0 0 0 0 0 0 2 2 3 4 8
C92 Mieloična levkemija
M 41 0 0 0 0 1 0 0 2 1 0 0 5 5 8 8 5 6
Myeloid leukaemia Ž 28 1 0 1 1 0 1 0 1 1 1 1 0 3 5 2 4 6
C93 Monocitna levkemija
M 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0
Monocytic leukaemia Ž 3 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 0 0
C95 Levkemija z neopredeljenim celičnim tipom
M 9 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 2 3
Leukaemia, unspecified cell type Ž 14 0 0 0 0 0 0 0 0 0 0 3 0 2 1 0 1 7
C96
Druge in neopredeljene maligne neoplazme 
limfatičnega, krvotvornega in sorodnega tkiva M 4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1
Other & unspecified malignant neoplasms of 
lymphoid, haemopoetic & related tissues Ž 7 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 4
C97
Maligne neoplazme na več neodvisnih 
(primarnih) mestih M 7 0 0 0 0 0 0 0 0 0 0 0 0 1 1 4 0 1
Malignant neoplasms of independant 
(primary) multiple sites Ž 8 0 0 0 0 0 0 0 0 0 0 0 1 1 2 0 2 2
Zgoraj neupoštevani
Not included above
D32 Meninge, benigna neopalzma
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Benign neoplasm of meninges Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
D33
CŽS, benigna neoplazma M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Benign neoplasm of brain and other parts 
of CNS Ž 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
D43 CŽS, neopredeljeno
M 4 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 1
CNS, uncertain or unknown Ž 4 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
87
IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in
Registra raka objavili v zadnjih petih letih (tudi v
sodelovanju z drugimi raziskovalci)
SELECTED PUBLICATIONS, published by the members of
Epidemiology and Cancer Registry in the last five years
(also in cooperation with other researchers)
2005
– Bray F, Carstensen B, Moller H, Zappa M, Žakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of
the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005; 14: 2191–9.
– Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Pompe-Kirn V, et al. Second primary cancers among
109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93: 159–66.
– Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tracey E, AndersenA, Pompe-Kirn V, et al. Second primary
malignancies in patients with male breast cancer. Br J Cancer 2005; 92: 1288–92.
– Kobal AB, Horvat M, Prezelj M, Pompe-Kirn V, Zadnik V, Osredkar J, et al. Vpliv elementarnega živega srebra na
peroksidacijo lipidov in funkcijsko sposobnost posameznih tarčnih organov pri prebivalcih mesta Idrija in delavcih
rudnika: zaključno poročilo raziskovalnega projekta (skrajšana verzija). Idrij Razgl 2005; 50: 20–30.
– Norčič G, Repše S, Pompe-Kirn V. Rak debelega črevesa in danke v Sloveniji - razlike v kirurškem zdravljenju in
preživetju bolnikov. Zdrav vestn 2005; 74: 12, 767–70.
– Pompe-Kirn V. Podrobnejši pregled trenda incidence raka ščitnice v obdobju 1983–2002 v Sloveniji. Onkologija
2005; 9: 12–4.
– Primic Žakelj M. Epidemiology of breast cancer: incidence and mortality trends, prevention and control. 3rd
Sarajevo breast cancer conference. Sarajevo: ESO, 2005: 15–27.
– Primic Žakelj M. Prenovljeni evropski kodeks proti raku. In: Štabuc B, ed. Poročilo Zveze in regijskih društev za
boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 6–11.
– Primic Žakelj M. Zgodnje odkrivanje pogostejših rakov pri starejših. In: Turk J, ed. Zdrava poznejša leta. Ljubljana:
Društvo za zdravje srca in ožilja Slovenije, 2005: 97–110. 
– Primic Žakelj M, Zadnik V. Epidemiologija raka dojk v Sloveniji in v svetu. In: Štabuc B, ed. Poročilo Zveze in regijskih
društev za boj proti raku Slovenije: leto 2004. Ljubljana: Zveza društev za boj proti raku Slovenije, 2005: 13–6.
– Primic Žakelj M, Zadnik V. Presejanje in zgodnje odkrivanje raka. In: Štabuc B, ed. Zgodnje odkrivanje raka - izzivi
za prihodnost. XIII. seminar "In memoriam dr. Dušana Reje", Zbornik. Ljubljana: Zveza slovenskih društev za boj
proti raku, 2005: 8–13.
– Primic Žakelj, Zadnik V. Raziskovalno delo službe epidemiologija in registri raka na Onkološkem inštitutu. In:
Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta, 2005: 125–34.
– Primic Žakelj, Zadnik V, Žagar T. Epidemiološki podatki o raku materničnega vratu v Sloveniji. In: Takač I, ed. 50 let
laboratorija za ginekološko citologijo v Mariboru. Mednarodni znanstveni simpozij. Maribor: Splošna bolnišnica,
2005: 151–60.
– Primic-Žakelj M, Zadnik V, Žagar T. Is cancer epidemiology different in Western Europe to that in Eastern Europe?
Ann Oncol 2005; 16 Suppl 2: ii 27–9.
– Zadnik V: Evropska raziskava vplivov dejavnikov tveganja na zbolevanje za rakom dojk pri mladih ženskah:
podatki za Slovenijo. In: Bilban M, ed. Cvahtetovi dnevi javnega zdravja 2005. Ljubljana: Medicinska fakulteta,
2005: 135–49.
– Zadnik V, Primic Žakelj M. Epidemiologija želodčnega raka. In: Omejc M, Repše S, eds: Kirurgija želodca - standardi
in novosti. Simpozij. Ljubljana: Klinični oddelek za abdominalno kirurgijo, SPS Kirurška klinika, Klinični center,
2005: 122–7.
– Žagar T, Primic Žakelj, Zadnik V. Povezovanje Registra raka za Slovenijo s sorodnimi državnimi podatkovnimi
zbirkami. In: Tkačik B, Urbas M, eds. Komuniciranje z dajalci in uporabniki statističnih podatkov ter podpora
EMU in Lizbonski strategiji. 15. statistični dnevi. Ljubljana: Statistični urad Republike Slovenije, Statistično društvo
Slovenije, 2005: 268–77.
– Žagar T. Lifetables for Slovenia 1982–2004. Rostock: Max Planck, 2005: 1–94. 
http: //www.lifetable.de/cgi-bin/country.plx?country=Slovenia.
Izbor publikacij Selected publications 
88
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
2006
– Hertl K, Primic Žakelj M, Žgajnar J, Kocijančič I. Performance of opportunistic breast cancer screening in Slovenia.
Neoplasma 2006; 53: 237–41.
– Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Pompe-Kirn V, et al. Risk of second cancer among
women with breast cancer. Int J Cancer 2006; 118: 2285–92.
– Pompe-Kirn V, Primic Žakelj M. Ali vemo, koliko je raka prostate v Sloveniji in kaj vpliva na razvoj te bolezni?
Onkologija 2006; 10: 9–13. 
– Pompe-Kirn V. Obolevnost za rakom dojk med ženskami, vključenimi v pilotno študijo. Onkologija 2006; 10: 96–8. 
– Primic Žakelj M, Zadnik V, Žagar T. Breast cancer risk factors. Liječ Vjesn 2006; 128, Suppl 3: 49–50. 
– Primic Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke (Epidemiology of colorectal
cancer. In: Repše S, Štor Z eds. Kirurgija raka debelega črevesa in danke: standardi in novosti. Zbornik simpozija
(Standards & novelties: proceedings of the symposium, Ljubljana 2006. Ljubljana: Kirurška šola, Klinični oddelek
za abdominalno kirurgijo, Kirurška klinika, Klinični center, 2006: 14–20. 
– Primic Žakelj M, Zadnik V, Žagar T. Ali se učinki programa ZORA že kažejo v incidenci invazijskega raka
materničnega vratu. In: Možina A ed. Dan ginekološke onkologije: rak jajčnikov. Zbornik. Ljubljana: Združenje za
ginekološko onkologijo, kolposkopijo in cervikalno patologijo: Ginekološka klinika, Klinični center, 2006: 55–6. 
– Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Pompe-Kirn V, et al. Second primary
cancers in thyroid cancer patients : a multinational record linkage study. J Clin Endocrinol Metab 2006; 91: 1819 25. 
– Scélo G, Boffetta P, Hemminki K, Pukala E, Olsen JH, Andersen A, Pompe-Kirn V, et al. Associations between small
intestine cancer and other primary cancers: an international population-based study. Int J Cancer 2006; 118: 189–96.
– Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E, Pompe-Kirn V, et al. A pooled analysis of
second primary pancreatic cancer. Am J Epidemiol 2006; 163: 502–11. 
– Snoj M, Zadnik V. Starostnik z rakom - kirurški bolnik. In: Smrkolj V ed. Kirurgija v starostnem obdobju: zbornik
povzetkov. Ljubljana: Združenje kirurgov Slovenije, 2006: 28–36.
– Strojan P, Šmid A, Čizmarevič B, Žagar T, Auersperg M. Verrucous carcinoma of the larynx: determining the best
treatment option. Eur J Surg Oncol 2006; 32: 984–8.
– Steliarova-Foucher E, Kaatsch P, Lacour B, Pompe-Kirn V, Eser S, Miranda A, et al. Quality, comparability and
methods of analysis of data on childhood cancer in Europe (1978–1997): report from the Automated Childhood
Cancer Information System project. Eur J Cancer 2006; 42: 1915–51. 
– Zadnik V, Primic Žakelj M. Breme želodčnega raka v svetu in Sloveniji (The burden of stomach cancer worldwide
and in Slovenia). In: Zbornik predavanj XII. podiplomskega tečaja kirurgije, 10.–11. februar 2006. Ljubljana:
Kirurška klinika, Klinični center, 2006: 77–80. 
– Zadnik V, Reich BJ. Analysis of the relationship between socioeconomic factors and stomach cancer incidence
in Slovenia. Neoplasma 2006; 53: 103–10. 
– Zadnik V. Geografska analiza razporejanja incidence raka. Onkologija 2006; 10: 92–5. 
– Zadnik V, Žagar T, Primic Žakelj M. Pojavljanje raka v občini Brežice v primerjavi z ostalo Slovenijo: geografska
analiza incidence raka v občini Brežice na podlagi podatkov Registra raka za Slovenijo: zaključno poročilo.
Ljubljana: Onkološki inštitut, 2006.
– Zadnik V, Žagar T, Primic Žakelj M. The geographical variation of cervical cancer screening efficiency in Slovenia.
In: Batagelj V, Ferligoj A, Žiberna A, eds. Data science and classification: program and abstracts. Ljubljana: Center
of Methodology and Informatics, Institute of Social Sciences at Faculty of Social Sciences, 2006; 173.
– Žagar T, Primic Žakelj M, Zadnik V. Pretok in uporaba informacij v Registru raka - najstarejšem zdravstvenem
registru v Sloveniji. Bilt ekon organ inform zdrav 2006; 22: 6. 
– Žagar T, Zadnik V, Pohar M, Primic Žakelj M. Complete yearly life tables by sex for Slovenia, 1982–2004, and their
use in public health [Popolne letne tablice umrljivosti za Slovenijo po spolu, 1982–2004, in možnosti uporabe
v javnem zdravju]. Radiol Oncol 2006; 40: 115–24. 
2007
– Arbyn M, Primic-Žakelj M, Raifu AO, Grce M, Paraskevaidis E, Diakomanolis E, et al. The burden of cervical cancer
in South-East Europe at the beginning of the 21st century. Coll Antropol 2007; 31 Suppl 2: 7–10.
– Bidoli E, Zadnik V, De Dottori M, Zanier L, Serraino D. Prostate cancer pattern in the bordering areas of Friuli-Venezia
Giulia, Italy, and Slovenia, 1995–2003. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. At the crossroad of tradition and
new technologies in cancer registration. The role of cancer registries in cancer control: programme and book
of abstracts. Ljubljana: Institute of Oncology, 2007.
89
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
– Bizjak-Ogrinc U, Čufer T, Pompe-Kirn V. Survival of patients with invasive urinary bladder cancer in Slovenia
regarding to stage of disease and treatment in years 1987–1997. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. At
the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer
control: programme and book of abstracts. Ljubljana: Institute of Oncology, 2007.
– Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Tracey E, Pompe-Kirn V, et al. Risk of second malignant
neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst 2007; 10: 790–800.
– Primic-Žakelj M. Epidemiologija raka pri moških in ženskah. In: Mlakar-Mastnak D, Lokar K, eds. Ženske, moški
in rak. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in
babiške nege Slovenije - Zvezi društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije; 2007.
– Primic-Žakelj M. Obvladovanje raka v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. slovenski kongres
preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvlečkov.
Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007.
– Primic-Žakelj M. Rak materničnega vratu v Sloveniji in program ZORA. In: Kraigher A, Berger T, Piškur-Kosmač D,
eds. 4. slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem
tisočletju: knjiga izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007.
– Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. Zdrav Vest 2007; 76: 775–80. 
– Primic-Žakelj M, Žagar T. Breast cancer epidemiology in Slovenia. Senologie 2007; 4: 205. 
– Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija malignega melanoma. Radiol Oncol 2007; 41 Suppl 1: S1–S12. 
– Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija pljučnega raka. In: Rott T, Luzar B, eds. Pljučni rak - današnje
stanje in perspektive. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2007.
– Ravnik M, Arko D, Žagar T, Primic-Žakelj M, Čufer T. Breast cancer and second malignancies. Senologie 2007; 4: 209. 
– Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V, et al. Second malignancies
among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007;
120: 623–31.
– Riska A, Pukkala E, Scélo G, Mellemkjaer L, Hemminki K, Weiderpass E, Pompe-Kirn V, et al. Second primary
malignancies in females with primary fallopian tube cancer. Int J Cancer 2007; 120: 2047–51.
Scélo G, Boffetta P, Autier P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V. Associations between ocular
melanoma and other primary cancers: an international population-based study. Int J Cancer 2007; 120: 152–9. 
– Scélo G, Boffetta P, Corbex M, Chia KS, Hemminki K, Friis S, Pompe-Kirn V, et al. Second primary cancers in patients
with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. Cancer Causes Control 2007; 18: 269–78.
– Tuohimaa P, Pukkala E, Scélo G, Olsen JH, Brewster DH, Hemminki K, Pompe-Kirn V, et al. Does solar exposure,
as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation.
Eur J Cancer 2007; 43: 1701–12. 
– Zadnik V, Pompe-Kirn V. Effects of 500-year mercury mining and milling on cancer incidence in the region of
Idrija, Slovenia. Coll Antropol 2007; 31: 897–903.
– Zver S, Zadnik V, Bunc M, Rogel P, Černelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide in patients with
multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007; 85: 408–14.
– Žagar T, Droljc A. Connection of Cancer Registry of Slovenia to other state databases. In: Primic-Žakelj M, Žagar
T, Zadnik V, eds. At the crossroad of tradition and new technologies in cancer registration. The role of cancer
registries in cancer control: programme and book of abstracts. Ljubljana: Institute of Oncology, 2007.
– Žagar T, Zadnik V, Primic-Žakelj M. Različne možnosti prikazovanja geografskega razporejanja incidence raka na
materničnem vratu v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. 4. slovenski kongres preventivne
medicine, Portorož, 17. do 19. maj 2007. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvlečkov. Ljubljana:
Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2007.
2008
– Baili P, Micheli A, De Angelis R, Weir HK, Primic Žakelj M, Pompe-Kirn V, et al. Life tables for world-wide
comparison of relative survival for cancer (CONCORD study). Tumori 94: 658–68.
– Besic N, Cernivc B, de Grève J, Lokar K, Krajc M, Novakovic S, et al. BRCA2 gene mutations in Slovenian male breast
cancer patients. Genet Test 2008; 12: 203–9.
– Chuang S, Hashibe M, Scelo G, Brewster DH, Pukkala E, Pompe-Kirn V, et al. Risk of second primary cancer
among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers
Prev 2008; 17: 1543–9.
– Chuang S, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Pompe-Kirn V, et al. Risk of second primary cancer among
patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer 2008; 123: 2390–6.
– Glumac N, Hocevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict non-sentinel
involvement in cutaneous melanoma patients. J Surg Oncol 2008; 98: 46–8.
90
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007
– Gondos A, Bray F, Brewster DH, Coebergh JWW, Hakulinen T, Primic Žakelj M, et al. Recent trends in cancer
survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J
Cancer 2008; 44: 1463–75.
– Gouveia J, Coleman MP, Haward R, Zanetti R, Hakama M, Primic-Žakelj M, et al. Improving cancer control in the
European Union: conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007. Eur J
Cancer 2008; 44: 1457–62.
– Krajc M. Screening. In: Kovačič L, Zaletel-Kragelj L, eds. Management in health care practice: a handbook for
teachers, researchers and health professionals. Lage: Hans Jacobs Publishing Company; 2008. p. 286–307.
– Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, et al. Five recurrent BRCA1/2 mutations are
responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 2008;
983–91.
– Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Risk of second malignant neoplasms
after childhood central nervous system malignant tumours: an international study. Eur J Cancer 2008; 44: 830–9.
– Primic-Žakelj M. Cancer epidemiology. In: Schrijvers D, Zakotnik B, eds. ESMO handbook of cancer prevention.
London: Informa Healthcare; 2008. p. 1–9.
– Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Bilban M, ed. Zbornik prispevkov Cvahtetovih dnevov. Ljubljana:
Katedra za javno zdravje; 2008.
– Primic-Žakelj M, Zadnik V, Žagar T. Karcinom debelega črevesa in danke v Sloveniji in v Evropi (Colorectal cancer
in Slovenia and in Europe). In: Luzar B, Cerar A, Štabuc B, eds. Tumorji debelega črevesa in danke. Ljubljana:
Inštitut za patologijo, Medicinska fakulteta; 2008.
– Primic-Žakelj M, Žagar T. Cancer control in Slovenia: achievements, shortcomings and opportunities. In:
Coleman MP, ed. Responding to the challenge of cancer in Europe. Ljubljana: Institute of Public Health of the
Republic of Slovenia; 2008.
– Primic-Žakelj M, Žagar T, Zadnik V. Lung cancer in Slovenia (Pljučni rak v Sloveniji). Endosk rev 2008; 13: 5–13.
– Repše-Fokter A, Primic-Žakelj M. Auditing screening laboratories in Slovenia. Cytopathology 2008; 19 Suppl 1: 20.
– Repše-Fokter A, Primic-Žakelj M. Cervical cancer screening in Slovenia. Cytopathology 2008; 19 Suppl 1: 3.
– Robins G, Crabtree JE, Bailey A, Forman D, Pompe-Kirn V, et al. International variation in Helicobacter pylori
infection and rates of oesophageal cancer. Eur J Cancer. 2008; 44: 726–32.
– Rojnik K, Naversnik K, Mateović-Rojnik T, Primic Žakelj M. Probabilistic cost-effectiveness modeling of different
breast cancer screening policies in Slovenia. Value Health 11: 139–48.
– Sant M, Allemani C, De Angelis R, Carbone A, de Sanjosè S, Pompe-Kirn V, et al. Influence of morphology on
survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008; 44: 579–87.
– Tercelj M, Ales A, Rott T, Sever N, Prodnik L, Primic-Žakelj M, et al. DNA-based sputum cell image analysis for lung
cancer in a clinical setting. Acta Cytol 2008; 52: 584–90.
– Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Primic Žakelj M, Pompe-Kirn V, et al. Survival in patients with uveal
melanoma in Europe. Arch Ophthalmol 2008; 126: 1413–8.
– Zadnik V, Ivanuš U, Florjančič M, Primic-Žakelj M. Vloga registra ZORA pri obvladovanju bremena raka
materničnega vratu v Sloveniji (The role of ZORA registry in cervical cancer burden control in Slovenia). Bilt-ekon
organ inform zdrav 2008; 24:179–83.
– Zadnik V, Primic-Žakelj M. Rak pri ženskah. In: Štabuc B, Primic Žakelj M, Klemenčič M, Piškur J, eds. Rak rodil.
Ljubljana: Zveza slovenskih društev za boj proti raku; 2008.
– Zadnik V, Zagar T, Drobne S, Primic Zakelj M. Estimation of cancer burden in Brezice municipality, a community
neighboring Krsko nuclear power plant in Slovenia. Croat Med J 2008; 49: 257–66.
– Zadnik V, Žagar T, Primic-Žakelj M. Ginekološki raki v Sloveniji (Gynecological cancers in Slovenia). In: Takač I, ed.
80 let hospitalne ginekologije in porodništva v Maribor: mednarodni znanstveni simpozij. Maribor: Univerzitetni
klinični center Maribor; 2008.
– Zver S, Zadnik V, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients
with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol.
2008; 88: 227–36.
– Zwitter M, Primic-Žakelj M. Lung cancer in Europe. In: Parikh PM, ed. Lung cancer. Mumbai: Green Room Media
& Event Management Services; 2008. p. 350–7.
2009
– Anttila A, Ronco G, Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Zadnik V, et al. Description of the national situation
of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009; 45: 2685–708. 
– Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Primic-Žakelj M, et al. Comparative cancer survival
information in Europe. Eur J Cancer 2009; 45: 901–8. 
91
Onkološki inštitut Ljubljana, Register raka RS Rak v Sloveniji 2007
– Ciccolallo L, Licitra L, Cantú G, Gatta G, Pompe-Kirn V, Primic Žakelj M, et al. Survival from salivary glands adenoid
cystic carcinoma in European populations. Oral Oncol 2009; 45: 669–74. 
– De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Primic-Žakelj M, et al. The EUROCARE-4 database on cancer
survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009;
45: 909–30. 
– Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Primic-Žakelj M, et al. The cure of cancer: a European
perspective. Eur J Cancer 2009; 45: 1067–79. 
– Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Primic-Žakelj M, et al. Survival of European children
and young adults with cancer diagnosed 1995–2002. Eur J Cancer 2009; 45: 992–1005. 
– Gondos A, Bray F, Hakulinen T, Brenner H, Usel M, Zakelj MP, et al. Trends in cancer survival in 11 European
populations from 1990 to 2009: a model-based analysis. Ann Oncol 2009; 20: 564–73. 
– Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Pompe-Kirn V, Primic Žakelj M, et al. European disparities in malignant
digestive endocrine tumours survival. Int J Cancer 2009; available from: http: //www.ncbi.nlm.nih.gov/pubmed/19569047.
– Nicula FA, Anttila A, Neamtiu L, Zakelj MP, Tachezy R, Chil A, et al. Challenges in starting organised screening
programmes for cervical cancer in the new member states of the European Union. Eur J Cancer 2009; 45: 2679–84. 
– Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Primic Žakelj M, Zadnik V, et al. Oral contraceptive use and
BRCA penetrance: a case-only study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2107–13. 
– Primic Žakelj M, Pogačnik A, Uršič-Vrščaj M, Ivanuš U. Presejalni program ZORA po petih letih delovanja že kaže
pomembne javnozdravstvene rezultate. Onkologija 2009; 13: 4–6. 
– Primic Žakelj M, Zadnik V, Žagar T. Epidemiologija kožnega raka (Epidemiology of skin cancer). In: Luzar B, Jurčić V,
Pižem J, Calonje E, eds. XL. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem, 3.–4.
december 2009, Ljubljana. Novosti v dermatopatologiji. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2009.
– Primic Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji
(Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut; 2009. 
– Primic Žakelj M, Krajc M, Zadnik V. Državni presejalni programi za raka (National cancer screening programs).
Farm vestn 2009; 60: 90–4. 
– Primic Žakelj M, Zadnik V. Epidemiologija raka prostate (Epidemiology of prostate cancer). In: Kramer F, ed.
Rak prostate: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec; 2009.
– Primic Žakelj M, Žgajnar J. Cervical and breast cancer screening in Slovenia. Public service review, European
Union. 2009; 18: 272. 
– Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Primic Žakelj M, et al. The cancer survival gap
between elderly and middle-aged patients in Europe is widening. Eur J Cancer 2009; 45: 1006–16. 
– Repše-Fokter A, Fležar M, Pogačnik A, Snoj V. Review of negative or low grade smears in women with invasive
cervical cancer in Slovenia. Virchows Arch 2009; 455 Suppl,1: S6–S7. 
– Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Primic Žakelj M, et al. Process performance of cervical
screening programmes in Europe. Eur J Cancer 2009; 45: 2659–70. 
– Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Primic Žakelj M, et al. Multiple tumours in survival
estimates. Eur J Cancer 2009; 45: 1080–94. 
– Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Primic Žakelj M, et al. EUROCARE-4. Survival of cancer
patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 2009 Apr; 45(6): 931–91.
– Snoj Z, Primic Žakelj M, Ličina M, Pregelj P. Psychosocial correlates of progesterone receptors in breast cancer.
Depress Anxiety 2009; 26: 544–9. 
– Trapido EJ, Primic-Zakelj M, Pogacnik A, Ursic-Vrscaj M, Krajc M, Lesnicar H, et al. Critical factors influencing the
establishment, maintenance and sustainability of population-based cancer control programs. Tumori 2009; 95:
637–45. 
– Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Primic Žakelj M, et al. Survival trends in European
cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009; 45: 1042–66. 
– Zadnik V, Žagar T, Primic Zakelj M. Pridobivanje in uporaba georeferenciranih podatkov v registru raka Republike
Slovenije (Georeferenced data aquistion and usage in the cancer registry of Republic of Slovenia). Bilt-ekon
organ inform zdrav 2009; 25 (izr. št.): 14. 
– Zwitter M, Kovač V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion,
both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
J Thorac Oncol 2009; 4: 1148–55. 
– Žagar T, Zadnik V, Primic Zakelj M. Register raka Republike Slovenije in pridobivanje informacij o bolnikih iz
drugih državnih podatkovnih zbirk po elektronski poti (Cancer Registry of Slovenia obtains patient information
from other state databases via electronic mediums). In: Orel M, ed. Nova vizija tehnologij prihodnosti. Ljubljana:
Evropska hiša; 2009.
92
Institute of Oncology Ljubljana, Cancer Registry of RS Cancer in Slovenia 2007